var title_f30_37_31312="NSCLC bone met PETCT";
var content_f30_37_31312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PET-CT showing two foci of hypermetabolic activity in a lumbar vertebral body in a 76-year-old woman with metastatic adenocarcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31312=[""].join("\n");
var outline_f30_37_31312=null;
var title_f30_37_31313="Junctional EB non-Herlitz";
var content_f30_37_31313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa (JEB) non-Herlitz",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 383px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive erosions on the leg and foot of a newborn with junctional EB non-Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31313=[""].join("\n");
var outline_f30_37_31313=null;
var title_f30_37_31314="Antibiotics before procedures";
var content_f30_37_31314=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Antibiotics before procedures (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/37/31314/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31314/contributors\" id=\"au2060\">",
"       Daniel J Sexton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/37/31314/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31314/contributors\" id=\"se1937\">",
"       Stephen B Calderwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/37/31314/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31314/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/37/31314?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Many people are told that they need to take an antibiotic before having a dental, surgical, or other invasive medical procedure. This topic discusses the benefit of taking a pre-procedure antibiotic, who should take antibiotics, as well as an explanation of when antibiotics are usually recommended.",
"    </p>",
"    <p>",
"     Certain procedures, such as a root canal or tooth extraction, may allow bacteria from the mouth to enter the bloodstream. Rarely these bacteria can infect the heart valves and lining of the heart, causing them to become inflamed. This inflammation is called infective endocarditis. Infective endocarditis has the potential to cause catastrophic medical problems, including heart failure and leakage of the heart valves.",
"    </p>",
"    <p>",
"     When taken before a procedure, antibiotics may prevent bacteria from being released into the bloodstream. This is known as antibiotic prophylaxis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INFECTIVE ENDOCARDITIS",
"     </span>",
"    </p>",
"    <p>",
"     Infective endocarditis (IE) is an infection of the lining of heart chambers or valves with bacteria, fungi, or other organisms. IE occurs most commonly in people who have abnormal heart valves or had previous heart surgery; less commonly, it can occur in otherwise healthy people who have do not have heart disease (see",
"     <a class=\"local\" href=\"#H3\">",
"      'Guidelines for antibiotic prophylaxis'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Infective endocarditis develops following a sequence of events:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bacteria circulate in the bloodstream and stick to the lining or valves of the heart, usually at a site of previous injury or surface irregularity or abnormality.",
"      </li>",
"      <li>",
"       The bacteria then grow on the valve surface, forming a small mass (called a vegetation) on the heart valves or lining. The valve or surface that is infected may then become secondarily damaged.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     IE can develop in a very small percentage of people who undergo dental or other medical procedures that can cause bacteria to be transiently released into the bloodstream. Antibiotics are commonly given to people undergoing dental procedures who have preexisting heart murmurs or known problems with their heart valves, although the evidence that these antibiotics are always necessary or effective is not conclusive. Some studies show that antibiotics can help to prevent IE while others show no benefit.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Guidelines for antibiotic prophylaxis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the past, American Heart Association guidelines recommended that most patients with a heart murmur receive antibiotics prior to almost any dental procedures, even minor ones. However, these guidelines have changed considerably over time as more information has become available about the actual risk of dental procedures for patients with heart conditions. Review of studies performed between 1950 and 2006 which included thousands of patients has shown that there was no benefit of using preventive antibiotics, except in the highest risk patients [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/37/31314/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Highest risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with the following conditions are considered to be at the highest risk of developing infective endocarditis. Preventive antibiotics are generally recommended for people with the following conditions before certain procedures:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A prosthetic heart valve",
"      </li>",
"      <li>",
"       Valve repair with prosthetic material",
"      </li>",
"      <li>",
"       A prior history of infective endocarditis",
"      </li>",
"      <li>",
"       Many congenital (from birth) heart abnormalities, such as single ventricle states, transposition of the great arteries, and tetralogy of Fallot, even if the abnormality has been repaired. Patent foramen ovale, the most common congenital heart defect, does not require prophylaxis",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The list of procedures that require pretreatment with antibiotics is available below. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Antibiotic recommendations'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Moderate risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with the following conditions are considered to be at moderate risk of developing infective endocarditis. Antibiotic prophylaxis is",
"     <strong>",
"      NOT",
"     </strong>",
"     generally recommended for people with moderate risk conditions. This is an important change from prior recommendations [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/37/31314/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Valve repair without prosthetic material",
"      </li>",
"      <li>",
"       Hypertrophic cardiomyopathy",
"      </li>",
"      <li>",
"       Mitral valve prolapse with valvular regurgitation",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       valvular thickening",
"      </li>",
"      <li>",
"       Most other congenital cardiac abnormalities not listed above",
"      </li>",
"      <li>",
"       Unrepaired ventricular septal defect, unrepaired patent ductus arteriosus",
"      </li>",
"      <li>",
"       Acquired valvular dysfunction (eg, mitral or aortic regurgitation or stenosis)",
"      </li>",
"      <li>",
"       Atrial septal defect, ventricular septal defect, or patent ductus arteriosus that was successfully closed (either surgically or with a catheter based procedure) within the past six months",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Low risk",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with the following conditions are thought to have a low risk of infective endocarditis. Antibiotics have never been recommended for people with these conditions:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Physiologic, functional, or innocent heart murmurs",
"      </li>",
"      <li>",
"       Mitral valve prolapse without regurgitation or valvular leaflet thickening",
"      </li>",
"      <li>",
"       Mild tricuspid regurgitation",
"      </li>",
"      <li>",
"       Coronary artery disease (including previous coronary artery bypass graft surgery)",
"      </li>",
"      <li>",
"       Simple atrial septal defect",
"      </li>",
"      <li>",
"       Atrial septal defect, ventricular septal defect, or patent ductus arteriosus that was successfully closed (either surgically or with a catheter based procedure) more than six months previously",
"      </li>",
"      <li>",
"       Previous rheumatic fever or Kawasaki disease without valvular dysfunction",
"      </li>",
"      <li>",
"       People with pacemakers or defibrillators",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Dental care recommendations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anyone who is at risk of developing infective endocarditis should follow a program of careful mouth and tooth care. This includes a professional cleaning every six months, twice daily tooth brushing, and once daily flossing. These measures can help to prevent plaque and bacteria from building up around the gums and teeth.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ANTIBIOTIC RECOMMENDATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The following treatment suggestions come from the American Heart Association's guidelines on antibiotic prophylaxis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Dental, oral, or upper respiratory tract procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are at HIGHEST risk for IE (see",
"     <a class=\"local\" href=\"#H4\">",
"      'Highest risk'",
"     </a>",
"     above) should take one dose of an antibiotic by mouth (pills or liquid) one hour before certain dental, oral, or upper respiratory tract procedures; a second dose is not necessary.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People allergic to penicillin &mdash; People who are allergic to penicillin can be treated one hour before the procedure with an alternate antibiotic.",
"      </li>",
"      <li>",
"       People unable to take oral medications &mdash; People who are unable to take oral medications can be treated with an antibiotic injection 30 minutes before the procedure.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Genitourinary or gastrointestinal procedures",
"     </span>",
"     &nbsp;&mdash;&nbsp;The American Heart Association does not consider surgeries or procedures on the digestive or urinary system to have a high risk of causing infective endocarditis. This includes colonoscopy, sigmoidoscopy, cystoscopy, and many other procedures.",
"    </p>",
"    <p>",
"     Antibiotics are no longer routinely recommended before these procedures, even in people with the highest risk heart conditions [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/37/31314/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnant women who are at highest risk for IE (see",
"     <a class=\"local\" href=\"#H4\">",
"      'Highest risk'",
"     </a>",
"     above) should take an antibiotic before certain dental, oral, or upper respiratory tract procedures.",
"    </p>",
"    <p>",
"     A pregnant woman who has a high risk of IE does",
"     <strong>",
"      NOT",
"     </strong>",
"     usually need antibiotic prophylaxis before a normal vaginal delivery or cesarean section. Antibiotics may be recommended before labor or cesarean section for other reasons, including prevention of complications related to group B streptococcus. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11248?source=see_link\">",
"      \"Patient information: Group B streptococcus and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Children",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with a moderate or high risk of developing infective endocarditis are usually given antibiotics before selected dental and surgical procedures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      No treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The guidelines provided above may not apply to every situation. There may be instances in which a person has a high or moderate risk of IE and antibiotics are not recommended. In such cases, it is important to understand the risks and benefits of taking versus not taking preventive antibiotics. You should discuss these issues with your healthcare provider before the procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784795416\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21383556\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/60/19394?source=see_link\">",
"      Patient information: Mitral regurgitation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/4/21571?source=see_link\">",
"      Patient information: Mitral valve prolapse (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/25/2450?source=see_link\">",
"      Patient information: Tetralogy of Fallot (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21383566\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11248?source=see_link\">",
"      Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33415?source=see_link\">",
"      Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=see_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=see_link\">",
"      Candida endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18249?source=see_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26649?source=see_link\">",
"      Complications of Staphylococcus aureus bacteremia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=see_link\">",
"      Culture-negative endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14840?source=see_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40215?source=see_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=see_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17718?source=see_link\">",
"      Pathogenesis of vegetation formation in infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=see_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/8/20617?source=see_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22297?source=see_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/endocarditis.html\">",
"      www.nlm.nih.gov/medlineplus/endocarditis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/\">",
"      www.heart.org/HEARTORG/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/37/31314/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/37/31314?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31314/abstract/1\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31314/abstract/2\">",
"      American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31314/abstract/3\">",
"      Duval X, Alla F, Hoen B, et al. Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis 2006; 42:e102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31314/abstract/4\">",
"      Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_37_31314=[""].join("\n");
var outline_f30_37_31314=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INFECTIVE ENDOCARDITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ANTIBIOTIC RECOMMENDATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31315="Sulconazole: Patient drug information";
var content_f30_37_31315=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulconazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/46/2787?source=see_link\">",
"     see \"Sulconazole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exelderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Exelderm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11057 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31315=[""].join("\n");
var outline_f30_37_31315=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223672\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223673\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013273\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013272\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013277\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013278\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013280\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013275\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013276\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013281\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013282\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/46/2787?source=related_link\">",
"      Sulconazole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31316="Normal human PMN";
var content_f30_37_31316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60666&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal human neutrophil",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear shows a normal polymorphonuclear neutrophil (PMN). The nucleus is segmented into four lobes connected by thin chromatin strands. The cytoplasm is pink with fine, azure bluish granules. The predominant specific secondary granules are finely dispersed and stains the cytoplasm faintly pink.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31316=[""].join("\n");
var outline_f30_37_31316=null;
var title_f30_37_31317="Nadolol: Patient drug information";
var content_f30_37_31317=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nadolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35063?source=see_link\">",
"     see \"Nadolol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/33/28182?source=see_link\">",
"     see \"Nadolol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corgard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Nadolol;",
"     </li>",
"     <li>",
"      Apo-Nadol&reg;;",
"     </li>",
"     <li>",
"      Corgard&reg;;",
"     </li>",
"     <li>",
"      Novo-Nadolol;",
"     </li>",
"     <li>",
"      Teva-Nadolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not stop taking this drug all of a sudden. If you do, chest pain that is worse and in some cases heart attack may occur. The risk may be greater if you have certain types of heart disease. To avoid side effects, you will want to slowly stop this drug  as ordered by your doctor. Call your doctor right away if you have new or worse chest pain or if other heart problems occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop tremor (essential).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart attack to stop future heart attacks and lengthen life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop performance anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop rebleeding from esophageal varices in cirrhosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bold or forceful actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by drugs that are used for mood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nadolol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, very weak heart, or slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 12 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may hide the signs of low blood sugar. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10884 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31317=[""].join("\n");
var outline_f30_37_31317=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022626\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022628\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022627\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022632\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022633\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022635\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022630\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022631\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022636\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022637\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/15/35063?source=related_link\">",
"      Nadolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/33/28182?source=related_link\">",
"      Nadolol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31318="Screening to prevent sudden cardiac death in athletes";
var content_f30_37_31318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening to prevent sudden cardiac death in athletes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Antonio Pelliccia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31318/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/37/31318/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death (SCD) associated with athletic activity is a rare but devastating event. Victims are usually young and apparently healthy, but many have underlying cardiovascular disease that is not diagnosed until after the event. As a result, there is great interest in detecting such abnormalities early, and then defining appropriate activity restrictions for affected individuals to minimize the risk of SCD.",
"   </p>",
"   <p>",
"    The majority of SCD events in athletes are due to malignant arrhythmias, usually ventricular tachycardia (VT) or ventricular fibrillation (VF). In the small number of individuals with certain cardiac disorders, athletics may increase the likelihood of these events in two ways: prolonged physical training induces changes in cardiac structure (eg, chamber dilation and physiologic hypertrophy) that may create arrhythmic substrate, and the immediate physiologic demands of intense athletics may trigger malignant arrhythmias and SCD in susceptible individuals with underlying cardiac abnormalities.",
"   </p>",
"   <p>",
"    The potential for SCD associated with athletic activity generates two questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How should individuals be evaluated prior to initiating athletic activity?",
"     </li>",
"     <li>",
"      What restrictions should be placed upon individuals with known cardiovascular disease?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Answers to these questions are complicated and controversial, and vary based upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The age of the individual",
"     </li>",
"     <li>",
"      The type of underlying heart disease",
"     </li>",
"     <li>",
"      The nature of the activity (ie, competitive versus recreational athletics)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although definitions vary, \"young\" often refers to high school and college athletes, but applies in general to individuals under age 35 in whom SCD is usually due to congenital heart disease. Less young, or \"masters\", athletes include individuals over age 35, in whom SCD is most commonly due to coronary heart disease.",
"   </p>",
"   <p>",
"    Competitive athletics include organized team or individual sports in which there is regular competition, placing a premium on achievement. This definition implies that individuals will engage in high levels of exertion, and may not have the opportunity or the judgment to limit their activity. This most frequently applies to high school, college, or professional sports.",
"   </p>",
"   <p>",
"    In contrast, recreational sports do not generally require systematic training and do not involve the same pressures to excel. Activity levels may still be vigorous, and the distinction from competitive athletics is not always clear. However, defining recreational athletics separately permits the development of guidelines for noncompetitive athletes with cardiovascular disease.",
"   </p>",
"   <p>",
"    The role of screening to detect serious underlying diseases that might predispose to SCD in athletes will be reviewed here. Issues related to the management of athletes with known disease as well as the broader range of arrhythmias and conduction disturbances that occur in athletes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4184?source=see_link\">",
"     \"Electrocardiographic abnormalities and conduction disturbances in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHALLENGES IN SCREENING PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the devastating nature of SCD and the potential to detect many of the associated disorders with noninvasive testing, there is a strong incentive to screen athletes for these disorders prior to athletic participation. However, there are a number of obstacles to widespread screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The large number of competitive athletes. In the United States, for example, it has been estimated that there are approximately four million high school-age athletes, 500,000 collegiate athletes, and 5000 professional athletes.",
"     </li>",
"     <li>",
"      The low prevalence of underlying congenital heart disease, estimated at approximately 0.2 to 0.3 percent of the athletic population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of diseases to be considered, each with distinct diagnostic criteria and optimal testing modalities.",
"     </li>",
"     <li>",
"      The impact of uncertain and false-positive screening study results, which is significant when screening for rare disorders and the imperfect specificity of the current screening modalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In combination, these issues have a substantial impact on both the feasibility and the cost-effectiveness of screening the large population of athletes. If, for example, the occurrence of hypertrophic cardiomyopathy in a young population is assumed to be 1 in 500 and the cost of echocardiography is $500 per study, it would cost $250,000 to detect one previously undiagnosed case.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Impact of screening programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data and no randomized trials on the impact screening programs have on the incidence of SCD in athletes. Observational data are limited by the low incidence of SCD and the heterogeneity of both populations studied and screening protocols.",
"   </p>",
"   <p>",
"    The efficacy of the Italian national screening program was illustrated in an observational series from the Veneto region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/2\">",
"     2",
"    </a>",
"    ]. All sudden deaths in athletic and nonathletic populations between the years 1979 and 2004 were recorded. A mandatory screening program, which included a 12-lead ECG in all subjects, was instituted in 1982. The annual incidence of SCD in athletes decreased from",
"    <span class=\"nowrap\">",
"     3.6/100",
"    </span>",
"    000 person-years in 1979 to 1980 to",
"    <span class=\"nowrap\">",
"     0.4/100",
"    </span>",
"    000 person-years in 2003 to 2004 (89 percent reduction). There was no change in the incidence of SCD among nonathletes in that age group over the same time period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) have proposed guidelines for preparticipation screening for young athletes planning to begin competitive sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/1,3-6\">",
"     1,3-6",
"    </a>",
"    ]. The most significant difference between these two proposals is that the AHA guidelines include a preparticipation history and physical examination without further routine testing, while the ESC proposal includes a standard 12-lead ECG, based upon a national screening program that has been in effect in Italy since 1982 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these recommendations, preparticipation screening protocols are inconsistent throughout both the United States and Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AHA recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA guideline for cardiovascular preparticipation screening of competitive athletes has separate recommendations for high school or college athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/1\">",
"     1",
"    </a>",
"    ] and for masters athletes (over age 35) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Younger athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for preparticipation screening in high school and college athletes were updated in 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/1\">",
"     1",
"    </a>",
"    ], although the suggested approach in the update was similar to that of earlier AHA guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The following recommendations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial complete personal and family history and physical examination should be performed before beginning training and competition. Twelve major points to be included were defined including five personal history elements, three family history elements, and four physical examination elements:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The personal history elements are exertional chest",
"      <span class=\"nowrap\">",
"       pain/discomfort;",
"      </span>",
"      unexplained",
"      <span class=\"nowrap\">",
"       syncope/near-syncope",
"      </span>",
"      (judged not to be",
"      <span class=\"nowrap\">",
"       neurocardiogenic/vasovagal);",
"      </span>",
"      excessive exertional and unexplained",
"      <span class=\"nowrap\">",
"       dyspnea/fatigue,",
"      </span>",
"      associated with exercise; prior recognition of a heart murmur; and elevated systemic blood pressure.",
"     </li>",
"     <li>",
"      The family history elements are premature death in one relative (sudden and unexpected, or otherwise) before age 50 years due to heart disease; disability from heart disease in a close relative &lt;50 years of age; specific knowledge of certain cardiac conditions in family members including hypertrophic or dilated cardiomyopathy, long-QT syndrome or other ion channelopathies, Marfan syndrome, or clinically important arrhythmias.",
"     </li>",
"     <li>",
"      The physical examination elements are heart murmur (by auscultation in supine and standing positions or with Valsalva maneuver), femoral pulses to exclude aortic coarctation, physical stigmata of Marfan syndrome, and brachial artery blood pressure (sitting position, preferably in both arms).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To avoid inaccuracies due to poor compliance and inadequate medical knowledge, parents should be responsible for filling out the history form for minors.",
"     </li>",
"     <li>",
"      Athletic screening should be performed by a healthcare worker with the requisite training, medical skills, and background to reliably obtain a detailed cardiovascular history, perform a physical examination, and recognize heart disease. The guidelines stated that it is preferred that such evaluations be performed by licensed clinicians. Recognizing that it is not always possible to have clinicians available, however, the guidelines further recommended the establishment of a standardized certification process for non-clinician examiners.",
"     </li>",
"     <li>",
"      For high school students, the comprehensive history and physical examination should be repeated every two years, with an interim history during the intervening years.",
"     </li>",
"     <li>",
"      For collegiate athletes, an interim history and blood pressure measurement should be repeated annually in each of the subsequent three to four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The routine use of a 12 lead ECG, echocardiography, or exercise testing is",
"      <strong>",
"       not recommended",
"      </strong>",
"      , based upon both practical and cost-efficiency considerations, as well as the implications of false-positive screening tests. The AHA panel felt that these limitations prohibited the implementation of national standards that included noninvasive screening tests. However, the panel also stated that it did not oppose smaller scale programs that included such tests, provided that they were \"well designed and prudently implemented\".",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Masters athletes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Masters sports are organized forms of competition specifically designed for older athletes. Such sports programs primarily include apparently normal and healthy individuals over the age of 35, although many participants are greater than 50 or 60 years of age. In 2001, the AHA published recommendations for preparticipation medical evaluations before entry into masters sports training programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial complete personal and family history and physical examination should be performed before beginning training and competition. Twelve major points to be included were defined.",
"     </li>",
"     <li>",
"      Exercise testing is recommended for masters athletes who have a moderate-to-high cardiovascular risk profile for coronary heart disease; this risk profile includes men &gt;40 years of age and women &gt;50 years of age (or postmenopausal) with one or more independent coronary risk factors (hypercholesterolemia or dyslipidemia, hypertension, current or recent cigarette smoking, diabetes mellitus, or a history of myocardial infarction or sudden death in a first degree relative &lt;60 years old).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An exercise test is also recommended for masters athletes of any age with symptoms suggestive of coronary heart disease or those &ge;65 years of age even in the absence of risk factors or symptoms. A positive test necessitates further evaluation to establish the presence and anatomic severity of coronary artery stenoses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard 12-lead ECG is of limited diagnostic value for detecting CHD in the asymptomatic masters population. While the AHA has recommended a routine ECG as part of a routine evaluation for all masters athletes &gt;40 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/5\">",
"       5",
"      </a>",
"      ] since it occasionally identifies a prior myocardial infarction and can be helpful in detecting certain diseases that are less common in the older population, such as hypertrophic cardiomyopathy, long QT syndrome, Brugada syndrome, Wolff-Parkinson-White, and arrhythmogenic right ventricular cardiomyopathy, the United States Preventive Services Task Force recommended against routine ECG in asymptomatic low risk patients and made no recommendation (due to insufficient evidence) in asymptomatic intermediate to high risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/7\">",
"       7",
"      </a>",
"      ]. The USPSTF recommendation was directed toward all asymptomatic adults and does not specifically comment on the use of routine screening ECG in competitive athletes.",
"     </li>",
"     <li>",
"      Diagnostic echocardiography is indicated when clinical, historical, or physical findings suggest the possibility of structural heart disease (valvular disease, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, prior myocardial infarction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ESC recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2005, the ESC published guidelines for preparticipation screening of young competitive athletes (",
"    <a class=\"graphic graphic_algorithm graphicRef64043 \" href=\"mobipreview.htm?25/5/25694\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/6\">",
"     6",
"    </a>",
"    ]. The following recommendations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial complete personal and family history and physical examination should be performed before beginning training and competition.",
"     </li>",
"     <li>",
"      The evaluation should be performed by a clinician with specific training, medical skill and cultural background to identify clinical symptoms and signs associated with cardiovascular diseases associated with SCD. In Italy, clinicians primarily responsible for these examinations are trained in postgraduate sports medicine programs full-time for four years, and work in sports medical centers dedicated to periodic evaluation of athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Screening evaluations should be repeated at least every two years.",
"     </li>",
"     <li>",
"      A 12-lead ECG should be obtained, seeking evidence of a standardized list of abnormalities (",
"      <a class=\"graphic graphic_table graphicRef64686 \" href=\"mobipreview.htm?23/56/24460\">",
"       table 1",
"      </a>",
"      ). If a specific diagnosis is considered, more detailed ECG review may be helpful (",
"      <a class=\"graphic graphic_table graphicRef59279 graphicRef67009 \" href=\"mobipreview.htm?10/31/10750\">",
"       table 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with abnormal findings on history, physical examination, family history, or ECG are referred for further testing, such as echocardiography, ambulatory monitoring, exercise treadmill testing, or cardiac MRI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most significant difference between the AHA and ESC guidelines is the recommendation of a 12-lead ECG by the ESC. In addition, the ESC guidelines recommend that the evaluation be performed by a clinician, while the AHA guidelines recommend a trained healthcare worker. In practice, the Italian system upon which the ESC recommendations are based, employs a group of specially trained clinicians in dedicated healthcare facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comparison of guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two screening strategies have not been directly compared. However, in a retrospective analysis of 134 cases of SCD in high school and college athletes in the United States, cardiovascular abnormalities were suspected by standard history and physical examination in only 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/9\">",
"     9",
"    </a>",
"    ]. The potential advantage of the ECG is most commonly attributed to its ability to detect hypertrophic cardiomyopathy, in which the ECG is abnormal in up 95 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the AHA's objections to the routine use of ECG screening is the risk of false-positive results. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'AHA recommendations'",
"    </a>",
"    above.) The prevalence of such findings was addressed in a series of 32,652 Italian subjects who underwent routine pre-participation screening that included an ECG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/11\">",
"     11",
"    </a>",
"    ]. The prevalence of markedly abnormal ECG patterns suggestive of significant structural heart disease was &lt;5 percent. However, these results cannot be generalized to other countries. In addition to the potential impact of genetic differences, the nature of pre-participation screening is unique in Italy, where it is performed by trained and licensed sports medicine specialists who practice in dedicated sports clinics.",
"   </p>",
"   <p>",
"    Data from Italian experience illustrate the potential impact of the screening ECG. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Impact of screening programs'",
"    </a>",
"    above.) In one series, 33,735 athletes were screened over a 17 year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/12\">",
"     12",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1058 athletes were disqualified for medical reasons, 621 related to cardiovascular disease.",
"     </li>",
"     <li>",
"      Of the 621 cardiovascular abnormalities, the most common were arrhythmias and conduction abnormalities (38 percent), hypertension (27 percent), and mitral valve disease (21 percent).",
"     </li>",
"     <li>",
"      3016 patients were referred for echocardiography (8.9 percent of all screened athletes).",
"     </li>",
"     <li>",
"      22 patients were diagnosed with hypertrophic cardiomyopathy, all of whom were disqualified from athletic participation. Eighteen of these patients had an abnormal ECG, while five had abnormalities on initial history and physical examination.",
"     </li>",
"     <li>",
"      None of the patients with hypertrophic cardiomyopathy died over eight years of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate series of 4485 elite Italian athletes evaluated the efficacy with which the national screening program detected patients with HCM and removed them from competitive athletics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31318/abstract/13\">",
"     13",
"    </a>",
"    ]. Each year approximately 500 highly trained athletes considered for national or international competition were referred for a comprehensive evaluation that included echocardiography.",
"   </p>",
"   <p>",
"    Over eight years, four athletes were found to have borderline LVH (13 mm). One was later confirmed to have HCM by genetic analysis and a second was considered to have possible HCM. In addition, 12 athletes were diagnosed with other cardiac structural abnormalities including mitral valve prolapse, myocarditis, Marfan's syndrome, arrhythmogenic right ventricular cardiomyopathy, and bicuspid aortic valves. Because the prevalence of HCM in this series of elite athletes is lower than that reported in other unselected series of young adults (approximately 1 in 500), the authors suggest that the national pre-participation screening program is detecting most individuals with HCM at a younger age and removing them from competitive athletics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the basis of these observation, it appears that the screening ECG improves the ability to detect hypertrophic cardiomyopathy, although the degree to which this might lower mortality cannot be determined.",
"   </p>",
"   <p>",
"    The screening ECG also can detect arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, and Brugada syndrome. However, given the rarity of these disorders, the incremental value of the ECG over a standard personal and family history is difficult to determine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECREATIONAL ATHLETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is screening an asymptomatic subject, particularly men over age 50, who is about to begin a recreational exercise program. The data are conflicting on the value of such an approach. The exercise prescription is also important in older individuals who are beginning to exercise. The approach to recreational exercise and the prescription of exercise for cardiovascular disease prevention are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for coronary heart disease\", section on 'Recommendations from major societies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=see_link&amp;anchor=H20#H20\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'The exercise prescription'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H431533\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden cardiac death (SCD) associated with athletic activity is a rare but devastating event. Victims are usually young and apparently healthy, but many have underlying cardiovascular disease that is not diagnosed until after the event. The majority of SCD events in athletes are due to malignant arrhythmias, usually ventricular tachycardia (VT) or ventricular fibrillation (VF). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Due to the devastating nature of SCD and the potential to detect many of the associated disorders with noninvasive testing, there is a strong incentive to screen athletes for these disorders prior to athletic participation. However, there are a number of obstacles to widespread screening, including the large numbers of competitive athletes, low prevalence of congenital heart disease, and the impact of uncertain or false-positive results. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Challenges in screening programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few data and no randomized trials on the impact screening programs have on the incidence of SCD in athletes. Observational data are limited by the low incidence of SCD and the heterogeneity of both populations studied and screening protocols. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Impact of screening programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) have proposed guidelines for preparticipation screening for young athletes planning to begin competitive sports. The most significant difference between these two proposals is that the AHA guidelines include a preparticipation history and physical examination without further routine testing, while the ESC proposal includes a standard 12-lead ECG in all patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Major society guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two screening strategies from the American Heart Association (AHA) and the European Society of Cardiology (ESC) have not been directly compared. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comparison of guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H560036715\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Drs. David Bharucha and Roger Marinchak, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/1\">",
"      Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2007; 115:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/2\">",
"      Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA 2006; 296:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/3\">",
"      Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996; 94:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/4\">",
"      Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletes: addendum: an addendum to a statement for health professionals from the Sudden Death Committee (Council on Clinical Cardiology) and the Congenital Cardiac Defects Committee (Council on Cardiovascular Disease in the Young), American Heart Association. Circulation 1998; 97:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/5\">",
"      Maron BJ, Ara&uacute;jo CG, Thompson PD, et al. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2001; 103:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/6\">",
"      Corrado D, Pelliccia A, Bj&oslash;rnstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/7\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/8\">",
"      Pelliccia A, Maron BJ. Preparticipation cardiovascular evaluation of the competitive athlete: perspectives from the 30-year Italian experience. Am J Cardiol 1995; 75:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/9\">",
"      Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/10\">",
"      Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/11\">",
"      Pelliccia A, Culasso F, Di Paolo FM, et al. Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening. Eur Heart J 2007; 28:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/12\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31318/abstract/13\">",
"      Pelliccia A, Di Paolo FM, Corrado D, et al. Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur Heart J 2006; 27:2196.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 960 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31318=[""].join("\n");
var outline_f30_37_31318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H431533\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHALLENGES IN SCREENING PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Impact of screening programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AHA recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Younger athletes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Masters athletes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ESC recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comparison of guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECREATIONAL ATHLETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H431533\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H560036715\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/960|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?25/5/25694\" title=\"algorithm 1\">",
"      ESC Athlete Screening Protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/56/24460\" title=\"table 1\">",
"      General screening ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/20/39244\" title=\"table 2A\">",
"      Screening ECG features SCD A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/38/9837\" title=\"table 2B\">",
"      Screening ECG features SCD B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4184?source=related_link\">",
"      Electrocardiographic abnormalities and conduction disturbances in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31319="Temozolomide: Pediatric drug information";
var content_f30_37_31319=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Temozolomide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"    see \"Temozolomide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/60/32709?source=see_link\">",
"    see \"Temozolomide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Temodar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ahi-Temozolomide Capsules;",
"     </li>",
"     <li>",
"      Temodal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Alkylating Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"      see \"Temozolomide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents: Limited data available; further studies are needed:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Neuroblastoma, relapsed or refractory:",
"     </b>",
"     Infants, Children, and Adolescents: Oral: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days, repeat cycle every 21 days for up to 6 cycles; use in combination with irinotecan; administer 1 hour prior to irinotecan (Bagatell, 2011).",
"     <b>",
"      Note:",
"     </b>",
"     Temozolomide doses were rounded to the nearest capsule size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive:",
"     </b>",
"     Children &ge; 2 years and Adolescents: Oral: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days, repeat cycle every 21 days (in combination with irinotecan; administer 1 hour prior to irinotecan) (Casey, 2009); dosing based on a retrospective review",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Solid tumors, relapsed or refractory",
"     </b>",
"     [including but not limited to brain tumor (astrocytomas, gliomas, medulloblastoma), neuroblastoma, and sarcomas]: Infants, Children, and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling: Children &ge;3 years and Adolescents: 160-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternative dosing: 200-215 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-5 every 21-28 days; dose was decreased to 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for patients who received prior craniospinal irradiation or relapsed after bone marrow transplant (De Sio, 2006; Nicholson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anaplastic astrocytoma, refractory:",
"     </b>",
"     Initial dose: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days; repeat every 28 days. Subsequent doses of 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days per treatment cycle; based upon hematologic tolerance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Dosage modification for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; reduce dose by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for subsequent cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC 1000-1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets 50,000-100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Postpone therapy until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; maintain initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     on day 22 or day 29 (day 1 of next cycle): Increase dose to or maintain dose at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 5 days for subsequent cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Glioblastoma multiforme (newly diagnosed, high-grade glioma):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Concomitant phase: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 42 days with focal radiotherapy (60 Gy administered in 30 fractions).",
"     <b>",
"      Note:",
"     </b>",
"     PCP prophylaxis is required during concomitant phase and should continue in patients who develop lymphocytopenia until lymphocyte recovery to &le;grade 1. Obtain weekly CBC.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continue at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily  throughout the 42-day concomitant phase (up to 49 days) as long as ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicity &le;grade 1 (excludes alopecia, nausea/vomiting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <i>",
"      Dosage modification for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     but &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &ge;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     but &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     grade 2 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Interrupt therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     platelet count &lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      or",
"     </b>",
"     grade 3/4 nonhematologic toxicity (excludes alopecia, nausea/vomiting): Discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance phase (consists of 6 treatment cycles): Begin 4 weeks after concomitant phase completion.",
"     <b>",
"      Note:",
"     </b>",
"     Each subsequent cycle is 28 days (consisting of 5 days of drug treatment followed by 23 days without treatment). Draw CBC within 48 hours of day 22; hold next cycle and do weekly CBC until ANC &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelet count &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; dosing modification should be based on lowest blood counts and worst nonhematologic toxicity during the previous cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cycle 1: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days; repeat every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cycles 2-6: May increase to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily for 5 days every 28 days [if ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and nonhematologic toxicities for cycle 1 are &le;grade 2 (excludes alopecia, nausea/vomiting)];",
"     <b>",
"      Note:",
"     </b>",
"     If dose was not escalated at the onset of cycle 2, do not increase for cycles 3-6.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Dosage modification (during maintenance phase) for toxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or grade 3 nonhematologic toxicity (excludes alopecia, nausea/vomiting) during previous cycle: Decrease dose by 1 dose level (50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for 5 days), unless dose has already been lowered to 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose, then discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     If dose reduction &lt;100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose is required or grade 4 nonhematologic toxicity (excludes alopecia, nausea/vomiting), or if the same grade 3 nonhematologic toxicity occurs after dose reduction: Discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;36 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     : No effect on temozolomide clearance was demonstrated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;36 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     ): Use with caution; no dosage  adjustments provided in manufacturers labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis patients: Use has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Adults: Severe hepatic impairment: Use with caution; no dosage adjustments provided in manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temodar&reg;: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temodar&reg;: 100 mg [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Standard antiemetics may be administered if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Oral: Swallow capsule intact with a glass of water; do not chew; if patient is unable to swallow capsule, open capsule and dissolve in apple juice or applesauce taking precautions to avoid exposure to the cytotoxic agent; administer on an empty stomach or at bedtime to reduce the incidence of nausea and vomiting; absorption is affected by food; may administer with food as long as food intake and administration are performed at the same time each day to ensure consistent bioavailability. Do not repeat if vomiting occurs after dose is administered; wait until the next scheduled dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Parenteral: I.V.: Bring to room temperature prior to reconstitution. Reconstitute each 100 mg vial with 41 mL sterile water for injection to a final concentration of 2.5 mg/mL. Swirl gently; do not shake. Place dose without further dilution into an empty sterile polyvinyl chloride infusion bag. Infuse over 90 minutes. Infusion must be completed within 14 hours of reconstitution. Flush line before and after administration; may be administered through the same I.V. line as NS. Do not administer other medications through the same I.V. line.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F12705157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Normal saline",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Refrigerate intact vials for injection at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted vials may be stored for up to 14 hours at room temperature (25&deg;C or 77&deg;F). Infusion must be completed within 14 hours of reconstitution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory anaplastic astrocytoma with progression after initial therapy with a nitrosourea and procarbazine (FDA approved in adults); treatment of newly-diagnosed glioblastoma multiforme (initially in combination with radiotherapy, then as maintenance treatment) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Active against recurrent glioblastoma multiforme, low-grade astrocytoma, low-grade oligodendroglioma, metastatic CNS lesions, refractory primary CNS lymphoma, anaplastic oligodendroglioma, primitive neuroectodermal tumors (PNET), including medulloblastoma, pediatric neuroblastoma, advanced or metastatic melanoma, cutaneous T-cell lymphomas [mycosis fungoides (MF) and Sezary Syndrome (SS)], carcinoid tumors, advanced neuroendocrine tumors (carcinoid or islet cell), Ewing&rsquo;s sarcoma (recurrent or progressive), soft tissue sarcomas (extremity/retroperitoneal/intra-abdominal or hemangiopericytoma/solitary fibrous tumor)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temodar&reg; may be confused with Tambocor&trade;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Temozolomide may be confused with temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F225305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     With CNS malignancies, it may be difficult to distinguish between CNS adverse events caused by temozolomide versus the effects of progressive disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, anxiety, ataxia, confusion, coordination abnormality, depression, dizziness, fatigue, fever, headache, hemiparesis, insomnia, memory impairment, paresis, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dry skin, erythema, pruritus, radiation injury (maintenance phase after radiotherapy), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, hypercorticism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysphagia, nausea, stomatitis, taste perversion, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, urinary tract infection, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthralgia, back pain, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, vision abnormality (visual deficit/vision changes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, alveolitis, anaphylaxis, aplastic anemia, cholestasis, emotional lability, erythema multiforme, febrile neutropenia, flu-like syndrome, hallucination, hematoma, hemorrhage, hepatitis, hepatotoxicity, herpes simplex, herpes zoster, hyperbilirubinemia, hyperglycemia, hypokalemia, injection site reactions (erythema, irritation, pain, pruritus, swelling, warmth), interstitial pneumonia/pneumonitis, myelodysplastic syndrome, opportunistic infection (eg, PCP), oral candidiasis, pancytopenia (may be prolonged), peripheral neuropathy, petechiae, pneumonitis, pulmonary fibrosis, secondary malignancies (including myeloid leukemia), Stevens-Johnson syndrome, toxic epidermal necrolysis, transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to temozolomide, dacarbazine, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe renal or hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Thrombocytopenia and neutropenia are dose-limiting toxicities which occur late in the treatment cycle and usually resolve within 14 days; prior to therapy initiation patients must have an absolute neutrophil count (ANC) &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and a platelet count &ge;100 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; obtain a CBC on day 22 and weekly until the ANC &gt;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelet count &gt;100 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L. Prolonged pancytopenia resulting in aplastic anemia has been reported; concurrent use of temozolomide with medications associated with aplastic anemia (eg, carbamazepine, sulfamethoxazole and trimethoprim, phenytoin) may obscure assessment for development of aplastic anemia.",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) may occur; risk is increased in those patients receiving steroids or longer dosing regimens; PCP prophylaxis is required in patients receiving radiotherapy in combination with the 42-day temozolomide regimen. Rare cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukemia, have been reported. May cause fetal harm; pregnancy should be avoided during therapy. Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May enhance the adverse/toxic effect of Temozolomide. Divalproex may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May enhance the adverse/toxic effect of Temozolomide. Valproic Acid may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food reduces the rate and extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm when administered to pregnant women. Animal studies, at doses less than used in humans, resulted in numerous birth defects. Testicular toxicity was demonstrated in animal studies using smaller doses than recommended for cancer treatment. There are no adequate and well-controlled studies in pregnant women. Male and female patients should avoid pregnancy while receiving drug.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with ANC (absolute neutrophil count) and platelet count; monitor for CNS effects, gastrointestinal disturbance, myelosuppression, opportunistic infection, vision disturbance, and cough on a regular basis; dosage adjustments may be necessary for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temozolomide is a prodrug which is rapidly and nonenzymatically converted to the active alkylating metabolite MTIC [(methyl-triazene-1-yl)-imidazole-4-carboxamide]; this conversion occurs under physiologic conditions in all tissues to which it distributes. The cytotoxic effects of MTIC are manifested through alkylation (methylation) of DNA at the O",
"     <sup>",
"      6",
"     </sup>",
"     , N",
"     <sup>",
"      7",
"     </sup>",
"     guanine positions which lead to DNA double strand breaks and apoptosis. Noncell cycle specific.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapidly and completely absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive tissue distribution; crosses the blood brain barrier; V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 100% (on a mg-per-mg basis, I.V. temozolomide, infused over 90 minutes, is bioequivalent to an oral dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: At a neutral or alkaline pH, hydrolyzes to active MTIC (3-methyl-(triazen-1-yl) imidazole-4-carboxamide) and temozolomide acid metabolite; MTIC is further metabolized to 5-amino-imidazole-4-carboxamide (AIC) and methylhydrazine (active alkylating agent); CYP isoenzymes play only a minor role in metabolism (of temozolomide and MTIC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.6-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1 hour; 2.3 hours after high fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% excreted in feces; 5% to 7% of unchanged temozolomide excreted renally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 5.5 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"     ; women have a &sim;5% lower clearance than men (adjusted for body surface area); children 3-17 years have similar temozolomide clearance as adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/60/32709?source=see_link\">",
"      see \"Temozolomide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Take always with food or always without food; taking at bedtime may reduce nausea or vomiting. Swallow whole with 8 ounces of water. Do not open, crush, or chew capsules; if capsule is accidentally broken, do not inhale powder (wash hands thoroughly if powder gets on skin). It may be necessary to take more than one strength of capsule each day for daily dose.  Women of childbearing potential should be advised to avoid becoming pregnant. Male and female patients should use appropriate contraceptive measures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Report immediately any swelling, pain, or burning at infusion site. May cause headache, dizziness, confusion, fatigue, anxiety, insomnia, impaired coordination, nausea, vomiting, loss of appetite, constipation, or diarrhea. Report chest pain or palpitations; acute headache; unusual swelling of legs or feet; visual disturbances; unresolved GI problems; itching or burning on urination or vaginal discharge; acute joint, back, bone, or muscle pain or unusual weakness; difficulty breathing; cough; or signs of respiratory infection. Women of childbearing potential should be advised to avoid becoming pregnant. Male and female patients should use appropriate contraceptive measures.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To minimize the risk of a wrong dose error, each strength of temozolomide must be packaged and dispensed in a separate vial or in its original glass bottle. Label each container with the appropriate number of capsules to be taken each day.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Increased MGMT (O-6-methylguanine-DNA methyltransferase) activity/levels within tumor tissue is associated with temozolomide resistance. Glioblastoma patients with decreased levels (due to methylated MGMT promoter) may be more likely to benefit from the combination of radiation therapy and temozolomide (Hegi, 2008; Stupp, 2009). Determination of MGMT status may be predictive for response to alkylating agents.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F4152326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL temozolomide oral suspension may be compounded in a vertical flow hood. Mix the contents of ten 100 mg capsules and 500 mg of povidone K-30 powder in a glass mortar; add 25 mg anhydrous citric acid dissolved in 1.5 mL purified water and mix to a uniform paste; mix while adding 50 mL Ora-Plus&reg; in incremental proportions. Transfer to an amber plastic bottle, rinse mortar 4 times with small portions of either Ora-Sweet&reg; or Ora-Sweet&reg; SF, and add quantity of Ora-Sweet&reg; or Ora-Sweet&reg; SF sufficient to make 100 mL. Store in plastic amber prescription bottles; label \"shake well\" and \"refrigerate\"; include the beyond-use date. Stable for 7 days at room temperature or 60 days refrigerated (preferred).",
"    </p>",
"    <div class=\"reference\">",
"     Trissel LA, Yanping Z, and Koontz SE, \"Temozolomide Stability in Extemporaneously Compounded Oral Suspension,\"",
"     <i>",
"      Int J Pharm Compound",
"     </i>",
"     , 2006, 10(5):396-9.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagatell R, London WB, Wagner LM, \"Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(2):208-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/21115869/pubmed\" id=\"21115869\" target=\"_blank\">",
"        21115869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagatell R, Wagner LM, Cohn SL, et al, &ldquo;Irinotecan Plus Temozolomide in Children With Recurrent or Refractory Neuroblastoma: A Phase II Children&rsquo;s Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15S) (abstract).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casey DA, Wexler LH, Merchant MS, et al, \"Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1029-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/19637327/pubmed\" id=\"19637327\" target=\"_blank\">",
"        19637327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Sio L, Milano GM, Castellano A, et al, \"Temozolomide in Resistant or Relapsed Pediatric Solid Tumors,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2006, 47(1):30-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/16047361/pubmed\" id=\"16047361\" target=\"_blank\">",
"        16047361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Esteller M, Garcia-Foncillas J, Andion E, et al, \"Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(19):1350-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/11070098/pubmed\" id=\"11070098\" target=\"_blank\">",
"        11070098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegi ME, Diserens AC, Gorlia T, et al, \"MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(10):997-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/15758010/pubmed\" id=\"15758010\" target=\"_blank\">",
"        15758010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegi ME, Liu L, Herman JG, et al, \"Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(25):4189-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/18757334/pubmed\" id=\"18757334\" target=\"_blank\">",
"        18757334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horton TM, Thompson PA, Berg SL, et al, \"Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(31):4922-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/17971589/pubmed\" id=\"17971589\" target=\"_blank\">",
"        17971589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loh KC, Willert J, Meltzer H, et al, &ldquo;Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies,&rdquo;",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2005, 27(5):254-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/15891559/pubmed\" id=\"15891559\" target=\"_blank\">",
"        15891559",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marchesi F, Turriziani M, Tortorelli G, et al, \"Triazene Compounds: Mechanism of Action and Related DNA Repair Systems,\"",
"      <i>",
"       Pharmacol Res",
"      </i>",
"      , 2007, 56(4):275-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/17897837/pubmed\" id=\"17897837\" target=\"_blank\">",
"        17897837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&rdquo; Version 2.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/cns.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 3.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicholson HS, Kretschmar CS, Krailo M, et al, \"Phase 2 Study of Temozolomide in Children and Adolescents With Recurrent Central Nervous System Tumors: A Report From the Children's Oncology Group,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 110(7):1542-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/17705175/pubmed\" id=\"17705175\" target=\"_blank\">",
"        17705175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicholson HS, Krailo M, Ames MM, et al, &ldquo;Phase I Study of Temozolomide in Children and Adolescents With Recurrent Solid Tumors: A Report From the Children's Cancer Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1998, 16(9):3037-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/9738573/pubmed\" id=\"9738573\" target=\"_blank\">",
"        9738573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stupp R, Hegi ME, Mason WP, et al, \"Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2009, 10(5):459-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/19269895/pubmed\" id=\"19269895\" target=\"_blank\">",
"        19269895",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villano JL, Seery TE, and Bressler LR, \"Temozolomide in Malignant Gliomas: Current Use and Future Targets,\"",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2009, 64(4):647-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/37/31319/abstract-text/19543728/pubmed\" id=\"19543728\" target=\"_blank\">",
"        19543728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12823 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-BC8603A877-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31319=[""].join("\n");
var outline_f30_37_31319=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225270\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225271\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050179\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050171\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225246\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225232\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050182\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12705157\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050174\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050181\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402099\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225305\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050170\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050169\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300110\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223210\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050188\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225242\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225255\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050168\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050184\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050176\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050186\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4152326\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=related_link\">",
"      Temozolomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/60/32709?source=related_link\">",
"      Temozolomide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31320="Pemphigoid gestationis umb";
var content_f30_37_31320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78383%7EDERM%2F63947%7EDERM%2F52776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78383%7EDERM%2F63947%7EDERM%2F52776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigold gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Periumbilical erythematous papules, vesicles, erosions, and crusts are present in this patient with pemphigold gestations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scattered erythematous, urticarial plaques are present on the abdomen of this patient with pemphigoid gestationis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDT7c0GlI/KjGO9eOdQ36DilwCfSlx2paBjRR3pSOKUdOlADcZIo24FKRRigQh9ulAHNKO9JQMaevHFO7/Sjj0oHI44oBiEYOe1IQPwpSKCBigQh55xQOtHY4pcc4HTFADe5pOxpxGKTGKLDExx2ppH5U8c54ppBoAjcZGMfjVdwMEYq0RkVFIuT/OqQGfJGP1qMx+nJq2681GV56VQEITPPFPVMDmn7efrS44oA53V12Xm7GOAa3rVt8KN6gVk69HgxsOM8Vf0d99khPUcVUvhTJW9i3jAJ70mOTTiKCOtQURMOoxSYqU9vSmEYoAixxTSKlYe9RtzyKAGEYFR471KwpjdKYEbc+5phBqQ/d9KaQPrSAglH0qpPwpq5KKp3PC/zqo7gx1uuFVsfw02NGdwqrkk8Y71PCf9Fz7V0nh3SCiLPOvzkfKp7Ck3y6hFXZLo+mi1g3OMyHmtAxMw5wKviIKoAH41FKFRSR2rHfU6oqysimYdgPJNUpNu/aAB+FXjcDJzk/hVdkWQ7hwTWkS1fqVJIC3Q7fcDtTGVFUqOTjqRzViXfGTt5BqujNuJcAVSKtcqzxM46HPeqksZU7Vk2Z6A962dwfA7H0pktsjfMcMfftVJpEmfa2x5LS5apXdkUh2LHtUiwsjb8fgOlOm5QheCepoE0ikxB/h4zSNCCuSOT3xUrgjGeajlkYrgHHtVW7FW7HTgZBpRz2pB+hpc9q5zgENK3X3o+tJj3oAMYoHQ0ueKMcUAIOlHfpR7UtADTwaDj2oPWjntQAvfIzSfWlP60Aj0oAaOvNBFOP1pP8aAEwBQR7Gl6cd6TofelcBPrR9BS445NGKYDSOeeKSnH8zQRx0oAjNRuMr71NgZprDHamMquv696i2+lWJPT8ai7YzVIBhFAXnmn9OM5pAPWgLGXrse6zJA+6fyqDw9JmF0HUGtPUE8y0lHqtYfh9sXbp6irWsRPRnQ9AKQin45prdTUDGkcU3HIp+e1NIycDmgBh96YxqVhUbD8KAIyAOQTmmnnrUhphpgRkYppxnpUh59abjmhgQSjNZ15071tQ+UrZlRnOeEzgH61o2el/brtbidFES9FUYBNNSURpX0RD4a0vMCS3C8dVUj9a6kfu14Bp8UQTAOAOwFTMuwH2rBvmdzojFRViJWJHzDmqt2/GNp/CrBkG3JJGegqPhjmqWhVjPB25BU800SKrBR+tXJUXdnOPYVXkt4x81Ui7oZJIuw5HSqlwokj3oBu9KtxorGiSHy23IBzVJBdIoIJDHt24PYmkPmBQrfd65q7v8AmxgAetLsDc8U0xNlTcWAzjHvTHRiDnAx7VacD0Gajc4HWmidzPZUz84JNQTlAB5fJ9x0qe5nAbGc49OlVJXLBigIz3q0y9Tq+1A5FA6Y6H0oz2rnscAfypM0poHHWgBB3owRTh0x70neiwABge9KfekFKOM0rAIR0pMY70ooPp3oAD600nk0pIxig5x0oASkPWnNwAO3rSUwDPekHWjtgUUDDvS9aBjmkyRxiluAHnBzSdRSnp7UnTntTENNB5pcj0pp9KAIpeDUDDpVmQYHbNVz16U0MaQcijv6ilPU0YNOwDHXKkEda5ezPkartPHzkV1XJFctqYMGqFhnkhhVwV7oUjpx2JoNNibfErDuKcagYn4Uwg1J0FNPWmBGabjk/wAqkbNNPHpSAiNNIH41IR+VNIGDmmBGRnPNNxzmpAvH9K2tK0cuFlugQvZT3pSdkUk2VtG0prhxNMCIweB611ccARAqAADgURgKAqDj2oYTllCbQufmJ549qycrm6jZCNGc4B+opvlkk7qsng4I+tMkJ28DiriMrSJkcAYqlOs3VMAVeIIz/WlOzA3VQ0zFDymUq4+Wn+Q0o6kVrEx7RwOfakZU2E4AoTRTkzPih2c5BPepWUMuDz7UkagscOSPSq91lJQyHnOMUXFa5FMgyOM+1Rzv5SAHbyOg5q2qhwQ3DenpULQAE56Ve4LzM5p28s7UP41FHLu+V8r9K1CiFdqgDNUri0ww+amrFJpleZIiM7d3PGaguJSV2BR71P5JVSW6emajlwCBkciqsgv2Oh70d/alxSYBPHFc9jgEPr1o4p3Bpo56UDButFIM5x6UpoEIeCKO+RThgkDpR0GKYDR1pScA0nXqeKU46UmAEDoBTSD2pe3PWk6UIBCTj+Qo/DpR1+lBPFMAoFH1oPbApAHT64ozmgjPbimnINACk47UAcH0pc+tNxmgBDnJzSfSjHFGOM5x6mgCNz+dQnNWHI9B+VQkdPemmMYRg80uKQ9SKPxpgJ2rnvE0eJIpF+ldD9MVQ1y1MtmzBSdhzxVRdnqDVxdJcy2MZHPFXB71n6FDMsJQxOvoCD0rbjsZm5K7D71LdnYpRb6FPvSHjFacOmSSAnegFWIdFV3wZ8fhS5kivZyMMhi2AOT6UjoynkEV1lrpMduxdJDnHsaSawjumC7AfrxU8+pSoto5EjJG0E57VIllO7hRE2T6iuoisLWIholCuOPUipzCdpG7jvmhzfQao9zM0vSUhIklw8nv0FbCwtjkjBqKNeO1DyMoOMcdqz1e5oo22LaKFOKkQKM5rM+0vwOi/Sj7Y643YNO4+RsuSkYI7+tVlBDHcxx70RTCTB6e1WGUdT371SdwtbRkaDcoIA571HIhzxirJRcYHH0phC8/1q0IzTuZtpOD6VKImKEdQalKjd05681MwGcZ600U5GZsdJOOmKzrwTJIx5Ck5BroXiGcqcUxowwIcAj3p8q6gp2MGZpXhjlMq7hxjoanDloVMhwT+lXprCAfMBz1xmo54lePEeOKdkthc1ykw2AEkEVRnucPjBHvT7uE7lVy3B65pNisCrAYHQ1SXctJLUZLLhQNoYGs64kaWQABRj0FacoVV+UZNUJWQZAGHHr0quUF5HRjmgk8UvrSfTpWB54E4NIeGpTQOtAAelJ0Gc/pS5xQfTOaEgEzQeaXII96TPWgAx7UlKT6UmaAA+/6UmfXmjocUfWkAAjHA4oJweKOPWjPTp0pgJnjGKQcAUuOaGP5UMBDz1pOtL2o/ShAIeKO3pStg03FFhh06E5pCRjmhgQByKkt4WkYAITuPYUnoNK4QwvPxEpIHUnoKtR6LPJGXHQD73atm2i+y2qhoCY2PJ/vEdqY9w88mF+VOy9AKxc5XsjphRXU5+fTZ4lJxuqOGwmnxhCB6mukxIXEaoWGOWpVP7sxvHjjgVcZyYOirlC1sILeH98iSS85Oc1bgMQUriIAJtAAGBVm2RCuwqGH0pywpFK8ixZjbqGFPl5tSlaOliGCNDwzfQ+1LNBArYjYucYPHFSIquXMXyg/w9hQA5LAN9QD1quVbFX1KsdkUfjK55xVkxhlIIGfpQpQ/wAR4HOGpkcm9SGLcHrjrTUbDuwMfljJwB9aZJKUyQc7e1PkZDICBmMjG2hymQoJweDkdKOXUDNF3hgZLeRQT94DOKsS3PlxlmZuRnjrTzGyuSvzIfbkUu5NrZCHIwC39KfKirplFdQtXUHzV44IIwaWK5tp8qsik+9MNs73IHkRmLGS565qw8UKw/vbcCL7u4KMA1LixvlGnHRcgVBNChUbydo5pLl0t3RYSXGO5qypEihgOCOeKTj1EV4yVKsnKjjir0JMhB3kY6VWaAMjPGOR1B6Ypgk28A8+lO1iHrsawwcAdDUbrnGAQc1WhuDIAN2Gq4uSAH69ciqiQ9DNedzOYiDuGccUsMxYgFcHNX57ZZSGwAR3HWseZ2R2QYY9ucGq5Sovm0RpSSqIjuIJAzWatwzCR94AUZA9ajDuxKOCFI71WTETFZgRxhSKJJ9AUUgnunbaRnGcHmp71pIUgmJjKuPuo2cD3HY1VgjLF9oyp6UslmIyCGJPp2pqF0OTSdguNz/MAT7VUOS2GyPatHJ2kY49qz51JbgEEflVcor30GSnKcc1RkUSYHQ+9WhII35zg9arXLAvuA5FUtdA2Ok4PBop3FITnI7VznCGaQUvFJkdKAEIzQBSjv6UnGO9MAGO1Lj2pAPWjvStcBBwTSkUlHeiwxQAc8nNJ7ZyKM0hoQhAABR9MUDv9KTIBoAXPPFIaD0z+FKBzmmAlJz06ipI42kbCAsfpWpa6ccZmJUd9tIuMHLYxwMngE1atbTfMPNDBByR0zWrFZqjDYQOc/WrG3nEjc/Spk29jaNLuQDT7SSJyE2Efd7/AJmpFjZogMhQvQAYFTKgAwOQT1Hal2BVJO7b6VKpvqbJJDYpT9mMLhm+bNMe38qRFILRvyCeCP8A61TyQtbyq0bCUY+cY6UKuNso555XuBVqnYd9Rpt2M3G7b2xUqxhAxkKuB1B4z+NWJJ1SI5I6cZ71FIGVFaRMK3OVOcitEl0JbfUYPLBDRRlVPJHpTJbogbAOD14pLpJVUbE8xTzgelZiW8kj77mVgOwXsPpSd+g4pPVlyAr9oZiCB2xVmYeeEAwm3rgc1Ua3MUSG3BKY+8eMGnwvIUZgT5hPcdapRuDV9StfaXul820kKSdSu7g/hUwKhgCpBAGfem3EgjvVNwAjgfKeead9qM4KjA3DOSKfK3qGthZYldMhiB1we1RzRSxMvmbdrLkHPOKdHu8sK5Lkjpin3MO+3QZJZTjNTyOwKVtxgkHlZwwT+91qtKkYiYzlQufqKsQyeXMF/gHylj0qoypeRvbDO0d6LW3KW5ajZW2mNsqQOtNu97wOqqWzzgDp70kaiCzSIfMQOT3FQSSSLLsUt84yOabjpqO2uhXMhhtmcxeaR2HWponDxAqCpI6Ulsk0eXkHy+3SpZDvgIRgshPBotYLoamRG7Bj0+ZKrSAPGzbTzyD6VIyBY1bcWYcEmo23FiSOQeR2o5bIlLUzLm5ntZ1zyuOMDNdBp12LiFSM7gM59RWXeHa5jAG09MjOKntpPKCYAHbFLlsOdnE6FXVolJB49Kyr63jlclRhuzDrU6zFG2pwOoPWmA+W+5/mBOaepgtChHamNtxPzY61HMEZtrkKcd/5VsSAOh9T3rIvocvtfkDlc1pa+w1K+4RbAuV655olXcDtHPpUUcc25nbGG5IHAqVQRu4JNUkTKyKjo6bgvBrNMuHIJJ9a17khVxnmsp4A8u4k8ccUNXLhJW1EZQ5GMYPrTJYl2gmp32xjk9KZIMxhqaM5Nmv9OtBwOtHH4UhAxXKc4melKcUN70nAHQ0AL0FJSjpkCkzQAntml6Y9aOopG4x70ALikwO2aUg7aUK2MigYwDPtQevvT1Ri33SG9hV2PS5ZAGUAexNA1FszQeSMHNSwwSS52KWI9q1ItLVSTLk45wOM1oRRrHgINvGCBxQaRpX1ZgpZTbsMCh9CKuwaZtAL9exatMt82+QsT35pytkdQynvStqaKmkRLH5IA2jae4GM090JGFYYPUVIYyTjIOO3rSqqsAQ4DHg55zVcpa0INhVVIJ9CDzmnSKrN9w8DoOoqWVQVC7SG7HHBpqFlkHmBhJjv3FCQ0xIlBAyeM1PJt3LtxnGMjtSIVJJ+6D1JFOQZ3DgEHnPGRVoLkbhAMK2eOc8UjBo5liJDbgDuxjBqzKGlUDAVgPoKqspz5mdq7ecetNR6iTJIbWK4kCF9qjrxQu8GZARIU6EimLKHICkAjpjqamGUYNETn+IkVSS6BK5Ta4cEEAoCMY6Yqqkzw5aZDsY4UdSKtanBLcOpVsLnkDvRDETEI3GT2yOtRLXQaaSuTQyxvEApwG5O7pSTxOE3oxAHzcCmosbEIqnJOfarsCZyh5P6VajpqTJ22KK4cEt8wYYBY1BJbEpnAJ6DHWpNQnKy7VTPHQjr9KZpwkVc7eWOQp6iktNB6pXM91mUFYsyZwPmOCnr9av/AGhvL5QYIwcdqlZQ1+JT0H3hiiUwFG2/K+SQMc1SXUblcq25a5gxJAvHykg/rUUwjtNzKcADJ96spmKMFOmainC3GdwxuPNGmwLfUZFLDOEdCdppsUe6Vj/EOAaI0VcKqgBOmPSnqwRx6Gi2g5PsUL+5jtWQSsRngDHf3p0UQYjLNjrx71Le28UzkypuwOKD5ccBB/1h6Fu1JrqPmVtCrM3lSmNuR2apEhZMkvuDDk1C6bGTztwLfMCelWZ2WKMDnBFJCbKV0PlDcZXge4qxbqsqAkDGOlRcOhXJLA1AZRAV8ps80Me6sbaKTFjuOM0qbXTPBK9fpWfa3hWUxycA8gnuKs27Ms7sRlGovYykrbk84ZU+U/KPSs+SQ7hkZx0NaIcmJh6VjXc4RCcHK9wKq3VCi76FlnULvGcY6elVWuMvgHOeDVdbyOWM/Pt9aghfMjlTuGeD7U07jcbbiX5eKTBxyM8GnxNuUYGCaLoIXAYbmPvUFrJkkdx04qtEyW/dGzxbmNHSLaamnfbkjqaps/y4yMmhkPU3uc4pMetKv40hB7/hXJYxDFJzzSgHsKeik5ABP0oDUjBzQMVcttNuJ/uxlR6mrUejS5+cigpRbMvA55qS3t5Z8lMYXqTxWymlLFGWf5sc7fSn/u4yVwq49BSbZrGk+pjfY5fvOFA6D5qv2diFb96SH7cVdCeYpI5HYU+FdikHuOM0JM09nFEYghQ5RMv655qXKgZwRng4prIAAASKcrHnfzjvimkWooAMr8vI9zR25GfoeRUqRnIIYHB64qXyWJztAz/Or5QdiNkXcGjPXselMSMbyGGzPOOxq0kPznjA9qHTMg546Gmok3GeWWBA7d806fLqgO0YPHal3BGCEkrn0qtNuQlixPdQPSm2kC1HTeYIwqMcg5A7UoBLI0oYPzyKfkhFP8J6MO1SSBTGXVzkDkdc1fKhFUyqrEKDlj1Hb8Kem0uqlsnuD2NV5X3NyNrevrVeaR1ZW64Iye5rJpxdy+W5qLE/m4P3egBpuoREwEKwGOSPUU60czwg9D2prxGTaH7E8+ta/EtCOplCWEtEy/NIOp/wrRhcNGC3y8fMM96ryW8ccpRECkHJPpUyLuh6EIT261MU0aOzRKJY42VwxwvGBTYTmNtpyCePaq7wFFB54PWprdCsi7Tx1q+W5LSS0GTTRwTNtHIJ5PFWbScbTg896oXcQySQDn8zTVdoiWTk46UcruDSaHXrTPck+X0y2RxUpLGIEN82PyqpAz3UpLja3QgHqKS13Q3Mnm5IOcUrW1Bkpk8tJA7jeRyD1FVYbgLITK2QR17Cp7mzDXEbs2TjOOmKgSDzNwGCw4xVJJDi1bUbLKIg3zblJBBHvUkj71ULgYOaiitHjQxgcM2SW5qyYlV1UnaTxmny9wbj0KzIEuMDg4yQKfIrcFV79aqTzBZjghirfePHFaMMytEeme1JeYpXRUnd1bcRhfSoJwz7XKgjsAanupMyFATtPGT61mu7RuYlk3Bj1NTvsNEl6f8ARFG4FsncvdfSm7/Nsxzhl4zUM0bSzrjACjt3+tLcxCOLYBhwN1FveuO/QkyNqhWxJ64qvHb5d1I+ZuQelZP26WG9CO37snB9q1dRuCIYtrKxQZyvpSe5bi4srOzLIEYnevA+lb9q4aIHpxzXMrM00iHyyGxgnsavWs5jkKBgVPX29qZlUTa0Noy7GIyOaytVCgEKCVPWrLSbkHGRVa7kUjA6VRjBtO5zsIZJgSp2k4yOOK1IpVG4DketQ3KfdZRkAdBVZHBbb29qaj2N5Pm1ZanDEeZGfu9KZafKzHuaVXADKxOBUStzkdB61VjnbJ7o/KCAxGcFscZrOvv3AA/eB8fOHGMH2rYMkVzp8MTXMduY2YlXyA2e+RWNrl4s8kUccnneWgUykffOT/8AqoaCLPQF05TgM+3P+zVyHTLbaPMcvnoR0q0jbnAcfMp5HfNJgKeFwPX1rk5Wa+ziLb6XCP8AVLz64rShsY1Ayo9+KbZTxxsOh9j0q48yAnKjB7Z4osjOV07IrO0UIAxxSBoZDkDg1VnkAyOOeOagL7FKjI5zQomip6Fm5QNkRYwRiqvkFtqyIDjoaljnIOSQR7d60rV4ZR8xBqlFD1gjOS1ZcbUDA0jWTs4wpAIxg+tb6oEHC8fSms6ggYq+VEKoYgtCU2AEODxz+dPW0ZUKnOOlbMccanJ5z602aSMJgBdvciiyHzt7GVbqqkDGRWpAqFcY4rMP2d3GGIYHOKcrvC+0sOOuTwaEEouRZu4lC/KeapiE5znk1I91vJVBk4zjNRG8VVyvXpg+tPQcYySJfJ353nHoRVYxHeCCTsOT9KtR3O5jHIoDdRjpUMjCKTcCQQfrVJ3QXY1pIREy4bJ5xS2hKYLYKt+YprJ5jtIRjHIGOtQRyEMdw+YdR6Uo36gtdES3UaSTKBxk5Bqoyh5lhCknPPtV6ZoXtVduCOQPQ0abGoZpARyenoaqyGpNK4+GBo9p9ODmpCys3BBYdqsMN3tis91McpbODQkQndhfxhomdQc9cVlaVK67vNbJz0NbQbewDZwfWq9xYIG8xMq3t3+tJxvsVGSWjIZjI+4g7lb07VUN4Ib3C5OR0xWpgRwnHHFYUoAvC2CCV4460SVloVBc2gy/knlnjkhyUVuRjGKvGIllOAQepB4FLEipbr1zjoakSETCQDITqKaQ5SS0IIGRL4qnJNT3KBpxs688+lRLAtrbiQAqWJw3UmmJOHUnoehNHWzI66CXzrIFEbEcYJ9KjgBgjJ3cdTmo8bnbBIBqS5INtIRjcB1oasGxbxdfZDOqJ5Y9TVN7kTq3GGAxg1Y04uLFpHxJGDyCegPesW5lRbnMeQucfhWcnKFm+oR1dh5iXyzhckn8zTEimidXdiI2+XFW4p1iDGRA+OB61U1W4eGYbcAMuNmc1U2Wm9iW7ZUeBl691zUci5nVFQDPOelUY5ZLqffg4GOPpVq5k/dnact6GnGxNrMgLEzsM4AO3I71ZhhDhmIPI6nmqlqjPOWUcAEnNacbIIcjpTRMnbYyLyytvNBkTIXnNUXiEs7BMhc8DPStido5ix7D361SunVrqIRKoBGBjik7Gik2rDLSFklAYgZ70kqFZQ4AIzT5JgYTzl06CoZ/MEccsWCByRQ3clN9SZLshsdFIpJR5iB88jistZ2Jd8c9h6VPbTiRyCTmiPcmcdLoS4IAI7VWT5GG3GBVqdSQeBx0zVCZlVSew4rWxCkWGcBCT19ag8wnJBqISgLz07UiyYdX2htpztboaVyZM3IGuW02D7DLBEct5m9lDNzweawNcNwLlTdSo8oXgoQRjPtV6TUocYOnWZ/A/wCNYepXglm3RW0cPy7SseQDT3ITse3DKSFuck85qQqrkEqFJ7A9TUaYYYAOc8g1KiGScEnheOBxWVrHYxrW5UqVH4A5q00MhjGOp7GtCyhEnJwVzVt7ZWTb6dKagrGUqmpzTxhHIZC0eB8pPINRL5buuCRuODn+GtK+tnSN8dRWY7eWI5Qcp0Py4wfSotZ2NoyuhLfcGcKw+VsZ9easTfuXjeHCvnaVxgGoiHeZ5FGFJztqZm3leCeDkDtT5Lg0a1pdBgN3BPbNOuXXJOBj1zWVZOdgU9VOM1elwV+Q/iaaMXFJlR7kzXHlBgFJ5I7Cq91uhlYxOTH1BNEYjgaVpWIwpIA7+1NuLmG5t1aEHzNvII60Knc0vZ6DGkBkVlGQR6cZ7053YxOQTujAIBqrZSYhAbPXqe9Szgu/yHCbMdc5oSuaEkEpkUSKAr9M5pGDZfcOc9fWpYkEagDPPBzVlkDxk4GKtRXUzciBmCzLuOQowDS3AVgGUnd0qBowXOTgDBx61I+CBtbII/Omo2F1EkaSSAgbg6jP1FJYx+cCvIccNnqafFh+SdrDpntVyzWOJySMOetFkiHJq9ihqdm0dm4XluoAqhpE0gf5wwD9zXR3n73gjt0FZbfuQTjIHP0qZQu7l05txszWT/V/N19aguIQQQKrWGoi5YowCnPGa0t2Vye9NWZjK8GUEDL97jFP+1Jv2PillOCVHWsS+JjfIyDnJxQ9NiopS3NC/QmB2T8KyNOdW+Vzl89zWlBOojVWbIPPNZN5biK/SRCdjtkn0pM0p9YjtRmkiAaLDYIH0HrVywucRMHGT1x65qigW65Q716Y9KsRbVj4H3eCKb3TQNaWJLmQ+RIpk2r1Xd0B74qpb5MW3jOetT7VlTGAaiaREK/Xn2qrLcmOmguQcqMAjvTBuZWiVQCcc0uosqW1uRJGS2SCrZYexqSwAePeep7mkt7MG7K5Ujaa3t5oo5sK42spHWs4Au6rgk5q1q0cZyzMVwOvrVXS5GdzycDoT6VlOi3K99AUmk2ySaZre/jYoGi3BihGeKpXtwkuqzOEwhY7R1wCeK07+NZtu0gNnGT0FY99sjuNkbFioHPp9Kub6GkLMs2LMLoiI4xyPrU9+W8sXLHJztYH0qnp2+SVYoVBkJ61d1lhFbmFyoI6isnBpXE371iBbgiI+SOCNufSobq8NvbFCCXUZINVNMbN0m5wqA5OelT6lIJ5nkYHcevOc0lJ2uFkpWKtrdi4XeoIRhzjtSXLg3IMRA2cgin2CRIg28AnHTpmqupBPtsggJKZIB6ZHrjtWi2uVdXG27O29mPB5HvTHuZYsjBZT2JqxCjDYg6kYApUQMG3hRt9T0q7J7mbbKA4R8kIzdAKfpeTLhjjHrVa7ccgYyODUlu2wKxxknvSSVtB9C/cuBI6ntWbIytxnB9KL6Qic553c8VQuZ9rAnqfSqiyeQsFw4IzgCozJ6txVcSnGScA1LbiOXfuIyBnFKUrGTQ52eTAjVmJO0YHU+lQ3/lwoI2hnjulA37zgZ+mOK0rW9jhtFKeaZbVZCsaISCzdHJHTAz1rB1++VzbxpI8pgiCNI4wXOSeh7c4oUrkOJ7tZS/6SWduSO/erQdonIwSG5PsapWw/fZPAx1NTl5HiZk+UAkGpitNTsZr2F6qsYz1HWtRLhCT83HvXL2ykTK4YfOM0+4mKW5bOZDJtGOuMfyp6rYylTTZv3aK8ZIx0rnruNZIvL3YXO7GKvQ3YaNQxzkdKztQYIwzxu6d8CnLa5VOPLoye1ZcABgcdqnaMLk9M8VThs3Ft9qU7UPTLDJ96jhu2L7WwT61KmthtXeheEOFZUPJ5/GpEGyM7/pmoo5xkBSG5xkU2ecupXOGI+X3qybMjcFmDSKpAU5z39Kq7dsYIHzZ61aUN5Y3DcOBz0qFlKSMC24DoBzxT5bal3FsY1eJ45nCr1CnjcfTPaks26q3LLxzUMqM7MygjaNwIpNPA4kYk5PP4UuXXQOhqGQEHIGBxUauxkCt0781FvDqQpGM5J9RTXV3jI5UA5NVYnRDoXRzMHJUYKqQM89utRfcYxsPmTA604DbkDo3OabJsUk5+f8A/VinbQC0sZMmcjOOR61XurptrqhHDAe5pY3kIMYYfICV9fw9aj8rB5QKqcE9ix7UOItty2LhkdUIL5ANPzE4ZT1PH0qldti5V0IAQ4Yd6c0vlvnjLYOPSpTJZTMEkF8h5CBuK1Rd54J/DPWobiWN7ZmwdyDv3rmre9uJZ33kKiN/FwcUWSRpG9XV9Do7y5ZU3gcZxmqd/KrxF+QQM1SvL9kQI5yjnIAHGcU12aYYGdpwMUWBRS3MUajO14iKzNGGxk/XtXSRPvkCsM545rJTTmhuvMZRw24VqQocAk4OcnFJQLqSTtYkMKWUhCLkqcsvY1lNNMkzSR7lDkjB7itLz98s0jDHB5Jxj0rLGWuQp6kUEJ9yzaOVcKQT6nt9KfebUaaNx86HaeevNVFkYRtsAPOP8TRfyRwztHGyOSF+YHPPer2DdkIQyyGI/LGrfLWjJJ5EAXkEVBAhQjJ561ZuHQjGMn6U+Wxm5XZTnUXKDPeo7eJYyf72eTTbubyYhtPXP/6qr2jP5ZLMaAa0LqlGlfdIBhTjIzk1z0oZJ5DIM7u4qxfsxwVOCBxiqCySTMFJBA6npSlC+pUW0aWn34sbwSFQwXBApmt3wvLgyqMBhnFRyQ75E2/ePUe1Q6lbG2CjI59DWVTms10Kjyt36kMLfMD2HSpJpgT8owMetVIW5PsOlSTZKBj3PGKwcJW0Lur3GxyEO208DB5pAfOu14wfc0lmm+R1x2q3fWD2nlSPJEVb+42SK1SXKrkyeoy8kME4Ct9cVUilG9i2SppbqVZygRs89T6VGSsanBqorm1Ib0sU5irSMhOBUU8jYwD05zS30gABTAOeaqK5MbFh2yauMbCvcU3RZiM1BK/PPQdDUCqSzMBxTZidxx+NPl0HexZabgDrVywkiitriWaORnI2xN0UH39fpWYkgK7SpJ7HNPZphAIyW8vO7HvWTlZkNXOg0+48+xWKO5iiPlzLLG7hN7MPlbnqO3tXK+KplMtpGJVmlihEcsinIZsnv3wCBn2rchMw0W2azsbe8cu/ms0PmMnPAI/rVfUrCTV2ltINOgjuI7ZJGMKhTFKWxsJHqOcHpUR7mc9Ee3xx5jT58Mo3D3xSK+52Vj98ZJ9adFLgfJyxUgH0PfFNiQRzo/LAqRtHXpXVy6XOlskjIjQ54OMDPcVGhJydpMgKkD86W8/cpGQSfmyTjvUsbf6RvySCM9MUkuw79SVIcZBGGBHfpVbUlYSIWHHSrhkVpgFIz1bntUd9seNy7EBQSN3UnsKJwurEqTT1HWUIFhLOwDIuFKk8jOe3pWTKSj7o+D1BqYXXlWzqrkZALL6+lV7YM6NLxsQgkNXM4qUlGJcbq7ZdSXAZ1AJyDj3xzTyS5BXllGailkRriVLZcK4BAx0HWrMAAVgzYAXc3rjGP8K6VG5Lktx8c6rbbuShPr3qKQ7VDIMFhleh4qlG2LVzvGQwRV9R61NDlGDj5gF4x3pxi2S7LYk2PEgZGxgHPrRaokdsMDnNJNL+7kUKzEDKnso/xqIysLJmBCurfd74PcU5aBfQnZyAqoB8xGD0qaO6KRAqV+/u5+tUGlDJEFVs4GcnNTXcYFlLsGCUGB1yacUKWtkSJIpEynAL52Adjn+VNijZ5/KPYc/SqFkf+JevmK4cckN1qdgRtYMQ7Hg555GMUtLajas7EkGCSTyAcCrMEImJQypHgclmwCAf51QC+TN5f8XQ5/rTZBst1iH3mGTg9acXoJq+w67kQ6hgggEAHByDgdRVqVY44o2JHmkdu4rNjjj4zktnHXkVPcs8kKxggEAhQB70lHe5DRZ+V4GXeCxH1/OqBsYXdZipLp69CTXLs13ZXjASMpDdO3NdJaXUs1oHmA2see1JST0Zu6coLmTH3Nt51ow7549jSWqmKOMSDLDpViCQeWVXkg81FLuFxkjjGBTsZpt6MuTOCoORkVEZFWFscHviqsshyowAM9DTZ7lFty+zGWxgU0hWsVrq7cSSHYFLH7noPrVFJJHuRkgEccVM5BVmcZ+bFS2kShMkDd7dqHCN9S3KyI5UZIWEQ+Y8En0qsu4MrSKpK9CBWrcOAu0cjHaqjpuTAXgnOafKmZqb6krzM6oVX5elRT3LRgkLkgce1EUgWE+tUri42Fjg/MMcUW7jjuQzytLsDYJyTU2WjgzweKpq21UPUnjNWzPH9mSLrMzY4GeKNlcctSq6yy7io+ULkn2qvENr8DpUk80gzGHwuSG/rUCsWOACF9fWkwvpqbmkWa3d6ZJt4tYV3SFRyAO1c3fXJmumklyEzgD0HpWvYXqG1khDMBn5hnrWHqnM4iQjBOcVE5KUeUmD953JRIhd3/gPQD0rWtltorFJbqKVQ2fLJHDH2NYzwM0StH0B2nPrU0j3AgijuHcwx/cXPAz1xSk7aDbutyNEkmnkWHqDnjripmm8i1mgmjBeTlW7iqunzql5PKZkjRULDcCd57KMdzUV5cm4cyhcZ4xWD213K6ldGPnbRxn3ptw+0Fd43A4471Su5sTKBnPTFQSzqGJBMj9MitKTfKD3LVyQuFzk9SapvNsz6e4pEJkDPI3HYd6jnZJHUopwB3rREDiw2HJ4qtPIqghTk02abb26dqpTzcliQMUE81jb0pVcHzBmrl48UcJAIHFciusNBkbd3pg4qrPq01wwDfKncDrWM7kWu7novhjRhqEMJjgldpxIWmEzRqm3ovHUmustdJsdFt4xYQGMTpvkZmLM7ZOSc1znhvXrGx0Sxc3M0aMWIijIwhBxnnvVnVPGenzShkkkkG3kvjP4Yrlnd6EtNu7PRRtt4gPvM33T1BPrT7S6RiFnyhAwCfy5qhJcC5igYKqE5LEdOP61IkhlwFX5Wwox26ZP416trHS9tS/dLvvPLbGCMcHA9jToCrXJCZbPyDBxk44/Wh43+1tEAGYj5s9yBRA6G8ZVC7icj5sjj/Cny2E5aDZG+zRsxBL/AHunbFLLMbi1DmMqGO4A9h/kU59jLk4znae45pk8sco8vYQqHqOmKXLcFIp3FtuYMSdzZ+Y9SatWtuViKAcEEH3/AM4plw6eXEN4IVm4+vf9KkkumRWNu5AIwCV5aqURNsiRv3W6NMFRgkVNvHnJux8wyCD09qqQo627F+p7GrEUQFym9sjPzY9ulCj3G3oSpEAwjZeAe1N3HJJGAGwABUtwzs5Zv4jzjsarzzxxW7h8+ZnI9KV+wrixph2LNweQPXilLILe4Lbd4IUAjrxVZJGkwHAGcHNRXx/eAKzeXjadvc0pRbQ1uWbeTcieo4q3b4cjdwAcH0qhb5S0Odw2kEg/oafbzFY8jJxyx9M0Q0G9S7c2xMbvlSCeD6j0pNLjVJS8qh2HRT0BquI5TKFJ2pndirMwNvZTXS/NHnZnsCe1RJXuZ3fwszdWuSl/5ykb93OKSF0dYXZwAueoPIzzk1m3Th4938WaliJFqFLMTjJ475zUUru9jZqyRLbvtbIUcnrVqRtsnJAc5wBVK0kLKTtyAx6nrSMwa5yD8oGK36aktajpLeG4uA9wuQOuOpq9BEkypGBsiQZ2n9KpPOEWNljLMevPQZqxPcKIQUZVJUEgfyNJ2Jk3ZIklMKSgBwQPT0qhcXDSSKFPEfAx6f41RMrsZX6AD8aiid3UkDk+tTZvcqKsWprjKFVycHOaS4MjwQsOMliV+mBUkcGY9/YU2dWKxhCSVUk+3Of8KpR6i5yJC7KR95V/Q1ZuXKWETtFsUkqjheJMdefUZFZjTFHwQNuaW5upJo0hLN5aZKKT0z1xWNaSXQq12PmuWZkVScnp9Ks2x3KQzdO1Y6zkzIvTGc1agm2MxxjHb1q6burk1F0RYu2AOD064FZ80qPGAud4ySadqU+5tnQ9wKpSZmVYYQS3J49KthF2WpJNcRsFVMkBefXNJaXAiZGUZfruPaqm0Mh44HUiopH4CICpHei473LBlEs8jggqTx9aZJKxkAAGAOgFQoTEVyRz2okmwcKv1NK1kSV7jzEcyROVPf3qNMLIXZtzgct6+1PldWI39O/NRuVU5HHehpALNetbspXsc4zTbvWWnAURkepJqrMd7evrVRlwxY9B0NZzgpasZ0mni3jg+Zlbdyc1Svbm3gywZQvuaxJSREpjLFiTxnAFVF+diG5P9ay9k1sxX1uXbdHvLveuQDwue3qaY5iFwyxnKj+I96a1y8KlIh95dhI7DvVMkKvP61qoqKsibvdl7O5GZiAiVTmuMKTuwO1QyMSuS3yDsKqPLnIHSmTzMlkl2oS3JNZVzOVPHJNPubk4IT8KpZ53MeaiU7CS5nYawJOWpCee9K1LEwSVHZFkVSCUbo3saxbua2tsdHptzcLoVsmn6jY2bh381JXUNIc8NyD24rH1q9vFu0+2XdvdOE4eFlYAZPHAAzUr6rZ9tCsOf9p/8aydTnS6lDw2cNqqrgpETgnPXk1WhlK59Wz2sUdyschJiBwccFeKdbARS4jxlTkEUviK6FzfLNDEY42XIGc02yDvEpRgWVMt+H/6+9dtuhrvG5oSRtLBGxKo2Nobp3JNYmmwrFczEglpHyGB4xVie+ieIrIxDABU2jr6k1BDPbwXCxkgE5IBP60r3kmwjdJonvrkWxB58vOTVy1eKazZgwA44A6g9qz9WsnmaIRr8xUNg9SKS1RcgPxtXB/wq1dOw7LkT6lnySwOF4Gev8qWTPnJHJ0UjcPrUs0aKQScp2I7/wCc1njdJOw28EnkUap6Ep3L0cwSMj7yD19SP/rVDFKzTZ2kt39KR4DHEwBxhgR7/SnBjFHJIm5XVcHsdxJokgTFuLvy7aXcW80yAjjjbjnn1qrNKJwhbk98nrVWZy0Qy2Nw6damhAKrHgmTIVT2NZqLTuy9ETr8sZY5OR26ik+6o3EZJ6e1TyYErRj5gg3N2x0qvLIjTsI/uqeO+Kq/REjZrlwjo4zGQMevHSnabKp8zcw2jpz3qFlDuAvLH1pwxbqQv3upxRbW476WJ5J44rwr5haMnAJ9K0vE1zCmj2drDJlixkbrznjJHqefwrmCcy/MAc85z/Okv5neIB26HPNZOVk0Ll95Mr7mkIRck9sVfkYoViYuWxkbeue386g8PrHJeL5rhEzyT2pdWu0Fwzw8YPBHfHes6XuRv3NW7y5RzPKjbM5YHp/So7iR/tBV12FevsfSoY5meZmLZLfMT7+tMV2eVmHzZ5O49a6lZol6FkzSxqCBtGN3PWq3mSSAkF89zUTNhsklj6ntSJcFW4XjPGR1osLcsSSeXEI8AbhyR1akRysWMYP8qiaXz5HeQBGySMDj6VGjlmyDx6Uuoma1ncYiLSD92o59/QfU02a8RIW3L8xJyR0+lVXWTZAsalvlMhH44B/Ssq9um2sjqck557VMthRjcsbjIxwDkHPNSXd4rw7PLO8DqKp2swWHHVjznvUN1JGSzLuwBzn1rKVNSSci1uLYtmUuwzxgD0qxLIWYHOFB65xzVFpSgwBhiOOOlMlnBUHBAH61qlyqyE9XcsB/nbLbiecmoGuDExCE8gjH86qs52nO7noKY0km3DcY4AFJsC2k4xtB4AyfahZVkBIGOOTVNlUJl2wD1GetHmcYXjimtCHqOJAkOOuakL7FOcEmqZlx8xIIqKa4JHJI9qLiY+dwAWJ78CmebvXOMcdaoNLls8k+9IZzgjgCpGyaeXaNozVVpCyYPOPSo/MDHIz/AI1FIR68D9aQXSJWlOBzuxwBUJkVFAHLd6glb359u1QFyHxu4Hc0Gdy1JP0B496qyzjB71FczqDhGDH6VTeVmYAZJ9BSuJsnkl65Jx6VXLSyN5cQJJ/SpobOaU7pvkXr71fSNI12oABWUqi6E3MuaJYEwTmQ/eNU25yatXz7pTzwKqkAYrLzN4KyGt2pYmRZUaRd6Agsucbh6ZpDyKaRQWdLYWcGoQGe18Ps0OSAzXpUHHXGfSsTxHaizvEjNmLQmMExCbze55J7fStCxvo0s7Bp4rjZbtJbuVX5GSQHOD/eHpVHxIY0nt7WNZy1rCIWedNjuck8j2BwKtIS3PpueJTbrIS2FH3SO4qbSJlt5llkRpbd1wdvBK+h9uKiuL37VblAPlALYA+7WdFqLR22XXkfKEHWvQnLlZlFNqxYnMLPIpZHIO5SO2e1ctJKqayk824Ih24HcDmtTT1PmFnUYY5AFJf6al2pltw29QcjPWsWnbTc66Uoxk7nSxIZXLvIoCxbxz644/Wq6FRJtUBnboD29Ko2cLR2SmWUs5XdknqMcVJFIIsSlsHBxjqP88Vsc9rPQ0jbyeUOipJkAsOgAycflVON40KKDknP/wCqo7jUs25Tcclt5Pv04/Oqlu6MYwcNjnINSm2xq9tTZina4Y5IUx8jcccf1qjqN1JGpYjLPw2DxiqU7tDKdmQOoJ6VXjke5k2y5APtTavoJR6mlEg+yNJjMmMc/Sm2tx5VurPg7G4x0qG5fy0VY3Yk9RjpVYSMUK4yOpBpSjfVAtdy1LqTfZXQE5djnH+elJby7Ewi7j6nsfWs884ATABHNWlceUDxg8DmlGDReltDQu2WCdVTAZVyT74qutyFz3Y1QhZ2mJOWAzye9TvGYyzuu3jqe9NrqyWktBXkBmLZxgDoOtVr98EhWBBGRii0vIRdNHMQMjjNVNauIlJ8g4Y8cd6wqS3GtJWGafcTBmWBVJfj5qWRnmceYAhHUDvUdjH+43ZG4cmkaQ7uR1OPenGnFJXNOa7bRcRljUDqzDmnsRxljg9dtRW0aMHkkkCKgHy9257U6a/jELxosYUtnJ6jitb23Mne42SXex2gYxgU6MptJ/IE1nPJwDjANOi3PIqg4yfWi42kXLkfdTOAe/pUbSpHgKcj+dVZGwxUtkg+vBpu4lw0mFA7UN6iOl0y8jttcgjnUPBHGiyIe+ASR+tYWqzxSJIVJwMjJqsJS9w7sxO45yarMVnmS3aRUjLfO57CsZSbXKJJJ3HROUUF+OOM1FK4ZuoCjnNJevGkvlxPvTPBIxketQSSxkZbkegNaJW0RdyVWeQM2crng0+V1IVf85qmLnAyRx2FQNOXYuq4+tF10J1LknyyA7tuPWo/tEcbN/FIBwfSqUjlQpY7mPQVB5rKTuPPoKWoXLbzs7jJBHWnwIJ84OxAMlqoMwVcuPmPUVHNfyRRFIj5e7jPtTvYjmJ55FD7VY4H5mq7Tlj1x7ZqgJTjP3qY0pycHB9RUjci7O6rgE/MR0qq0wJ4+4PWqzuMnJ470xpVAyxxnoBQTzFlps8JnPr0wKrvOQTyD6YqCSTIGAxLH7g61ZtrCSYDzf3K+mMk1EpxjuQ3cqvORkZ69h1ojt7mbom1fVuK14bWC3zsUEg9Tyaex9a55Vr7CM2PTEXmRyx9BwKsrGkYxGqrj2qUn0qNv61m5N7gNbnPpUNw+yMnNS4zVLUXwm0d6EhpXMxzk5NMbtSnvmmE1djpQme1HJ4HNJTopXikWSJirodysOoI70AbEP2e/wBItbWS7Nm9uzkh42ZJMnO7K9x05qtr80c0trFDJJMtvCIjM6kGQ5Jzg845wPpWtY3TWukQTXGs31r57uViiiDZ55br603XbIXMX2pdUmvZEtxOvnR7d0RbHBz2PUVXQR7rbXgQzrGcQsc4Ycgdv51Uuo+srcAjcg9RVpoYn+QFxNJHvjCjjIzkH8M/lWTqN+7wR27MG8voNvIz7+lejUdlqTBXkTwzjb8pO/Hap9IvBBcSIwBjZcc+1ZtsGk3cDd14FSQRyz3DLDgFAWZmOAAOprOEW3zGjS1RqXcySuxJAA6AdKol8Kgz1+WqckwcDB4zjrT/AC5JcsCAFzg54oi23YSjYZfXaooZwGbuD3FWYLoOgMceAy8jpWRen5GLg7lPGBV6xYywqxGzPBFU5alSilG5cxLPGjt8kbNtyabDei3nYnLY4U9efWrDm3lgzJOwuEG1R2xWbJCvnFYySM8Z71F3Zakpp6MswXDvI0jISg60Sy7G6FVPK5FT6dDIsqxxjdJI21Qad4jikstS8iaPZIgw4Pr6USbjsZqScrFB32Phvy9atwQZtTKxQKeQB9axZJP9IwfTOCelIt24LKh+Xuc9aandGjjpodKnkJZAJIPNJ4UcYHH86p6rcfa7qKKMFQFCgE1nfbrcpiZSroMZHeqIulaTzy/AO0DHP1qHO7sSo9SxfQLBuBAZznIbt6Y96oQwsDkAFjnk9qnnna4lD5YjoMio/P25J5wcc1e+pSbLgVlby2xuHpTJoioLBiOOvpVWK4IfcTgnse1SC4UsQWyueopN9Q1IrfUQzukQ3v8AdJI4qYxBG5IZj+VQulvFITCfmYbj2AqIypGxJLOSO1CVhNroWeWl5Iz6U+eR4ypQA461ShmflsfMfWnZc4LHqccUai21FcTIRJIjKvUBhjPpinWz/aZCZGA9B60atdgmPzZDwAgJPQdKma3SRFVJY9y9dpqbpO1xOd0XL9rSOGJLcmSYj5ycYH0rn2uY7eabdwcbVJGTUt9I1tEFZ8gHP41z4uVnuHfqq9/U1MpOcggrIvLOFILck9zSSOdpbjZ27VReQByep689qhluHkKgsAB+tPYdy89xhR3HaoTO7EZbAHIAqkWz1NJLcKq4zTRNy0ZcEu/Lfwk9qi89VBYksetZ0lxuJwScHNQvMSOW47Clcm5oS3fmNjp7+lVpZBk4YsB3qk8p3dyaljtrmZeEIU9C3AqXNIVxz3BxjPy+1RGZmYKi5b0q9FpKhGaaQsR2HAzVy2gjiGI1C9vrWLrdhXM2OxuZACSqD3q7FpsSurSM8jAdD0q8BSH1rGVSTEM2qv3VA/CnKcPQeOtNJ+bNTuA2QkMw96iLflUlwf3rVCenpQITvTCQPelJyeKa3HNNIANY17JvlPtWrM22MmsOU5fNUkaU1qR8U3jJpxprHAqjYaaQ0eppM5oA6TSGVNKhOqPY/Yy7fZxcIzPn+LbtwQufWodZvLuEyxMbVormJBFJAuF8kHhU9Bkc98iqttf2b2UVtqVrLKsBYxSQybWAJyVOQQRml1uRpDZEQrBamAfZ4w24hNx5J9Sc0xW1PcJrqRE3lyZAchu44/8A11WwHiUuRuPSqlzdEwbGPemwvuXeSdo4Fdzld6F20NORPKs3VTl2H3h2qBGe0tIi4PmMuSaijuGUsAcqR36UXV0JGXbyPQdBV+ZGt7CJmZiQmWPAA5rZs7xbeznjEeXdQoz/AAnPX+lU9IlhiuxLMpZAM/LwSaZc3GHlKIoB5GTWcpKMboHq7EE7hmBI68D0rUt7BlleKUFRtyr9B7H6VmaYrXF0BMvmQSHaVBxj0P4Gt6Yy6bDcWcE+6KQbHbqSuckD0GRThG8bsmpO2iMa68yzlPljzo2OCp6iobFmk1EGQFUBPB9abf3Ai3DIC7c5qjY3LNukbO4nIz1xWKai7FauJ1k8r22ZY8B1IKt3H0rFvrp5ZC8zl2c7ixPemXV1m3w/Ue9ZM9yuCznAFKpPoTThcfdyb51K5zjBxU9raTTITCjuuQGIHGTVSzwx82eJzG6Fo93Gff6VZj1AQfKZGhz8w2nAz2q6bUVeRcn0QuoQJBc+UZQRgZY8c+n9KrxsskwwDtXjjoTVK6mM84IYlSfvMetTPcR21qdrruP8Peq3dyLtIus7yXPlRqWkzgKKXUrGWzSIXBxK4J2/jWfpt2nnlzLsbGct1JqO81BZZWYuZD/ewetHPp5gr3JgeDtOR0qSJlEecgHvVSwnbenmbeWztbpVnULpFMgAXLd1xii6tqDl0RA8+5ti4HPJNI0yoCgGTn0qmkvmMTGuBnFNmuVicDAL+nancWxdW7VMblAGcZPb3rT+1W1qrSeaoGMrk5z71yl3KQwLgEnmq0kpeQZwBiobfQmVmX9TupL2XzHysAPyj196qpeNBkwM27OMdvrVeaYlArn5R05qv5qhsDhe5NFkx83QsXMlxdE+dISvp0FCkRLhGAIHUVTmus52nOOlQyTkgZ4pXjHYV2W2mXPLZpjT46YBqCKOeclbeMtjuBj9auRaNM4zNIqew5NQ6kUK5WknwPfr9aqs7ytwpb2AroIdLto8bgZD6sf6VbVERcIoUD0FYyr9guc3FY3Uwxs2L6vxVxdIjRAZZGZvbgVrnp7mopDxWbqSYjnUHlXLqR1rbjwsaD2rHvAFv1J6Eitktxnt2onqSt2Okb92q+rZNIvXpTG+/wB+BT1qBj/4hSE8kUo601z1oARjzmo92Dx0pSevNRk8+1MB1x9/PqBULntippv4T3xUDcj0NAg4FNPXmlzkcimkcYpgVL98RY9ayT34/Grt++ZNvpVEnrVxRtBDSfSmnmlPJpORTNBMelLEI/OTzt3lbhu2dcd8e9IDToInnmjhiGZZGCKvqSeKYGmR4fx9/VfyjqHWbq1uTZpZCYQ28HlAzY3H5mOePrUz6dpkLtFcav8AvlO1vKt2ZQe4znmqepWTWUsYWVJoZUEkUqZw69Oh6HIIxTYj1e7c3EvCkHv6VLEZQrocYXG2pZ2ERJABPpUEDqxZpQc+xxiuxJRY+a6JZS2cDHTFNJWNApyxbpjpUc8vlkt1FQxTs2SF68c1V+grmnFcQJBli4l6cciqlxJMBmRCOelWLaFZFQsTtYc9sVWmjeWTylwFX7zmo9kQppMu2iTsPOhGFx2qw92w5lY7h1BrJTV200eU43x/wsKydV1s3TlYMKT1Y9qhzcfdJtzPyLOo3yXN0U/5Zg/MP6VLZOXuEJLbTxz6VjafCGDux5+vNbFlrdqsSxyxEMhxuA4NLlstS3K2iLupyRxwgnGR3rnoJTqF6IyQsSnv/F/9arWs3Mczq4OI+vWsmzkD75Djy8n8ahQ5pXYKbUTenvfJlOcTSjgc/KBVTLXdwHkwSThQOgrNluh5W2JdrN1JHAFOt714kKKEOOjN1ra/Vk3si3MTHcCNCCy9z0FVi4MuXILdM9apGUiRzJIWJPJ9aRXJbjgU+YLl6PazgOwGTjntUt7dJEqW8TByORjoKyZZgr7RndnvSfMoLv8AxHqam4NmkJ0VcuRgdeagmn3glBsQ4HJyaoGTcx7j2qF5WccZJHTFS5IVzYmuXtY1O5GJ7VSaZSxdskn1qmkcztiOKR29gauppV9Jtyixj/aPNQ6qQrkMswJGePaq7zdcdO3Na8ehN5m6W4z3O1f8auxaXaRgfut59WOTUSrJCOX3PLgIrMx7AZNW4NJvJVBZAgP94/0rqEVVGFUKOnAxQemADWTrS6DMSDQkXm4lL47LwKvw2NtCP3cS/jzVk9aBz0rNzbAaAFGFAAHYU1qeetRk/wCFIQzvTc8Up/Km9KAEce9V5TweanPNVpTzz0poTMO9O6c+xFbUf3Ae2Oaxp13zEjqWwK1idqYHU8CrkTEQEkE8ZNSp6moFH6VOmMVJQ5utNJ/nSn9aY/8AOgBjdSKafSlpuaGIdMSVT6VCeaml5iTPvUBJ7UwDOOtMZuDTu2e9QXBCxse9G4GXdHc7emartUrHJqJutaI6orQbTTTqQimMaeOadDJJHcRyQEiVGDLjrkHikJ7UK7Rsrxkq6nIYHBBpAbbXcMzNLceHw07Hc7I0iKzdzt/wrO1S6mup0M0It0jQJHEqlVRfQZ5655reuJvE98kM8UeoRHywGKuQJCP4gvbIrndQlvJbkjUXmadPlImzuX25qnsSkesy3C4JPU9DVaO+VHZXjMikdu1ZP2mST5R16VZtSIpAx+Yg5weldbaluZvRWQ55ZJZANu2Ic89TU9zexRRDy3DN/dxg5pk8gkSZywQ84HasO/fySm2QOW5yD0pNpLQObudI+s2jQKP3iSY6KKjtbxZImkjlGc8qTzXLCZvvKSPqajMqgbQCD65qLu97k6Gvql75sghRgWJ5x2qqpQfd7daz1aNAQgy56nvU9qjSuo2SFf8AZUmhTtqx3stC27APgHJH3sdKjMgwQN3HUCnNYXjufs9uyR9AXwDT4dEvCRvMQB9WqXVinuJSKB2vIGccDoCelSCdVIA6e3StGPw/KzAz3Cr7ICcfnUzeHIWj/wBdIG9eMflWft4iuzFe5HzDPHtTWnBULGrepJ/pXS22h2ccW1081+7NVyK0giwIokUD0FQ8Qg1OPhSdmykbk+u2po7C8lziFgPc44rrwoAOKQ8DtWbxDA5hdDuSwLSRKevJJq0NBJUefcM5HYDAFbh68009al1ZMDPi0ezjxuQu3+0c1aW3hjGI4kX6KKmPWkNTzMBB6DgUhPOR1pTTW56GkA00005uBSUAJnNJk4OetIeDimk80AB9aSg96Zkk0AKx5ximt0680p9aYT+JpgMPXGKaTTm96iPPsaYgz1qpcvtjc+1WWOFOetZ2pPthb34qoq7FLRFS3XfNHntlquzNlgpzgDNQWEeEZ/XgfSnA+Y5J7mqlqKJYjHFTYwtRIMVKakoCcVExpxzTD2oEIeBnmm80N16mkz0xQBJIP3Cn3qDPHNWpF/0Rf96q+3600rgyM/WqeovhAPWtHZheax9RYGfHpxxVKI4asq54qI8mn80w8GqOsQDuaTvS5pODQIQgY5NS2cot7yCZl3rG6uV/vAHOKZ6cVYsPJF9bm6GYBIvmf7ueaYmaF3DZ3t3LcjXVUSsXxMjh1yenHBx7VT125iuZLWOGSSYQQiIzuuGlIJOcenOB9K2r+83X81jrJhks5DmGWEKTAp+6ykdsYyKo+J4BB/ZkSyRylLQKXjOVPztzQxJmnDqCxumEO0nGc109uvyZ+yNk9MsK8+uSVtlb0frXo2lyebp9u4PVBRUqyS0OZPmM67026uFYRyRxZ7Hmq6eG3Zw091uPfatdEaUVzurJlGKfDtsAoMsxPcgjmpodFsY/+WIf/eJNanU0nTpUucn1Arw2VtC37uGNe/AqdVVRx29KDgmkyAKm7ACOTig9gaM9z0pMihsBCcmk+ooz+VJn8qAFBB65opM8kg9aQHmgYZo+tBOelMoELwKQ4zmkPFJ1Bp2AKQtxyfwpDQT3oAb7UmcZ9KCec0hPJ9KYCEn3pD0oNNboM0ABPFNzRk54ppyBQAHr6Uh68Uh6UZpgGeKYc55pxJyaaT1osBG1RN1qVuahc80wGuflOKydSYlUUdSa05W454qgVEt3GG6DmrjoRLsSsPLgwDztxTIRxS3LZYL2J7U6IcdKQyZacKao6Yp6qe9FhjD3ppqYJ/exzQUJ/D0p8pNyBhkilCGptozSdatRFcldf9A4/vVVIGRirZwdPcc/eFVP1pxEMlbajE8ACuelbdIxPUmtjUJNsDDueKxP50PQ3orqI2McdaYae3sajPfNB0Dc4pM+v6UHk02mFh2aeD6ZJPpUWataXPHb6layzD93HKrN9AaBFw6ckTeVdXsEFx3jKs20+jEDAP8AKq11bSW0rRTABhg8HIIPQg9wfWt2SJkvrFzcyRPAAAqQs5k+YkshAw27Pf8AGs7XpV8+CFQFeJCHUHOzLMwT8AQKBXE1IYtOPWu58NsTo1tk/wANFFZ1fhRyQ+JmoOlHaiiubqaBR2oopiGmkHUUUUAgPf600ntRRSYDaUdTRRTQCEc0lFFMBCcZ+tIKKKAGgn8qAB1oooAYetIxODRRQA08qSaaaKKAYMKb60UUxMjY9PrSN3oooGB6H8qbRRTAKY3Jooo6gRNximOoFFFUhFefgGqlv/x9N9KKKvoS9xJx/pH4CrEYGAPaiijogLSqAOBTwBRRVAIf60zPINFFAmNHVqa31NFFUImU/wChS/hVMciiilH4gM3V/wCAdqzMUUUHVS2I3OOlMY80UUzYiY/PSZPNFFMBN2cUmc8UUUhFiC8uoYTFDczRxnOUWQgH8Khj5IzRRSEz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread erythematous plaques, bullae, and erosions are present on this patient with extensive disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31320=[""].join("\n");
var outline_f30_37_31320=null;
var title_f30_37_31321="Classification, clinical features and diagnosis of inguinal and femoral hernias in adults";
var content_f30_37_31321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     David C Brooks, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Ayman Obeid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Mary Hawn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31321/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/37/31321/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernias are among the oldest recorded afflictions of man. A hernia is defined as a protrusion or projection of an organ or a part of an organ through the body wall that normally contains it. Collectively, inguinal and femoral hernias are known as groin hernias. Inguinal hernia is more common than femoral hernia and other abdominal wall hernias (eg, umbilical, epigastric), but femoral hernias present with complications more often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classification, epidemiology, clinical features, and diagnosis of inguinal and femoral hernias will be reviewed. The management of groin hernias (nonsurgical and surgical) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29000?source=see_link\">",
"     \"Overview of treatment for inguinal and femoral hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9465?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Open techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=see_link\">",
"     \"Inguinal and femoral hernia repair: Laparoscopic techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inguinal hernias in children and abdominal wall hernias are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=see_link\">",
"     \"Overview of inguinal hernia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606339728\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groin hernias (inguinal or femoral hernia) were the third leading cause of ambulatory care visits for gastrointestinal complaints in 2004 and visit rates have not changed appreciably since 1975 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of groin hernias is estimated to be between 5 and 10 percent in the United States. Inguinal hernia is more common than femoral hernia and other abdominal wall hernias (eg, umbilical, epigastric) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/1\">",
"     1",
"    </a>",
"    ]. Although femoral hernias account for less than 10 percent of groin hernias, they present clinically with complications (incarceration, strangulation) more often than inguinal hernias. (See",
"    <a class=\"local\" href=\"#H606309980\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hernias are more common in men compared with women, and in whites compared with non-whites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Men are eight times more likely to develop a hernia and 20 times more likely to need a hernia repair compared with women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The lifetime risk of developing a groin hernia is about 25 percent in men but less than 5 percent in women. Women manifest groin hernias at a later age. In one review, the median age at presentation was 60 to 79 years of age for women compared with 50 to 69 years of age for men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6\">",
"     6",
"    </a>",
"    ]. The peak age range at presentation for indirect hernia in women is 40 to 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6\">",
"     6",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H606309980\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Groin hernias are classified anatomically as inguinal (indirect or direct) or femoral (see",
"    <a class=\"local\" href=\"#H606310492\">",
"     'Anatomic location'",
"    </a>",
"    below). In clinical reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 96 percent of groin hernias are inguinal and 4 percent are femoral [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indirect inguinal hernia is the most common groin hernia in both sexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6,8,9\">",
"       6,8,9",
"      </a>",
"      ]. In the Swedish registry, indirect inguinal hernia accounted for 49 percent of repairs in women and 54 percent in men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Direct inguinal hernia accounts for 30 to 40 percent of groin hernias in men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/9\">",
"       9",
"      </a>",
"      ], but about 14 to 21 percent of groin hernias in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6,8,9\">",
"       6,8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Femoral hernias account for &lt;10 percent of all groin hernias and only 2 to 4 percent of all groin hernia repairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Femoral hernias represent 20 to 31 percent of repairs in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6,11-13\">",
"       6,11-13",
"      </a>",
"      ] compared with only 1 percent in men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/9,11\">",
"       9,11",
"      </a>",
"      ]. Femoral hernias occur later in life than inguinal hernias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6,14\">",
"       6,14",
"      </a>",
"      ]. Over the age of 70, femoral hernias represent 52 percent of repairs in women, and 7 percent of repairs in men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606339779\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for hernia development include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/2-5,12,15-25\">",
"     2-5,12,15-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of hernia or prior hernia repair (including childhood)",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Caucasian race",
"     </li>",
"     <li>",
"      Chronic cough",
"     </li>",
"     <li>",
"      Chronic constipation",
"     </li>",
"     <li>",
"      History of abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Abdominal wall injury",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Family history of hernia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women, a retrospective review of data from National Health and Nutrition Examination Survey (NHANES) also found that rural residence and greater height were independently associated with a higher incidence of acquired inguinal hernia in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/12\">",
"     12",
"    </a>",
"    ]. In patients with low body mass index (BMI) &lt;20, there was a relative dominance of women, femoral hernias, and emergency presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/12\">",
"     12",
"    </a>",
"    ]. Although women accounted for only 8 percent of all groin hernias, they represented 30 percent of repairs in the low BMI group.",
"   </p>",
"   <p>",
"    Although groin hernia may be more difficult to diagnose in overweight patients, the available evidence appears to indicate that obesity is a negative risk factor for groin hernia in males and females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/12,26,27\">",
"     12,26,27",
"    </a>",
"    ]. A large observational study from a Swedish hernia registry involving 49,092 patients found a lower prevalence of groin hernia in obesity than in the general population (5 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606318076\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groin hernias can broadly be classified by etiology (congenital versus acquired) and anatomic location. Congenital hernias typically occur in the groin, although they may be found in other locations such as the umbilicus or femoral canal. The simplest and most common anatomic system separates groin hernias into direct and indirect inguinal hernias and femoral hernias.",
"   </p>",
"   <p>",
"    The term \"sports hernia\" refers to groin pain related to athletic participation, but is not necessarily associated with an anatomic hernia. Sports hernia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20373?source=see_link\">",
"     \"Sports-related groin pain or 'sports hernia'\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606310426\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernias are classified by etiology depending upon whether the hernia is due to a congenital defect or is acquired. Congenital hernia is a result of abnormal development whereas acquired hernia is due to alterations of otherwise normally developed tissues that lead to weakening or disruption. Males and females exhibit differences in the anatomic development of structures in the groin, which impacts the nature of hernia each develops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368943787\">",
"    <span class=\"h3\">",
"     Congenital hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital inguinal hernia is due to failure of the processus vaginalis to close. The processus vaginalis is an invagination of parietal peritoneum that precedes the migration and descent of the testicles in males. The same invagination occurs in females and the portion of the processus vaginalis within the inguinal canal is called &lsquo;the canal of Nuck&rsquo;, which usually obliterates around the eighth month of fetal life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In males, the gubernaculum (caudal genital ligament) normally migrates through the internal inguinal ring into the inguinal canal and through the external ring into the scrotum to allow descent of the testicle. Later in development, the upper portion of the gubernaculum degenerates and the lower portion remains as the scrotal ligament securing the testicle to the lower part of the scrotum limiting its mobility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/29\">",
"       29",
"      </a>",
"      ]. Once the testicle has descended, the internal ring normally closes. Failure of the internal ring to close combined with failure of obliteration of the processus vaginalis provides the necessary defect through which abdominal tissues can pass (eg, small bowel, cecum), which can occur during childhood or not until adulthood.",
"     </li>",
"     <li>",
"      In females, migration of the gubernaculum does not take place. The upper portion of the gubernaculum in females forms the suspensory ligament of the ovary running from the mid-portion of the fallopian tube and terminating just beyond the external ring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/30\">",
"       30",
"      </a>",
"      ]. The lower portion of the gubernaculum is bent into an angular form. Cephalic to the bend, it becomes the round ligament of the ovary (ie, ligamentum ovarii proprium) and caudal to it, the round ligament of the uterus (ie, ligamentum teres uteri). Thus, the inguinal component of the gubernaculum remains in females as the round ligament, whereas it degenerates in males. The round ligament runs through the internal ring, through the inguinal canal, and ends in the of fat of the labium majora, or terminates just outside the external ring without attachment or extension to the labium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The internal ring is narrower in women and may explain the lower incidence of indirect inguinal hernia in women (see",
"      <a class=\"local\" href=\"#H606339728\">",
"       'Epidemiology'",
"      </a>",
"      above). The ligamentous structure found within the inguinal hernia sac in female patients is often erroneously identified as the round ligament. However, detailed anatomic examination identifies this structure as the suspensory ligament of the ovary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/31\">",
"       31",
"      </a>",
"      ], which helps explain the occasional presence of the fallopian tube or ovary in the hernia sac in female patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606309543\">",
"    <span class=\"h3\">",
"     Acquired hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired hernias are due to a weakening or disruption of the fibromuscular tissues of the body wall allowing intraabdominal contents to protrude through the acquired defect. Acquired groin hernias can develop as a result of inherent connective tissue abnormalities, chronic abdominal wall injury, or possibly drug effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissues of the groin may disrupt as a result of inborn or acquired biochemical or metabolic processes that weaken connective tissue due to disturbed collagen metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A tendency toward hernia formation may be evident in the patient history or family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/3,25\">",
"     3,25",
"    </a>",
"    ]. Abdominal aortic aneurysm, which is linked to connective tissue abnormalities, is also associated with groin hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. Although rare, a number of inborn errors of metabolism, such as abnormalities in collagen type I and III synthesis can be the underlying cause for the development of hernias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/37\">",
"     37",
"    </a>",
"    ]. Weakening of the tissues may also result from pharmacologic effects. Chronic glucocorticoid administration is associated with thinning of skin and weakening of the soft tissues which may predispose to hernia development. Other factors that affect the integrity of connective tissue include older age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/5,12\">",
"     5,12",
"    </a>",
"    ], and smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic overstretching of the musculoaponeurotic structures due to increased intraabdominal pressure or abdominal wall injury is another factor contributing to acquired hernia. Elevations in intraabdominal pressure can also result from chronic cough, constipation, strenuous",
"    <span class=\"nowrap\">",
"     exercise/activity,",
"    </span>",
"    and pregnancy. Direct hernias occur with unusual frequency in athletic individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The relationship between inguinal hernias and intermittent straining or heavy lifting is not clear; some studies suggest that the incidence of hernia is no higher in professions performing heavy manual labor than in sedentary professions, while others have come to the opposite conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/27,41-43\">",
"     27,41-43",
"    </a>",
"    ]. Pectineus muscle atrophy with age may contribute to femoral hernia formation. The higher incidence of femoral hernia in women may relate to comparatively less baseline muscle bulk compared with men, or a weakening of the musculature from childbirth. However, in one small study, multiple deliveries were not found to be significantly associated with the development of hernia in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606310492\">",
"    <span class=\"h2\">",
"     Anatomic location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groin hernias are classified according to the anatomic location of the abdominal wall defect. Several classification schemes for groin hernias exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/34\">",
"     34",
"    </a>",
"    ], but the simplest and most useful system identifies groin hernias by the anatomic site of the tissue defect separating groin hernias into indirect and direct inguinal hernias, and femoral hernias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Indirect inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect inguinal hernias are the most common type of hernia in males and females. Indirect hernias protrude at the internal inguinal ring, which is the site where the spermatic cord in males and the round ligament in females exit the abdomen (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"mobipreview.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    ). The origin of the hernia sac is located lateral to the inferior epigastric artery. Indirect hernias develop more frequently on the right in both sexes, which is thought to be due, in males, to a later descent of the right testicle, and in females, by the asymmetry of the female pelvis. (See",
"    <a class=\"local\" href=\"#H368943787\">",
"     'Congenital hernia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most indirect inguinal hernias in adults are congenital, even though they may not be clinically apparent in the neonatal period or childhood. A shutter mechanism, which is postulated to close the internal inguinal ring to a slit may be dysfunctional in patients with a patent processus vaginalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Increases in intraabdominal pressure in association with reduced muscle tone or other connective tissue abnormalities can then force abdominal contents through the widened internal ring into the inguinal canal resulting in a clinically detectable hernia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Direct inguinal hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct inguinal hernias protrude medial to the inferior epigastric vessels within Hesselbach's triangle, which is formed by the inguinal ligament (Poupart's ligament) inferiorly, the inferior epigastric vessels laterally, and the rectus abdominus muscle medially (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"mobipreview.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Direct inguinal hernias occur as a result of a weakness in the floor of the inguinal canal. This weakness appears to be due to connective tissue abnormalities in many cases, although some may occur due to deficiencies in the abdominal musculature resulting from chronic overstretching or injury. (See",
"    <a class=\"local\" href=\"#H606309543\">",
"     'Acquired hernia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Femoral hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral hernias are located inferior to the inguinal ligament and protrude through the femoral ring, which is medial to the femoral sheath and lateral to the lacunar ligament (",
"    <a class=\"graphic graphic_figure graphicRef61841 \" href=\"mobipreview.htm?7/18/7461\">",
"     figure 1",
"    </a>",
"    ). The femoral sheath contains the femoral nerve, femoral artery, and femoral vein. Femoral hernias are acquired. The femoral ring can widen and become patulous with aging, and following injury. Femoral hernias are more common in women.",
"   </p>",
"   <p>",
"    Although femoral hernias are the least common type of hernia, 40 percent present as emergencies with incarceration or strangulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H606339728\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Incarceration and strangulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606309980\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groin hernias have a variety of clinical presentations ranging from a finding of a bulge in the groin region on routine physical examination (with or without pain), to emergent, life-threatening presentations due to bowel strangulation. Incarcerated or strangulated hernias can present as acute mechanical intestinal obstruction without obvious symptoms or signs of a groin hernia, particularly if the patient is obese. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women are more likely to present emergently due to a higher incidence of femoral hernias, which are more likely to strangulate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/5,9,11\">",
"     5,9,11",
"    </a>",
"    ]. Another explanation may be that women presenting with hernias are older and exhibit smaller hernia defects due to relatively smaller internal inguinal and femoral rings. In a study from the Swedish hernia registry, emergent hernia repair was needed in 17 percent of the women (53 percent femoral hernias) compared with 5 percent of the men (7 percent femoral hernias) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common symptom associated with hernia is a heaviness or dull discomfort in the groin, which may or may not be associated with a visible bulge. Groin hernias in women can also result in vague pelvic discomfort. Moderate to severe pain with hernias is unusual, and, when present, should raise the possibility of incarceration or strangulation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Incarceration and strangulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Groin discomfort is most pronounced when intraabdominal pressure is increased, such as with heavy lifting, straining, or prolonged standing. Very little pressure is needed to create the discomfort, which resolves when the patient stops straining or lies down. This pain is due to constriction of the contents of the hernia (eg, bowel, fat) at the neck of the hernia sac. Typically, discomfort is more prominent at the end of the day or after prolonged standing. Thus, patients who work in manual or physically active professions will notice the discomfort more frequently than sedentary workers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/27,41,43\">",
"     27,41,43",
"    </a>",
"    ]. Pain with standing or straining may also arise from stretching of the ilioinguinal nerve, which is typically described as a radiating &ldquo;twinge&rdquo; when the nerve is stretched with prompt dissipation of the pain when the stretch is released.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549554470\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common physical finding in adults is a bulge in the groin (",
"    <a class=\"graphic graphic_figure graphicRef73484 \" href=\"mobipreview.htm?39/12/40128\">",
"     figure 2",
"    </a>",
"    ). Patients will frequently be aware of the bulge and bring it to the attention of the examiner. In many cases it is easier and more reliable to demonstrate a hernia bulge with the patient standing, although some hernias, particularly strangulated hernias, can be appreciated while the patient is supine. Two-thirds of groin hernias are located on the right side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/8,13,47-50\">",
"     8,13,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination for hernia is best done with the patient standing and the physician seated in front of the patient. Observation of the groin will occasionally reveal an obvious bulge. This can be confirmed as a hernia by placing the hand over the bulge and asking the patient to cough or perform a Valsalva maneuver. When coughing, hernias produce a distinct, soft impulse that increases the protrusion. The sensation is distinct from the firmer impulse that is felt when the intact abdominal wall is tensed with coughing.",
"   </p>",
"   <p>",
"    If a visible or palpable hernia is not evident, additional maneuvers in male or female patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male patients &ndash; Many groin hernias in men are obvious on physical examination. Smaller hernias can be identified by invaginating some of the redundant scrotal skin into the inguinal canal, traversing as best as possible the external ring. When the patient is instructed to cough or Valsalva, occult hernias may be felt extending into the canal and touching the tip of the finger [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/51\">",
"       51",
"      </a>",
"      ]. Using the index finger, the examiner places the finger at the base of the scrotum, gently pushing and directing the finger toward the pubic tubercle. The finger will rest adjacent the spermatic cord, and the fingertip will be just within the external ring. There will always be some degree of pressure against the finger with this maneuver, but a true hernia can typically be felt as a \"silky\" impulse tapping against the finger when the patient coughs or strains.",
"     </li>",
"     <li>",
"      Female patients &ndash; Groin hernias in women often do not have a visible bulge. Moreover, the examination used in a man (ie, invagination of scrotal skin) is not possible in women. In women, the layers of the abdominal wall absorb the hernia impulse making the external ring difficult to locate. Ultrasound or diagnostic laparoscopy may be needed to detect hernia in women. (See",
"      <a class=\"local\" href=\"#H606315346\">",
"       'Identifying occult hernia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The femoral region should also be examined with particular attention to the area medial to the femoral canal. The space is found by identifying the femoral artery pulsation caudal to the inguinal ligament in the upper portion of the thigh and moving medial from it toward the pubic tubercle. Femoral hernias may be difficult to clinically differentiate from inguinal hernias preoperatively on physical exam when located overlying the inguinal ligament or superior to it. (See",
"    <a class=\"local\" href=\"#H606315541\">",
"     'Differentiating inguinal from femoral hernia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incarceration and strangulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incarceration refers to trapping of hernia contents within the hernia sac such that reducing them back into the abdomen or pelvis is not possible. Reduced venous and lymphatic flow leads to swelling of the incarcerated tissue, which can be bowel (small, large, appendix), omentum, bladder or ovary, or other structures. As edema accumulates, venous, and, ultimately, arterial flow to the contents of the hernia sac can become compromised, resulting in ischemia and necrosis of the hernia contents, which is referred to as strangulation.",
"   </p>",
"   <p>",
"    The risk of incarceration and strangulation is overall low, estimated between 0.3 and 3 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. In two trials that compared elective repair of inguinal hernias with watchful waiting (control), strangulation occurred in the control groups at rates of 1.8 per thousand (0.18 percent) and 7.9 per thousand (0.79 percent) occurrences per patient-year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Risk factors associated with incarceration, and the need for emergent hernia surgery, include advancing age, femoral hernia, and recurrent hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/52,53,57\">",
"     52,53,57",
"    </a>",
"    ]. Although all groin hernias can strangulate, femoral hernias appear to be more predisposed to this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, an incarcerated or strangulated hernia may be painful to palpation. The patient may also be febrile, and erythema of groin skin may be apparent. Strangulated hernias may manifest with symptoms of bowel obstruction, including nausea, vomiting, abdominal pain and bloating, and possibly systemic symptoms if strangulation and bowel necrosis has occurred. Generalized peritonitis typically does not occur since the ischemic or necrotic tissue is trapped within the hernia sac. However, if a strangulated segment of bowel is reduced (spontaneously or unwittingly), generalized peritoneal signs may be present. The clinical manifestations of bowel obstruction are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of cases, a diagnosis of inguinal or femoral hernia can be made based upon history and physical examination, without the need for further studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/58\">",
"     58",
"    </a>",
"    ]. Although the data are limited, one study reported a sensitivity of 75 percent and specificity of 96 percent for a diagnosis of inguinal hernia on physical exam by surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H549554470\">",
"     'Physical findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When the diagnosis is not apparent, imaging can help to identify occult hernia, differentiate inguinal from femoral hernia, and distinguish hernia from other clinical entities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. Imaging is also important for evaluating patients for hernia complications. In the absence of suspected intraabdominal complications, we suggest groin ultrasound as the initial diagnostic modality, because it is noninvasive, and inexpensive, and overall has a high sensitivity and specificity for hernia (confirmed by surgery), particularly in the presence of a palpable mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/65\">",
"     65",
"    </a>",
"    ], distinguishing hernia from other inguinal and scrotal pathologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60,64\">",
"     60,64",
"    </a>",
"    ]. Other modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and herniography (peritoneography) may be useful under specific clinical circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H606315346\">",
"     'Identifying occult hernia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H606315541\">",
"     'Differentiating inguinal from femoral hernia'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H606316485\">",
"     'Evaluating hernia complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606315346\">",
"    <span class=\"h2\">",
"     Identifying occult hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the best initial diagnostic modality for identifying occult inguinal hernia in patients with suggestive symptoms but no detectable hernia on physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60,65\">",
"     60,65",
"    </a>",
"    ]. In a systematic review and metaanalysis of studies evaluating occult hernia, ultrasound and herniography (peritoneography) were most often used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60\">",
"     60",
"    </a>",
"    ]. Herniography (peritoneography) involves the injection of contrast into the abdominal cavity with subsequent radiographic imaging of the groin region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60\">",
"     60",
"    </a>",
"    ]. In the metaanalysis, pooled estimates for sensitivity and specificity were 86 and 77 percent for ultrasound (six studies), 91 and 83 percent for herniography (16 studies), and 80 and 65 percent for computed tomography (two studies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60\">",
"     60",
"    </a>",
"    ]. Although herniography may be slightly more accurate, it is invasive and is rarely needed given more readily available and noninvasive imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. If imaging fails to identify the suspected hernia or an alternative diagnosis, diagnostic laparoscopy can be used to definitively identify or exclude a hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/58\">",
"     58",
"    </a>",
"    ]. In one study, laparoscopy identified undiagnosed inguinal hernia contralateral to the operative side in 11 percent of the patients undergoing laparoscopic inguinal hernia repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/61\">",
"     61",
"    </a>",
"    ]. On the other hand, herniography, where available, may eliminate the need for surgical exploration in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606315541\">",
"    <span class=\"h2\">",
"     Differentiating inguinal from femoral hernia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing inguinal from femoral hernia can be difficult, particularly in obese individuals, and has clinical implications since the location of the hernia impacts the approach to treatment. Watchful waiting may be an option for asymptomatic or minimally symptomatic inguinal hernia, but is not recommended for femoral hernia due to the high risk for complications. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29000?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of treatment for inguinal and femoral hernias\", section on 'Surgery versus watchful waiting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most hernias, the location will be obvious on physical examination; femoral hernias most commonly present inferior to the inguinal ligament and medial to the femoral artery. However, in situations when a femoral hernia location cannot be definitively excluded on physical examination, we suggest additional imaging. Ultrasonography of the groin may be particularly useful if confusion exists as to the location of the hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT of the groin region can help differentiate femoral from inguinal hernias. Sufficiently thin slices using multidetector CT may allow localization of the hernia sac. If the hernia sac extends medial to the pubic tubercle on CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/69\">",
"     69",
"    </a>",
"    ], a diagnosis of inguinal hernia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87220 \" href=\"mobipreview.htm?37/1/37908\">",
"     image 1",
"    </a>",
"    ) can be made with certainty, but a hernia sac located lateral to the pubic tubercle associated with venous compression suggests a diagnosis of femoral hernia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87219 \" href=\"mobipreview.htm?28/0/28679\">",
"     image 2",
"    </a>",
"    ). A study that evaluated the CT appearance of 215 patients with groin hernia found that the combination of a localized sac and venous compression was more often associated with femoral hernia compared with inguinal hernia (100 versus 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) appears to differentiate inguinal from femoral hernia with a sensitivity and specificity of more than 95 percent, which is superior to computed tomography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/59\">",
"     59",
"    </a>",
"    ]. However, cost and lack of uniform availability limits the practicality of MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606316485\">",
"    <span class=\"h2\">",
"     Evaluating hernia complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with nausea, vomiting, and abdominal distention associated with a history of groin pain or mass, bowel obstruction due to bowel incarceration or strangulation should be suspected. For most patients with incarcerated hernia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    strangulation, additional imaging is generally not necessary prior to surgical exploration and repair.",
"   </p>",
"   <p>",
"    For patients with clinical features of bowel obstruction in whom the diagnosis of groin hernia isn&rsquo;t clear and who do not have indications for immediate surgical exploration, computed tomography (CT) is generally more useful than ultrasound. Although obtaining CT scan may not alter the management plan for exploration and repair, it may add valuable information concerning the organs involved or the extent of bowel strangulation. Features on CT associated with bowel obstruction are discussed in detail elsewhere. The clinical features and diagnosis of bowel obstruction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of inguinal hernia includes any pathology that can produce pain or a mass within the groin region, including soft tissues, lymphoid tissue, bony structures, associated vessels, or structures associated with male or female reproduction. For most patients, groin hernia can be distinguished from other inguinal and scrotal pathologies on physical examination, but when this is not the case, ultrasound is recommended as the initial imaging modality.",
"   </p>",
"   <p>",
"    Acute and nonacute scrotal pathologies can produce groin mass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    groin pain and may appear similar to groin hernia. The pain associated with testicular pathologies is more likely to be localized to the scrotum instead of the inguinal or femoral region. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/51/5942?source=see_link\">",
"     \"Evaluation of nonacute scrotal pathology in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute scrotum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testicular torsion",
"     </li>",
"     <li>",
"      Epididymitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonacute scrotal conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hydrocele",
"     </li>",
"     <li>",
"      Varicocele",
"     </li>",
"     <li>",
"      Spermatocele",
"     </li>",
"     <li>",
"      Epididymal cyst",
"     </li>",
"     <li>",
"      Testicular tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Orthopedic causes of groin pain include osteitis pubis, sports hernia, adductor muscle strain, lumbar radiculopathy and hip problems. A groin bulge will be absent, but the nature of the groin pain may raise the question of occult hernia. If ultrasound is unrevealing, magnetic resonance imaging (MRI) is useful for differentiating inguinal hernia from musculoskeletal causes of groin pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31321/abstract/59\">",
"     59",
"    </a>",
"    ]. The evaluation of these conditions is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    Aneurysm and pseudoaneurysm of the iliac or common femoral arteries present as a mass in the pelvic or groin region, respectively; however, these are pulsatile, are rarely confused as a hernia, and can be easily identified on ultrasound. On occasion, a thrombosed aneurysm may present as a nonpulsatile mass, or a vascular infection will present with overlying erythema, mimicking strangulated hernia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=see_link\">",
"     \"Iliac artery aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/62/42977?source=see_link\">",
"       \"Patient information: Inguinal and femoral (groin) hernias (The Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hernia is defined as a protrusion or projection of an organ or a part of an organ through the body wall that normally contains it (",
"      <a class=\"graphic graphic_figure graphicRef61841 \" href=\"mobipreview.htm?7/18/7461\">",
"       figure 1",
"      </a>",
"      ). Congenital hernias are due to lack of closure of the processus vaginalis. Acquired hernias are due to a weakening or disruption of the fibromuscular tissues of the groin. (See",
"      <a class=\"local\" href=\"#H606318076\">",
"       'Classification and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Groin hernias are classified by anatomic location as inguinal or femoral. Inguinal hernias are further divided into indirect, direct, and femoral. The sac of indirect hernia protrudes lateral to the epigastric vessels (",
"      <a class=\"graphic graphic_figure graphicRef61841 \" href=\"mobipreview.htm?7/18/7461\">",
"       figure 1",
"      </a>",
"      ), whereas direct hernias protrude medial to the epigastric vessels through Hesselbach&rsquo;s triangle. Indirect inguinal hernia is the most common type of groin hernia in both men and women. Femoral hernias protrude through the femoral canal. (See",
"      <a class=\"local\" href=\"#H606310492\">",
"       'Anatomic location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk for inguinal hernia is highest among white males. Other risk factors for groin hernias",
"      <strong>",
"      </strong>",
"      include a history of another hernia, older age, chronic overstretching of the abdominal wall due to increased intraabdominal pressure (eg, chronic cough, chronic constipation, strenuous exercise), abdominal wall injury, family history of hernia, history of abdominal aortic aneurysm, and smoking. (See",
"      <a class=\"local\" href=\"#H606339779\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Groin hernias have a variety of clinical presentations ranging from a finding of a painless bulge in the groin region on routine physical examination to emergent, life-threatening presentations due to bowel strangulation. The most common symptom is a heaviness or dull sense of discomfort with straining or lifting, which is relieved once the pressure is removed. Although femoral hernias are the least common type of hernia, 40 percent present as emergencies with incarceration or strangulation. Older women are more likely to present with a hernia emergency due to a higher incidence of femoral hernia. (See",
"      <a class=\"local\" href=\"#H606309980\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most hernias can be diagnosed on physical exam as a bulge in the groin while coughing or straining. It is usually easier to demonstrate a hernia in a patient who is standing. If the diagnosis is not apparent, imaging can help to identify an occult hernia, differentiate inguinal from femoral hernia, and distinguish hernia from other clinical entities that may cause a groin mass or pain. In the absence of suspected hernia complications, we suggest groin ultrasound as the initial diagnostic modality. Other modalities, including computed tomography and magnetic resonance imaging, may be useful under specific clinical circumstances. (See",
"      <a class=\"local\" href=\"#H606309980\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of inguinal hernia includes any pathology that can produce pain or a mass in any of the tissues of the groin region, including soft tissues, lymphoid tissue, bony structures, associated vessels, or structures associated with male or female reproduction. Ultrasound distinguishes groin hernia from masses originating from the testicle, fluid-filled masses (hydrocele), and dilated vessels (varicocele, venous aneurysm, arterial aneurysm). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/1\">",
"      Dabbas N, Adams K, Pearson K, Royle G. Frequency of abdominal wall hernias: is classical teaching out of date? JRSM Short Rep 2011; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     Everhart, JE. The burden of digestive diseases in the United States. NIH Publication No. 09-6443, US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Washington, DC: US Government Printing Office, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/3\">",
"      McIntosh A, Hutchinson A, Roberts A, Withers H. Evidence-based management of groin hernia in primary care--a systematic review. Fam Pract 2000; 17:442.",
"     </a>",
"    </li>",
"    <li>",
"     Bendavid, R. Femoral hernias in females. Facts, figures and fallacies. In: Abdominal wall hernias, Springer, New York 2001. p.639.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/5\">",
"      Rosemar A, Anger&aring;s U, Rosengren A, Nordin P. Effect of body mass index on groin hernia surgery. Ann Surg 2010; 252:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/6\">",
"      Kark AE, Kurzer M. Groin hernias in women. Hernia 2008; 12:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/7\">",
"      Rutkow IM, Robbins AW. Demographic, classificatory, and socioeconomic aspects of hernia repair in the United States. Surg Clin North Am 1993; 73:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/8\">",
"      Kesek P, Ekberg O. Herniography in women under 40 years old with chronic groin pain. Eur J Surg 1999; 165:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/9\">",
"      Koch A, Edwards A, Haapaniemi S, et al. Prospective evaluation of 6895 groin hernia repairs in women. Br J Surg 2005; 92:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/10\">",
"      Bendavid R. Femoral pseudo-hernias. Hernia 2002; 6:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/11\">",
"      Dahlstrand U, Wollert S, Nordin P, et al. Emergency femoral hernia repair: a study based on a national register. Ann Surg 2009; 249:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/12\">",
"      Ruhl CE, Everhart JE. Risk factors for inguinal hernia among adults in the US population. Am J Epidemiol 2007; 165:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/13\">",
"      GLASSOW F. Inguinal hernia in the female. Surg Gynecol Obstet 1963; 116:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/14\">",
"      Arenal JJ, Rodr&iacute;guez-Vielba P, Gallo E, Tinoco C. Hernias of the abdominal wall in patients over the age of 70 years. Eur J Surg 2002; 168:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/15\">",
"      Pitoulias GA, Donas KP, Chatzimavroudis G, et al. The role of simple renal cysts, abdominal wall hernia, and chronic obstructive pulmonary disease as predictive factors for aortoiliac aneurysmatic disease. World J Surg 2012; 36:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/16\">",
"      Pannu R, McPhail IR. Prevalence of abdominal wall hernia in participants with abdominal aortic aneurysm versus peripheral arterial disease--a population-based study. Angiology 2012; 63:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/17\">",
"      Antoniou GA, Giannoukas AD, Georgiadis GS, et al. Increased prevalence of abdominal aortic aneurysm in patients undergoing inguinal hernia repair compared with patients without hernia receiving aneurysm screening. J Vasc Surg 2011; 53:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/18\">",
"      Pleumeekers HJ, De Gruijl A, Hofman A, et al. Prevalence of aortic aneurysm in men with a history of inguinal hernia repair. Br J Surg 1999; 86:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/19\">",
"      Lehnert B, Wadouh F. High coincidence of inguinal hernias and abdominal aortic aneurysms. Ann Vasc Surg 1992; 6:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/20\">",
"      Cannon DJ, Casteel L, Read RC. Abdominal aortic aneurysm, Leriche's syndrome, inguinal herniation, and smoking. Arch Surg 1984; 119:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/21\">",
"      Leme PL, Turatti RC. [Who smokes does have more chance to show inguinal hernia?]. Rev Assoc Med Bras 2010; 56:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/22\">",
"      Sorensen LT, Friis E, Jorgensen T, et al. Smoking is a risk factor for recurrence of groin hernia. World J Surg 2002; 26:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/23\">",
"      Bielecki K, Pu��awski R. [Is cigarette smoking a causative factor in the development of inguinal hernia?]. Pol Tyg Lek 1988; 43:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/24\">",
"      Cannon DJ, Read RC. Metastatic emphysema: a mechanism for acquiring inguinal herniation. Ann Surg 1981; 194:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/25\">",
"      Akbulut S, Cakabay B, Sezgin A. A familial tendency for developing inguinal hernias: study of a single family. Hernia 2010; 14:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/26\">",
"      Rosemar A, Anger&aring;s U, Rosengren A. Body mass index and groin hernia: a 34-year follow-up study in Swedish men. Ann Surg 2008; 247:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/27\">",
"      Liem MS, van der Graaf Y, Zwart RC, et al. Risk factors for inguinal hernia in women: a case-control study. The Coala Trial Group. Am J Epidemiol 1997; 146:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/28\">",
"      De Meulder F, Wojciechowski M, Hubens G, Ramet J. Female hydrocele of the canal of Nuck: a case report. Eur J Pediatr 2006; 165:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/29\">",
"      McClusky DA 3rd, Mirilas P, Zoras O, et al. Groin hernia: anatomical and surgical history. Arch Surg 2006; 141:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/30\">",
"      Attah AA, Hutson JM. The anatomy of the female gubernaculum is different from the male. Aust N Z J Surg 1991; 61:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/31\">",
"      Ando H, Kaneko K, Ito F, et al. Anatomy of the round ligament in female infants and children with an inguinal hernia. Br J Surg 1997; 84:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/32\">",
"      Golash V, Cummins RS. Ovulating ovary in an inguinal hemia. Surgeon 2005; 3:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/33\">",
"      Gurer A, Ozdogan M, Ozlem N, et al. Uncommon content in groin hernia sac. Hernia 2006; 10:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/34\">",
"      Holzheimer RG. Inguinal Hernia: classification, diagnosis and treatment--classic, traumatic and Sportsman's hernia. Eur J Med Res 2005; 10:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/35\">",
"      Read, RC. Metabolic factors contributing to herniation: a review. Hernia 1998; 2:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/36\">",
"      Klinge U, Binneb&ouml;sel M, Mertens PR. Are collagens the culprits in the development of incisional and inguinal hernia disease? Hernia 2006; 10:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/37\">",
"      Peacock EE Jr, Madden JW. Some studies on the effects of beta-aminopropionitrile in patients with injured flexor tendons. Surgery 1969; 66:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/38\">",
"      Chernyavsky VS, Davidov T, Trooskin SZ, Boyarsky A. Athlete's hernia--a true, early direct inguinal hernia: diagnosis, pathophysiology, and surgical treatment. Am Surg 2011; 77:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/39\">",
"      B&aacute;torfi J, Simon E, Parti K, et al. [Occult inguinal-hernia in athletes]. Magy Seb 2012; 65:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/40\">",
"      Swan KG Jr, Wolcott M. The athletic hernia: a systematic review. Clin Orthop Relat Res 2007; 455:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/41\">",
"      Kang SK, Burnett CA, Freund E, Sestito J. Hernia: is it a work-related condition? Am J Ind Med 1999; 36:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/42\">",
"      Pathak S, Poston GJ. It is highly unlikely that the development of an abdominal wall hernia can be attributable to a single strenuous event. Ann R Coll Surg Engl 2006; 88:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/43\">",
"      Vad MV, Frost P, Bay-Nielsen M, Svendsen SW. Impact of occupational mechanical exposures on risk of lateral and medial inguinal hernia requiring surgical repair. Occup Environ Med 2012; 69:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/44\">",
"      Dubbs W, MacLeod WA, O'Connell TX. Restoration of the shutter mechanism in inguinal herniorrhaphy. Am J Surg 1980; 139:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/45\">",
"      Fortuny G, Rodr&iacute;guez-Navarro J, Sus&iacute;n A, et al. A simulation finite element model for the mechanics of the internal oblique muscle: a defense mechanism against inguinal hernia formation? Comput Biol Med 2009; 39:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/46\">",
"      Read RC. British contributions to modern herniology of the groin. Hernia 2005; 9:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/47\">",
"      Ajmani ML, Ajmani K. The anatomical basis for the inguinal hernia. Anat Anz 1983; 153:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/48\">",
"      Gullmo A. Herniography. The diagnosis of hernia in the groin and incompetence of the pouch of Douglas and pelvic floor. Acta Radiol Suppl 1980; 361:1.",
"     </a>",
"    </li>",
"    <li>",
"     White J, Haller A. Groin hernia in infants and children. In: Hernia, 2nd ed, Lippincott, Philadelphia 1978. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/50\">",
"      Perry CP, Echeverri JD. Hernias as a cause of chronic pelvic pain in women. JSLS 2006; 10:212.",
"     </a>",
"    </li>",
"    <li>",
"     Amerson JR. Inguinal canal and hernia examination. In: Clinical Methods: the history, physical and laboratory examinations, 3rd ed, Hall WD, Hurst JW.  (Eds), Butterworths, Boston 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/52\">",
"      Neutra R, Velez A, Ferrada R, Galan R. Risk of incarceration of inguinal hernia in Cell Colombia. J Chronic Dis 1981; 34:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/53\">",
"      Gallegos NC, Dawson J, Jarvis M, Hobsley M. Risk of strangulation in groin hernias. Br J Surg 1991; 78:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/54\">",
"      Leubner KD, Chop WM Jr, Ewigman B, et al. Clinical inquiries. What is the risk of bowel strangulation in an adult with an untreated inguinal hernia? J Fam Pract 2007; 56:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/55\">",
"      Fitzgibbons RJ Jr, Giobbie-Hurder A, Gibbs JO, et al. Watchful waiting vs repair of inguinal hernia in minimally symptomatic men: a randomized clinical trial. JAMA 2006; 295:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/56\">",
"      O'Dwyer PJ, Norrie J, Alani A, et al. Observation or operation for patients with an asymptomatic inguinal hernia: a randomized clinical trial. Ann Surg 2006; 244:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/57\">",
"      Abi-Haidar Y, Sanchez V, Itani KM. Risk factors and outcomes of acute versus elective groin hernia surgery. J Am Coll Surg 2011; 213:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/58\">",
"      Rosenberg J, Bisgaard T, Kehlet H, et al. Danish Hernia Database recommendations for the management of inguinal and femoral hernia in adults. Dan Med Bull 2011; 58:C4243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/59\">",
"      van den Berg JC, de Valois JC, Go PM, Rosenbusch G. Detection of groin hernia with physical examination, ultrasound, and MRI compared with laparoscopic findings. Invest Radiol 1999; 34:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/60\">",
"      Robinson A, Light D, Kasim A, Nice C. A systematic review and meta-analysis of the role of radiology in the diagnosis of occult inguinal hernia. Surg Endosc 2013; 27:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/61\">",
"      Sayad P, Abdo Z, Cacchione R, Ferzli G. Incidence of incipient contralateral hernia during laparoscopic hernia repair. Surg Endosc 2000; 14:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/62\">",
"      Grant T, Neuschler E, Hartz W 3rd. Groin pain in women: use of sonography to detect occult hernias. J Ultrasound Med 2011; 30:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/63\">",
"      Korenkov M, Paul A, Troidl H. Color duplex sonography: diagnostic tool in the differentiation of inguinal hernias. J Ultrasound Med 1999; 18:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/64\">",
"      Bradley M, Morgan D, Pentlow B, Roe A. The groin hernia - an ultrasound diagnosis? Ann R Coll Surg Engl 2003; 85:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/65\">",
"      Robinson A, Light D, Nice C. Meta-analysis of sonography in the diagnosis of inguinal hernias. J Ultrasound Med 2013; 32:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/66\">",
"      Hamlin JA, Kahn AM. Herniography: a review of 333 herniograms. Am Surg 1998; 64:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/67\">",
"      Hall C, Hall PN, Wingate JP, Neoptolemos JP. Evaluation of herniography in the diagnosis of an occult abdominal wall hernia in symptomatic adults. Br J Surg 1990; 77:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/68\">",
"      Shadbolt CL, Heinze SB, Dietrich RB. Imaging of groin masses: inguinal anatomy and pathologic conditions revisited. Radiographics 2001; 21 Spec No:S261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/69\">",
"      Ianora AA, Midiri M, Vinci R, et al. Abdominal wall hernias: imaging with spiral CT. Eur Radiol 2000; 10:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31321/abstract/70\">",
"      Suzuki S, Furui S, Okinaga K, et al. Differentiation of femoral versus inguinal hernia: CT findings. AJR Am J Roentgenol 2007; 189:W78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3686 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-217.117.136.88-07197F826D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31321=[""].join("\n");
var outline_f30_37_31321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606339728\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606339779\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606318076\">",
"      CLASSIFICATION AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606310426\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H368943787\">",
"      - Congenital hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H606309543\">",
"      - Acquired hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606310492\">",
"      Anatomic location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Indirect inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Direct inguinal hernia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Femoral hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H606309980\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549554470\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incarceration and strangulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606315346\">",
"      Identifying occult hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606315541\">",
"      Differentiating inguinal from femoral hernia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606316485\">",
"      Evaluating hernia complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3686|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/1/37908\" title=\"diagnostic image 1\">",
"      Inguinal hernia on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?28/0/28679\" title=\"diagnostic image 2\">",
"      Femoral hernia on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3686|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/18/7461\" title=\"figure 1\">",
"      Groin hernia anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/12/40128\" title=\"figure 2\">",
"      Groin hernias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/51/5942?source=related_link\">",
"      Evaluation of nonacute scrotal pathology in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=related_link\">",
"      Inguinal and femoral hernia repair: Laparoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9465?source=related_link\">",
"      Inguinal and femoral hernia repair: Open techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29000?source=related_link\">",
"      Overview of treatment for inguinal and femoral hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/62/42977?source=related_link\">",
"      Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20373?source=related_link\">",
"      Sports-related groin pain or 'sports hernia'",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31322="Principles of labor induction";
var content_f30_37_31322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of labor induction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Deborah A Wing, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/37/31322/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/37/31322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of labor refers to techniques for stimulating uterine contractions to accomplish delivery prior to the onset of spontaneous labor. It is one of the most commonly performed obstetrical procedures in the United States. Between 1990 and 2010, the overall frequency of labor induction more than doubled, rising from 9.5 to 23.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/1\">",
"     1",
"    </a>",
"    ], and early term (in the 37",
"    <sup>",
"     th",
"    </sup>",
"    and 38",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation) inductions quadrupled, rising from 2 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of this increase is related to a rise in the number of medically and obstetrically indicated inductions; however, it appears that marginally indicated and elective inductions account for a large proportion of the increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/3\">",
"     3",
"    </a>",
"    ]. Reasons for the increase in these inductions include the availability of better cervical ripening agents, patient and provider desire to arrange a convenient time of delivery, and more relaxed attitudes toward marginal indications for induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/4\">",
"     4",
"    </a>",
"    ]. Patient and provider concerns about the risk of fetal demise with expectant management near term or postterm have also contributed to the increased rate of induction.",
"   </p>",
"   <p>",
"    Principles of induction of labor in women with an unscarred uterus will be discussed here. Issues regarding induction of labor in women who have had a previous cesarean delivery and methods of cervical ripening are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=see_link\">",
"     \"Cervical ripening and induction of labor in women with a prior cesarean delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700778\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major societies, such as the",
"    <a class=\"external\" href=\"file://www.acog.org/\">",
"     American College of Obstetricians and Gynecologists",
"    </a>",
"    (ACOG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], the",
"    <a class=\"external\" href=\"file://www.nice.org.uk/CG70\">",
"     National Institute for Health and Clinical Excellence (NICE)",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/7\">",
"     7",
"    </a>",
"    ], and the",
"    <a class=\"external\" href=\"file://www.sogc.org/guidelines/index_e.asp\">",
"     Society of Obstetricians and Gynaecologists of Canada",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/8\">",
"     8",
"    </a>",
"    ], have published guidelines for labor induction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DELIVERY BEFORE ONSET OF LABOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7531323\">",
"    <span class=\"h2\">",
"     Obstetrical and medical indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery before the onset of labor is indicated when the",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risks associated with continuing the pregnancy are thought to be greater than the",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risks associated with early delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/5\">",
"     5",
"    </a>",
"    ]. The only options are induction of labor or cesarean delivery. When there are no contraindications to labor and vaginal birth (see",
"    <a class=\"local\" href=\"#H10700886\">",
"     'Contraindications to induction'",
"    </a>",
"    below), induction of labor is generally preferred, given the increased maternal risks associated with cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21449?source=see_link&amp;anchor=H3#H3\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21449?source=see_link&amp;anchor=H17#H17\">",
"     \"Cesarean delivery: Postoperative issues\", section on 'Long-term risks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the magnitude of",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risk of early delivery can rarely be determined with precision. The relative risk of delivery versus continuation of pregnancy is influenced by factors such as gestational age,",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of fetal lung maturity, severity of the clinical condition, and cervical status. Although timely induction of women with some pregnancy complications has been recommended to improve maternal-fetal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], there is only limited high quality evidence establishing any benefits for specific medical and obstetrical indications for induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of conditions where induction is often indicated include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postterm pregnancy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=see_link\">",
"       \"Postterm pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prelabor (premature) rupture of membranes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"       \"Preterm premature rupture of membranes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=see_link\">",
"       \"Management of premature rupture of the fetal membranes at term\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preeclampsia, eclampsia, HELLP (Hemolysis, Elevated Liver enzymes, Low Platelets) syndrome (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal demise (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=see_link\">",
"       \"Diagnosis and management of stillbirth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maternal diabetes (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"       \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4313?source=see_link\">",
"       \"Obstetrical management of pregnancies complicated by gestational diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal growth restriction (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"       \"Fetal growth restriction: Evaluation and management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Twins (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=see_link\">",
"       \"Twin pregnancy: Labor and delivery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chorioamnionitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link\">",
"       \"Intraamniotic infection (chorioamnionitis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abruptio placentae (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34663?source=see_link\">",
"       \"Placental abruption: Management\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications for delivery before the onset of labor are discussed in detail in individual topics on the management of maternal and fetal disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elective induction at term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major concerns associated with elective (&ldquo;social&rdquo;) induction of labor at term are the potential for increased rates of cesarean delivery, neonatal morbidity from prematurity or early term birth, and cost. There are, however, potential advantages to scheduled induction of labor, such as reduction in term stillbirth, macrosomia, and meconium passage (but not meconium aspiration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, there is a reduced risk of delivery en route to the hospital among patients with a history of rapid labor or who live far away (&gt;30 minutes) from the hospital. Lastly, elective induction reduces the chance of sudden disruption of the patient's (and provider's) work and non-work related responsibilities.",
"   </p>",
"   <p>",
"    Currently, there is expert consensus that elective induction should not be performed before 39 weeks of gestation; however, there are insufficient data to recommend for or against elective induction of labor at &ge;39 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Randomized trials with adequate statistical power to evaluate maternal and neonatal safety and determine neonatal benefit as a reflection of reduced unexplained fetal death, as well as",
"    <span class=\"nowrap\">",
"     cost-effectiveness/cost-benefit",
"    </span>",
"    analyses, are needed to clarify the risks and benefits of this approach. Until better data are available, we avoid elective induction of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cesarean delivery rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is insufficient to determine whether elective induction of labor at &ge;39 weeks of gestation leads to higher or lower rates of cesarean delivery than expectant management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/14\">",
"     14",
"    </a>",
"    ]. Any increase in risk of cesarean delivery related to induction appears to be related primarily to an unfavorable cervix at admission (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Bishop score'",
"    </a>",
"    below). Most studies, including one small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/17\">",
"     17",
"    </a>",
"    ], report that women with favorable cervices are not at increased risk of cesarean birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cohort studies of nulliparous women with vertex, singleton term pregnancies consistently report that the rate of cesarean delivery is increased approximately two-fold in women who undergo elective or medical induction of labor compared to those who experience spontaneous labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/19-26\">",
"     19-26",
"    </a>",
"    ]. However, women in spontaneous labor are not an appropriate control group for these studies. Using these women as controls biases differences in cesarean rates to favor the control group because many patients managed expectantly would have gone on to have an indicated scheduled cesarean delivery rather than spontaneous labor. When cesarean delivery rates for electively induced nulliparous women with unfavorable cervixes were compared to nulliparous women with unfavorable cervixes at the same gestational age managed expectantly, cesarean delivery rates for both groups were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/27\">",
"     27",
"    </a>",
"    ]. Similarly, a retrospective cohort study observed that cesarean delivery rates were not increased among low-risk nulliparous women who underwent induction of labor at 39 weeks compared with women who continued pregnancy with delivery at 40, 41, or 42 weeks by either spontaneous labor or induction of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of multiparous women who have had a previous vaginal delivery consistently report a low risk of cesarean delivery with induction, and the risk of cesarean delivery is lower than for nulliparous women undergoing induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Almost all of these reports are retrospective, but one small randomized trial confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pediatric issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal intensive care unit admissions for respiratory problems are the major pediatric concerns with elective delivery at term (&ge;37 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/29\">",
"     29",
"    </a>",
"    ]. Respiratory problems can result from inadvertent delivery of a premature infant or transient tachypnea related to cesarean delivery after failed induction. Although data are limited, elective induction of labor at &ge;39 weeks in well-dated pregnancies is not associated with an increased risk of transient tachypnea of the newborn, suspected or proven neonatal sepsis, seizures, hypoglycemia, jaundice, or low five-minute Apgar scores (less than 7) compared with expectant management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, early term infants",
"    <span class=\"nowrap\">",
"     (37",
"     <sup>",
"      0/7ths",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     38",
"     <sup>",
"      6/7ths",
"     </sup>",
"     )",
"    </span>",
"    have greater neonatal morbidity and health care utilization during their entire first year of life than",
"    <sup>",
"    </sup>",
"    infants born at 39 to 40 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Health care cost estimates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decision analysis assessed the economic consequences of elective induction of labor at term in a cohort of 100,000 women for whom an initial decision was made to either (1) induce labor at 39 weeks of gestation or (2) follow expectantly through the remainder of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/35\">",
"     35",
"    </a>",
"    ]. All patients in this model underwent elective induction at 42 weeks. Using baseline estimates, the major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A policy of elective induction would result in over 12,000 excess cesarean deliveries and impose a cost to the United States medical system of nearly $100 million per year.",
"     </li>",
"     <li>",
"      A policy of induction at any gestational age, regardless of parity or cervical ripeness, required additional economic expenditures. Although never cost-saving, inductions were less expensive at later gestational ages, for multiparous patients, and for women with favorable cervices.",
"     </li>",
"     <li>",
"      The inductions most costly to the health care system were those performed in nulliparas with unfavorable cervices at 39 weeks. When nulliparous women with favorable cervices underwent labor induction, the estimated cost was approximately halved compared to nulliparas with unfavorable cervices; however, it still resulted in an overall added expenditure and additional cesarean deliveries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700886\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In each of the following settings, there is general consensus that the",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risks associated with labor and vaginal delivery, and therefore induction, are greater than the risks associated with cesarean delivery; therefore, induction of labor is usually contraindicated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior classical or other high risk cesarean incision (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link&amp;anchor=H15065622#H15065622\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'High-risk uterine scars'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prior uterine rupture (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link&amp;anchor=H15065629#H15065629\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'Prior uterine rupture'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prior transmural uterine incision entering the uterine cavity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=see_link&amp;anchor=H25#H25\">",
"       \"Pregnancy in women with uterine leiomyomas (fibroids)\", section on 'Management of patients with prior myomectomy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Active genital herpes infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=see_link&amp;anchor=H14710006#H14710006\">",
"       \"Genital herpes simplex virus infection and pregnancy\", section on 'Evidence for cesarean delivery'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Placenta previa or vasa previa (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42952?source=see_link\">",
"       \"Management of placenta previa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=see_link\">",
"       \"Velamentous umbilical cord insertion and vasa previa\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Umbilical cord prolapse or persistent funic presentation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=see_link\">",
"       \"Umbilical cord prolapse\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Transverse fetal lie (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22662?source=see_link\">",
"       \"Management of the fetus in transverse lie\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Invasive cervical cancer (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=see_link&amp;anchor=H26#H26\">",
"       \"Cervical cancer in pregnancy\", section on 'Delivery route'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Category III fetal heart rate tracing (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38311?source=see_link&amp;anchor=H11183979#H11183979\">",
"       \"Management of intrapartum category I, II, and III fetal heart rate tracings\", section on 'Category III FHR tracings'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinical scenarios (eg, previous low transverse or low vertical incision for cesarean delivery, nonreactive nonstress test) may be associated with an increased risk of maternal or fetal morbidity during induction. We feel these pregnancies warrant close monitoring during labor, with a low threshold for intervention if labor is not progressing or in the absence of reassuring signs of fetal well-being, but labor and vaginal delivery, and therefore induction, are not contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREDICTING A SUCCESSFUL INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful labor induction varies widely depending upon several factors: the characteristics of the population being induced (eg, intact or ruptured membranes, primiparous or multiparous, baseline cervical status), management of the induction, and choice of endpoints (eg, delivery within 24 hours, delivery within 48 hours,",
"    <span class=\"nowrap\">",
"     dose/duration",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , interval from preinduction cervical ripening to delivery versus time from induction to delivery, route of delivery, maternal and neonatal morbidity).",
"   </p>",
"   <p>",
"    Cervical status is one of the most important factors for predicting the likelihood of successfully inducing labor. The Bishop score appears to be the best available tool for assessing cervical status and predicting the likelihood that induction will result in vaginal delivery. Systematic reviews of controlled studies concluded the Bishop score is as, or more, predictive of the outcome of labor induction than fFN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/36\">",
"     36",
"    </a>",
"    ] or sonographic measurement of cervical length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], and that dilatation is the most important element of the Bishop score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/36\">",
"     36",
"    </a>",
"    ]. Some other cervical scoring systems are also available for this purpose (Fields system; Burnett, Caldor, and Friedman modifications of the Bishop system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/39\">",
"     39",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    The time of day when induction is started does not appear to be a factor in success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bishop score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Bishop score is the system most commonly used in clinical practice in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/41\">",
"     41",
"    </a>",
"    ]. This system tabulates a score based upon the station of the presenting part and four characteristics of the cervix: dilatation, effacement, consistency, and position (",
"    <a class=\"graphic graphic_table graphicRef65320 \" href=\"mobipreview.htm?26/41/27291\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the Bishop score is high, the likelihood of vaginal delivery is similar whether labor is spontaneous or induced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/22,41\">",
"     22,41",
"    </a>",
"    ]. In contrast, a low Bishop score increases the likelihood that induction will fail to result in vaginal delivery.",
"   </p>",
"   <p>",
"    Although Bishop scoring was originally described in multiparous women, these relationships are particularly strong in nulliparous women who undergo induction (",
"    <a class=\"graphic graphic_table graphicRef59851 \" href=\"mobipreview.htm?4/46/4843\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. As an example, a study of 4635 spontaneous and 2647 induced labors in nulliparous women at term reported the cesarean rate was twice as high with induced than spontaneous labor, 24 versus 12 percent, and the cesarean delivery rates were almost doubled for induced labors with Bishop scores &lt;5 versus &ge;5, 32 versus 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Bishop score has come under scrutiny. In a cohort of over 5400 nulliparous women undergoing labor induction at term, only dilation, station, and effacement, which represent three of the original five characteristics comprising the Bishop score, were significantly associated with vaginal delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/43\">",
"     43",
"    </a>",
"    ]. For predicting successful labor induction (defined as achieving vaginal delivery), a simplified Bishop score using these three components had similar or better positive predictive value (87.7 versus 87.0 percent), negative predictive value (31.3 versus 29.8 percent), positive likelihood ratio (2.34 versus 2.19), and correct classification rate (51.0 versus 47.3 percent) compared with the conventional Bishop score.",
"   </p>",
"   <p>",
"    The relationship between a low Bishop score and failed induction, prolonged labor, and a high cesarean birth rate was first described prior to widespread use of cervical ripening agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this relationship has persisted even after the introduction of these agents (",
"    <a class=\"graphic graphic_table graphicRef80607 \" href=\"mobipreview.htm?25/15/25851\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2571235\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of fetal fibronectin (fFN) as a tool for selecting women likely to have a successful induction is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/46-53\">",
"     46-53",
"    </a>",
"    ]. More data, including cost-benefit analysis, are needed before this test can be recommended for choosing candidates for semi-elective induction.",
"   </p>",
"   <p>",
"    Sonographic assessment of cervical length for predicting the outcome of labor induction has been evaluated in numerous studies. In a systematic review of 20 prospective studies, cervical length did not perform significantly better than Bishop score for predicting a successful induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/37\">",
"     37",
"    </a>",
"    ]. These data are limited by substantial heterogeneity among the studies. As with fFN, the role of ultrasound examination as a tool for selecting women likely to have a successful induction is uncertain. More data, including cost-benefit analysis, are needed before this test can be recommended in choosing candidates for semi-elective induction.",
"   </p>",
"   <p>",
"    In observational studies, characteristics associated with successful induction include multiparity (previous vaginal delivery), tall stature (over 5 feet 5 inches), increasing gestational age, nonobese maternal weight or body mass index (BMI), and infant birthweight less than 3.5 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/36,54\">",
"     36,54",
"    </a>",
"    ]. However, these characteristics are predictive of success even in spontaneous labors, which suggests they are more predictive of the route of delivery than the likelihood that the patient will reach the active phase of labor during induction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701134\">",
"    <span class=\"h1\">",
"     PREINDUCTION ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Checklists have been published to help with preinduction and preoxytocin assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/15,55\">",
"     15,55",
"    </a>",
"    ]. A thorough evaluation of the maternal and fetal condition is important prior to undertaking labor induction to make sure the indication is appropriate, confirm the absence of contraindications to labor or vaginal delivery, and assess the likelihood of successful induction. At a minimum, this includes reviewing prenatal assessment of gestational age, estimating fetal size and potential for dystocia, determining fetal presentation, performing a cervical examination, assessing the fetal heart rate pattern, and reviewing the patient's pregnancy and medical history. The indications for and alternatives to the procedure, techniques for cervical ripening and labor induction, and the possibility of cesarean delivery or induction over several days should be reviewed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533648\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is probably the most common method of labor induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/56\">",
"     56",
"    </a>",
"    ]. Because it is less successful when used in women with a low Bishop score, a ripening process generally should be used prior to administering oxytocin to women with unfavorable cervixes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537379\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is a polypeptide hormone produced in the hypothalamus and secreted from the posterior lobe of the pituitary gland in a pulsatile fashion. It is identical to its synthetic analog, which is among the most potent uterotonic agents known.",
"   </p>",
"   <p>",
"    Synthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration is a proven method of labor induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/56\">",
"     56",
"    </a>",
"    ]. Exogenous oxytocin administration produces periodic uterine contractions first demonstrable at approximately 20 weeks of gestation, with increasing responsiveness with advancing gestational age. There is little change in myometrial sensitivity to oxytocin from 34 weeks to term; however, once spontaneous labor begins, the uterine sensitivity to oxytocin increases rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/57\">",
"     57",
"    </a>",
"    ]. The gestational increase in uterine sensitivity is due primarily to an increase in myometrial oxytocin binding sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/58\">",
"     58",
"    </a>",
"    ]. Progress during spontaneous labor is not related to increasing oxytocin concentration, uterine contractions are not associated with changes in plasma oxytocin concentration, and hypocontractile labor does not appear to be the result of a deficit of oxytocin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537386\">",
"    <span class=\"h3\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is most commonly given intravenously. It cannot be administered orally because the polypeptide is degraded into small, inactive forms by gastrointestinal enzymes. The plasma half-life is short, estimated at three to six minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/60\">",
"     60",
"    </a>",
"    ]. Steady state concentrations are reached within 40 minutes of initiation or dose change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, synthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    was diluted by placing 10 units in 1000 mL of an isotonic solution, such as normal saline, yielding an oxytocin concentration of 10",
"    <span class=\"nowrap\">",
"     mU/mL.",
"    </span>",
"    A common practice is to make a solution of 60 units in 1000 mL crystalloid to allow the infusion pump setting to match the dose administered, eg, 1 mU per minute equals a pump infusion rate of 1 mL per hour. This practice is becoming more common in an attempt to improve safety by avoidance of simple arithmetical errors in dosing. Infusion pumps are used to allow continuous, precise control of the dose administered.",
"   </p>",
"   <p>",
"    We suggest that hospitals implement a standardized protocol to minimize errors in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration, as well as complications from oxytocin administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/55,62,63\">",
"     55,62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=see_link&amp;anchor=H13#H13\">",
"     \"Reducing adverse obstetrical outcomes through safety sciences\", section on 'Oxytocin administration'",
"    </a>",
"    .) However, the optimum regimen for oxytocin administration is controversial and no protocol has been subjected to the scientific scrutiny necessary to demonstrate its superiority in both efficacy and safety over another.",
"   </p>",
"   <p>",
"    Some examples of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion protocols are described in the table (",
"    <a class=\"graphic graphic_table graphicRef69023 \" href=\"mobipreview.htm?1/3/1084\">",
"     table 4",
"    </a>",
"    ). Protocols differ as to initial dose (0.5 to 6",
"    <span class=\"nowrap\">",
"     mU/min),",
"    </span>",
"    time period between dose increments (10 to 60 minutes), and maximum dose (16 to 64",
"    <span class=\"nowrap\">",
"     mU/minute)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/62\">",
"     62",
"    </a>",
"    ], but success rates for varying protocols are strikingly similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/5\">",
"     5",
"    </a>",
"    ]. A literature review of randomized trials of high- versus low-dose oxytocin regimens for augmentation or induction of labor concluded high-dose oxytocin decreased the time from admission to vaginal delivery, but did not decrease the incidence of cesarean delivery compared with low-dose therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/64\">",
"     64",
"    </a>",
"    ]. Only one double-blinded randomized trial has been published, and reported the same findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/65\">",
"     65",
"    </a>",
"    ]. High-dose regimens are associated with a higher rate of tachysystole than low-dose regimens and, in some studies, this has resulted in a higher rate of cesarean delivery for nonreassuring fetal heart rate tracings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/66\">",
"     66",
"    </a>",
"    ], but no significant difference in neonatal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/67\">",
"     67",
"    </a>",
"    ]. We use a low-dose protocol.",
"   </p>",
"   <p>",
"    The dose is typically increased until there is normal progression of labor, or strong contractions occurring at two- to three-minute intervals, or uterine activity reaches 150 to 350 Montevideo units (ie, the peak strength of contractions in mmHg measured by an internal monitor multiplied by their frequency per 10 minutes). There is no benefit to increasing the dose after one of these endpoints has been achieved. We maintain the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion until delivery based on our clinical experience and data from a noninferiority study and a randomized trial that discontinuation prolongs labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, there is no consensus that the oxytocin infusion needs to be maintained. The authors of two randomized trials concluded that there was no significant benefit in continuing oxytocin infusion after the onset of active labor and continuing oxytocin may result in a higher rate of cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When uterotonic drugs are administered, continuous monitoring of uterine activity and fetal heart rate are important so the dose can be adjusted up or down if uterine activity is inadequate or excessive (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Tachysystole'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Some examples of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    regimens are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low-dose",
"      </strong>",
"      &mdash; Low-dose protocols attempt to mimic a physiologic approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/5\">",
"       5",
"      </a>",
"      ]. The dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      is initiated at 0.5 to 1 mU per minute and increased by 1 mU per minute at 30- to 40-minute intervals. This interval was based upon studies showing approximately 40 minutes were required for any particular dose of oxytocin to reach a steady-state concentration and maximal uterine contractile response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/61\">",
"       61",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Slightly higher doses (begin at 1 to 2",
"      <span class=\"nowrap\">",
"       mU/min",
"      </span>",
"      and increase by 1 to 2",
"      <span class=\"nowrap\">",
"       mU/min)",
"      </span>",
"      and shorter incremental time intervals (15 to 30 minutes) have also been recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       High-dose",
"      </strong>",
"      &mdash; Active management of labor regimens, and others, use a high-dose&nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      infusion with short incremental time intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. A maximum oxytocin dose has not been established; however, most labor units do not go above 40",
"      <span class=\"nowrap\">",
"       mU/min.",
"      </span>",
"      The most common complication of the high-dose regimen is uterine tachysystole (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Tachysystole'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Pulsatile",
"      </strong>",
"      &mdash; Pulsatile administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      at 6- to 10-minute intervals is effective and may better simulate normal labor than continuous oxytocin administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]. Advantages of pulsatile administration include significantly lower total doses of oxytocin and less hyperstimulation. However, pulsatile administration does not reduce the rate of failed vaginal birth. The time from the start of the infusion to delivery is not shortened, and may be longer than with continuous oxytocin administration. Pulsatile oxytocin administration requires special equipment and is rarely used in contemporary obstetrical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537841\">",
"    <span class=\"h2\">",
"     Amniotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotomy alone may be an effective method of labor induction, but can only be performed in women with partially dilated and effaced cervixes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/78\">",
"     78",
"    </a>",
"    ]. To reduce the risk of cord prolapse, the clinician should ensure that the fetal vertex is well-applied to the cervix and the umbilical cord or other fetal part is not presenting. We document the fetal heart rate before and after the procedure, and also note the color of the amniotic fluid.",
"   </p>",
"   <p>",
"    In a Cochrane review of randomized trials, the combination of amniotomy plus intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration was more effective than amniotomy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/79\">",
"     79",
"    </a>",
"    ]. With the combined regimen, fewer women were undelivered at 24 hours than with amniotomy alone (RR 0.13, 95% CI 0.04-0.41). To achieve the greatest impact on duration of labor, a randomized trial showed that oxytocin should be initiated immediately after amniotomy, not delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although amniotomy plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is more effective than amniotomy alone, it is not known whether amniotomy plus oxytocin is more effective than oxytocin alone. In a randomized trial, routine early amniotomy (defined as cervical dilation &le;4 cm) in nulliparous labor induction shortened the time to delivery by &gt;2 hours and increased the proportion of deliveries within 24 hours (68 versus 56 percent; RR 0.72, 95% CI 0.59-0.89) compared with standard management of induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/81\">",
"     81",
"    </a>",
"    ]. In the standard management group, amniotomy was performed at physician discretion and the mean cervical dilation at rupture of membranes was 7.4 cm. These findings support our practice to perform early amniotomy during oxytocin induction if the fetus is engaged.",
"   </p>",
"   <p>",
"    Complications of amniotomy include introducing infection, disruption of an occult placenta previa, rupture of a vasa previa, and umbilical cord prolapse. Many of these same risks, and inadvertent amniotomy, also apply to membrane stripping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699126\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, prostaglandin E2 or E1 is typically administered to promote cervical ripening as the first step in labor induction of women with unfavorable cervixes. This alone initiates labor in many women, and obviates the need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    in these patients. Use of prostaglandins for cervical",
"    <span class=\"nowrap\">",
"     ripening/labor",
"    </span>",
"    induction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link&amp;anchor=H92003895#H92003895\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\", section on 'Prostaglandins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative advantages of prostaglandins over traditional methods of induction are less clear for women with favorable cervixes. Although few randomized trials have been performed, they have reported that prostaglandins are effective for labor induction, and may be as, or more, effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/56,82-85\">",
"     56,82-85",
"    </a>",
"    ]. The optimal type, dose, and route of prostaglandin for induction of labor when the cervix is favorable have not been determined. The advantages and disadvantages of this approach compared to use of an oxytocin infusion require further study. Until more data on safety and efficacy are available, we avoid use of prostaglandins to induce labor in women with favorable cervixes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537917\">",
"    <span class=\"h2\">",
"     Ancillary outpatient procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7537993\">",
"    <span class=\"h3\">",
"     Membrane stripping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stripping or sweeping of the membranes is a widely utilized, but often undocumented, technique performed on ambulatory patients. It involves inserting the examiner's finger beyond the internal cervical os and then rotating the finger circumferentially along the lower uterine segment to detach the fetal membranes. Membrane stripping is typically performed during an office visit for a pregnant woman with a partially dilated cervix who wants to hasten the onset of spontaneous labor.",
"   </p>",
"   <p>",
"    The efficacy of membrane sweeping was demonstrated in a meta-analysis of 22 trials in which 20 trials compared sweeping of membranes to no treatment, 3 compared sweeping to prostaglandin administration, and 1 compared sweeping to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration before formal induction of labor at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/86\">",
"     86",
"    </a>",
"    ]. Sweeping the membranes increased the likelihood of spontaneous labor within 48 hours (RR 0.77; 95% CI 0.70 to 0.84) or delivery within one week (RR 0.71; 95% CI 0.65 to 0.78). Compared to no intervention, membrane sweeping was associated with reduced frequency of pregnancy continuing beyond 41 weeks (RR 0.59, 95% CI 0.46-0.74) and 42 weeks of gestation (RR 0.28, 95% CI 0.15-0.50), and reduced frequency of formal induction (RR 0.72, 95% CI 0.52-1.00). Overall, eight women would need to undergo membrane sweeping to avoid one formal induction of labor. The rates of maternal fever, maternal infection, neonatal infection, and cesarean delivery were similar in both groups.",
"   </p>",
"   <p>",
"    We do not recommend routine membrane stripping, given that there is no evidence that this practice results in an improvement in maternal or neonatal outcome. However, compared to no intervention, weekly membrane stripping at term shortens the interval of time to onset of spontaneous labor and reduces the need for formal induction. For this reason, we offer membrane stripping to patients &ge;39 weeks of gestation who wish to hasten the onset of spontaneous labor.",
"   </p>",
"   <p>",
"    While the existing meta-analysis on the use of membrane stripping was not associated with an increase in neonatal infection, only one small study evaluated group B streptococcus (GBS) colonization associated with sweeping of the membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/86\">",
"     86",
"    </a>",
"    ]. Although there was no additional risk in women with sweeping, the study was too small to exclude an effect. No large trials have specifically addressed the safety of membrane stripping in known carriers of GBS. GBS colonization is not a contraindication to membrane sweeping as there is no direct evidence of harm, but given the paucity of safety data for the procedure in known GBS carriers, we carefully weigh the potential risks and benefits before performing the procedure in known carriers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link&amp;anchor=H95981696#H95981696\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Antepartum procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10698997\">",
"    <span class=\"h3\">",
"     Breast stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast stimulation causes uterine contractions and has been used to induce labor. A Cochrane meta-analysis did not find this technique to be useful in women with an unfavorable cervix and it was not more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    ; however, it appeared to be effective for initiating labor within 72 hours in women with favorable cervices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/87\">",
"     87",
"    </a>",
"    ]. The authors cautioned that neither the efficacy nor safety of breast stimulation has been adequately evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the safety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    efficacy of glucocorticoids, castor oil, hyaluronidase,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    , acupuncture, evening primrose oil, herbal preparations, or sexual intercourse for labor induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/88-97\">",
"     88-97",
"    </a>",
"    ]. However, patient initiated use of nonprescription, poorly evaluated methods is relatively common. In a study of 201 postpartum women who responded to a survey about methods they used to hasten onset of labor, 50 percent reported not trying to stimulate their own labor, while most of the remainder described walking, sexual intercourse, ingesting spicy food, and nipple stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/98\">",
"     98",
"    </a>",
"    ]. A few used laxatives, heavy exercise, masturbation, acupuncture, or herbal preparations to induce labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All methods of labor induction carry risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701403\">",
"    <span class=\"h2\">",
"     Oxytocin or prostaglandins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Tachysystole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal or excessive uterine contractions can occur with the use of prostaglandin compounds or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . There are no uniform worldwide definitions for such terms as tachysystole, hyperstimulation, and hypertonus. The American College of Obstetricians and Gynecologists (ACOG) suggests use of the term tachysystole, which is defined as more than 5 contractions in 10 minutes, averaged over a 30-minute window; the presence or absence of associated fetal heart rate changes should always be stated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other authorities have used alternative terminology. The term \"uterine hyperstimulation without fetal heart rate changes\" has been used to describe uterine tachysystole (&gt;5 contractions in 10 minutes for at least 30 minutes) or uterine",
"    <span class=\"nowrap\">",
"     hypersystole/hypertonus",
"    </span>",
"    (a contraction lasting at least 2 minutes) with a normal fetal heart rate. The term \"uterine hyperstimulation with fetal heart rate changes\" has been used to denote uterine hyperstimulation with fetal heart rate changes such as persistent decelerations, tachycardia, or decreased short-term variability. The reader should be mindful of these semantic differences.",
"   </p>",
"   <p>",
"    Since uterine activity causes intermittent interruption of blood flow to the intervillous space, excessive uterine activity that exceeds the critical level for an individual fetus will result in fetal hypoxemia. This, in turn, leads to nonreassuring fetal heart rate patterns and umbilical artery pH &le;7.11 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/100-103\">",
"     100-103",
"    </a>",
"    ]. Rarely, tachysystole may cause uterine rupture; this is more common in multigravidas than primigravidas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various PGE2 preparations have up to a 5 percent rate of uterine tachysystole, which is usually well tolerated and not associated with an adverse outcome. The reported risk of tachysystole with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    varies widely. Tachysystole occurs more frequently when higher doses of oxytocin, prostaglandin E2, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/67,104,106,107\">",
"     67,104,106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and a prostaglandin is believed to increase the risk of tachysystole since both drugs carry a risk of this complication. Additionally, data from human and animal studies show that prostaglandin administration increases uterine sensitivity to oxytocin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/108-112\">",
"     108-112",
"    </a>",
"    ]. Although some studies have not observed a statistically significant increase in excessive uterine activity with concurrent use, this is likely due to the small numbers of patients in these studies, differences in methodology (eg, uterine activity was not continuously monitored), and the relatively low frequency of adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/113-117\">",
"     113-117",
"    </a>",
"    ]. In one such trial, the frequency of uterine tachysystole with concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    and oxytocin administration was 14 percent versus 5 percent with oxytocin alone (p = 0.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701721\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removing the PGE2 vaginal insert (eg, Cervidil) usually reverses the effects of tachysystole. If prostaglandin gel was applied locally,",
"    <span class=\"nowrap\">",
"     cervical/vaginal",
"    </span>",
"    lavage is not helpful for removing the drug or reversing adverse effects.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is being infused, it should be discontinued if tachysystole is accompanied by fetal heart rate changes to quickly restore a reassuring fetal heart rate pattern. Placing the woman in the left lateral position, administering oxygen (10",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    of oxygen via nonrebreather mask), and increasing intravenous fluids (eg, fluid bolus of 500 mL of lactated Ringer's solution or more) also appear to be of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/102,118\">",
"     102,118",
"    </a>",
"    ]. If there is no prompt response to these measures, we suggest administering a tocolytic, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    250 mcg subcutaneously or intravenously or atosiban 6.75 mg intravenously over one minute for fetal resuscitation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    (60 to 90 mcg intravenously) is usually successful in recalcitrant cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38311?source=see_link&amp;anchor=H11183993#H11183993\">",
"     \"Management of intrapartum category I, II, and III fetal heart rate tracings\", section on 'Recurrent late decelerations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After tachysystole and fetal heart rate changes have resolved,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    can be resumed, if needed. No studies have evaluated the optimum approach to resuming the drug. One approach resumes oxytocin at one-half the previous dose if it has been discontinued for less than 30 minutes, and at the initial dose ordered if it has been discontinued for more than 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. We suggest using a low-dose protocol because it is associated with a lower frequency of tachysystole. (See",
"    <a class=\"local\" href=\"#H7537386\">",
"     'Regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If tachysystole is not accompanied by fetal heart rate changes, we still re-evaluate the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion rate. Decreasing the dose to titrate to an appropriate contraction frequency or discontinuation for a brief period of time are both reasonable options. If oxytocin is briefly discontinued, a lower dose should be used when the infusion is resumed. There is no evidence-base on which to base a dosage recommendation, so clinicians must use their best clinical judgment in these situations. For women who demonstrate tachysystole with frequent low amplitude contractions without the sensation of pain, it is reasonable to resume oxytocin at the penultimate level. For women with symptomatic tachysystole, a greater reduction in dose is prudent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10699992\">",
"    <span class=\"h3\">",
"     Uterine rupture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk of uterine rupture is increased in the setting of labor induction, but the absolute risk is low and most cases occur in women with a scarred uterus. In a series including 226,325 total maternal births in 2006, there were 41 true uterine ruptures",
"    <span class=\"nowrap\">",
"     (2/10,000",
"    </span>",
"    births): 27 occurred in women with prior uterine surgery (20 cesarean deliveries, 7 other uterine surgeries); of the remaining 14 patients with an unscarred uterus, 12 were exposed to oxytocics for induction or augmentation of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=see_link&amp;anchor=H3#H3\">",
"     \"Cervical ripening and induction of labor in women with a prior cesarean delivery\", section on 'Risk of uterine rupture'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=see_link\">",
"     \"Rupture of the unscarred uterus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700224\">",
"    <span class=\"h3\">",
"     Amniotic fluid embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A population-based retrospective cohort study including 3 million deliveries reported that medical induction of labor was associated with an increased risk of amniotic fluid embolism (adjusted OR 1.8, 95% CI 1.2-2.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/125\">",
"     125",
"    </a>",
"    ]. However, the absolute risk was small, 10.3 per 100,000 births with medical induction versus 5.2 per 100,000 births without medical induction. Moreover, given that these women were induced for medical indications, not inducing labor could potentially result in greater maternal-fetal",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    than inducing labor. These findings should be confirmed by others before changes in management of induction are considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700452\">",
"    <span class=\"h2\">",
"     Side effects of oxytocin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700347\">",
"    <span class=\"h3\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    has a similar structure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5511?source=see_link\">",
"     antidiuretic hormone",
"    </a>",
"    ) and can cross-react with the renal vasopressin receptor. If high doses (eg, 40",
"    <span class=\"nowrap\">",
"     mU/minute)",
"    </span>",
"    of oxytocin are administered in large quantities (eg, over 3 liters) of hypotonic solutions (eg, dextrose in water, D5W) for prolonged periods of time (&ge;7 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]), excessive water retention can occur and result in severe, symptomatic hyponatremia (similar to the syndrome of inappropriate antidiuretic hormone secretion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of severe acute hyponatremia include headache, anorexia, nausea, vomiting, abdominal pain, lethargy, drowsiness, unconsciousness, grand mal type seizures, and potentially irreversible neurologic injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    If water intoxication occurs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and any hypotonic solutions should be stopped. Correction of hyponatremia must be performed carefully and consists of restricting water intake, and careful administration of hypertonic saline if the patient is symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700374\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension can result from rapid intravenous injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    ; however, studies demonstrating this effect were performed in men, nonpregnant women, and first trimester women under general anesthesia. A randomized trial of oxytocin bolus versus slow infusion in women at delivery of the anterior shoulder did not find clinically significant differences in hemodynamic responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/131\">",
"     131",
"    </a>",
"    ]. Nevertheless, it is prudent to administer oxytocin by infusion pump or slow drip to avoid tachysystole, as well as possible hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700381\">",
"    <span class=\"h3\">",
"     Neonatal hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    use has been associated with hyperbilirubinemia in the neonate in some studies, but not others. Hyperbilirubinemia may be related more to factors related to induction (eg, preterm pregnancy) than to a direct effect of oxytocin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701387\">",
"    <span class=\"h2\">",
"     Side effects of prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of prostaglandins include fever, chills, vomiting, and diarrhea. The frequency of these side effects depends on the type of prostaglandin, dose, and route of administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FAILED INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction of labor usually culminates in vaginal delivery, but, as discussed above, this occurs less often than when women enter labor spontaneously. A low Bishop score, before or after attempts at cervical ripening, is a poor prognostic factor for successful induction. Women whose induction of labor does not lead to delivery are typically offered cesarean birth.",
"   </p>",
"   <p>",
"    There is no universal standard for what constitutes a failed induction. The key principle is to allow adequate time for cervical ripening and development of an active labor pattern before determining that an induction has failed. This minimizes the number of cesarean deliveries performed for failed induction in patients who are progressing slowly because they are still in the latent phase of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/45,132,133\">",
"     45,132,133",
"    </a>",
"    ]. Once induced women enter active labor, progression should be comparable to progression in women with spontaneous active labor, or faster [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/134\">",
"     134",
"    </a>",
"    ]. Several studies have shown that the duration of the second stage is similar in induced and spontaneous labors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/23,134-136\">",
"     23,134-136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A workshop convened by the United States National Institute of Child Health and Human Development (NICHD), Society of Maternal-Fetal Medicine (SMFM), and American College of Obstetricians and Gynecologists (ACOG) proposed that failed induction be defined as failure to generate regular contractions approximately every three minutes and cervical change after at least 24 hours of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/6\">",
"     6",
"    </a>",
"    ]. Membranes should be artificially ruptured, if safe and feasible. In this setting, failed induction can be defined as failure to generate regular contractions and cervical change with oxytocin administration for 12 hours after rupture of membranes.",
"   </p>",
"   <p>",
"    This definition is supported by the following lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two large studies that required a minimum of 12 hours of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      administration after membrane rupture before diagnosing failed labor induction reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/132,137\">",
"       132,137",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vaginal delivery occurred in 75 percent of all nulliparas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For nulliparous women with an unfavorable cervix, the overall rate of vaginal delivery was 63 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/137\">",
"       137",
"      </a>",
"      ]. Most of the 95 percent of women who exited the latent phase delivered vaginally and approximately 40 percent of the remaining 5 percent of women went on to deliver vaginally.",
"     </li>",
"     <li>",
"      For parous women, failed labor induction was eliminated as an indication for cesarean birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another study evaluated a group of 978 nulliparous women who had undergone either artificial or spontaneous rupture of membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/138\">",
"       138",
"      </a>",
"      ]. After membrane rupture and 10 hours of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      administration, the 8 percent of women not in the active phase of labor had a cesarean rate of approximately 75 percent; after membrane rupture and 12 hours of oxytocin administration, the cesarean rate was almost 90 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9189?source=see_link\">",
"       \"Latent phase of labor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11306?source=see_link&amp;anchor=H7769114#H7769114\">",
"       \"Abnormal labor: Protraction and arrest disorders\", section on 'Normal uterine activity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a retrospective cohort study, the duration of the first stage (defined as from 4 to 10 cm) was significantly longer in induced labor than in spontaneous labor; the median (95",
"      <sup>",
"       th",
"      </sup>",
"      percentile) for induced versus spontaneous labor for nulliparas was 5.5 hours (16.8 hours) versus 3.8 hours (11.8 hours); and for multiparas, 4.4 hours (16.2 hours) versus 2.4 hours (8.8 hours) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/139\">",
"       139",
"      </a>",
"      ]. Although the length of the active phase (defined as from 6 to 10 cm) was short (one hour or less) and similar for induced and spontaneous labors, each centimeter of dilation between 3 and 5 cm could take 8 to 10 hours (95",
"      <sup>",
"       th",
"      </sup>",
"      centile) in induced labor, and dilating from 5 to 6 cm could take 4 to 6 hours (95",
"      <sup>",
"       th",
"      </sup>",
"      centile).",
"     </li>",
"     <li>",
"      Another retrospective study observed that a latent phase as long as 18 hours during induction of labor in nulliparous women allowed the majority of these women to achieve a vaginal delivery, without increasing maternal or neonatal morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/37/31322/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701485\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10701493\">",
"    <span class=\"h2\">",
"     Previous cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=see_link\">",
"     \"Cervical ripening and induction of labor in women with a prior cesarean delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       \"Patient information: Labor and delivery (childbirth) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of labor is indicated when continuing the pregnancy is thought to be associated with greater maternal or fetal risk than intervention to deliver the pregnancy, and there is no contraindication to vaginal birth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for delivery before onset of labor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10700886\">",
"       'Contraindications to induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest avoiding elective induction of labor at term (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Elective induction has the potential for increased rates of cesarean delivery, iatrogenic prematurity, and higher health care costs, without proven",
"      <span class=\"nowrap\">",
"       medical/obstetrical",
"      </span>",
"      benefits. If elective induction is undertaken for nonmedical reasons, optimal candidates are women with favorable cervixes and well-dated pregnancies &ge;39 weeks, as these women are not at increased risk of cesarean delivery or iatrogenic prematurity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Elective induction at term'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Bishop score is the best available tool for predicting the likelihood that induction will result in vaginal delivery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Predicting a successful induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with favorable cervixes undergoing induction, we suggest administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      with or without amniotomy rather than amniotomy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7537379\">",
"       'Oxytocin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that hospitals implement a standardized protocol to minimize errors in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      administration, as well as complications from oxytocin administration (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7537386\">",
"       'Regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      regimens decrease the time from admission to vaginal delivery, but do not appear to decrease the incidence of cesarean delivery compared to low-dose therapy. High-dose regimens are associated with a higher rate of tachysystole than low-dose regimes, but no significant difference in neonatal outcomes. (See",
"      <a class=\"local\" href=\"#H7537386\">",
"       'Regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      induction is less successful when used in women with a low Bishop score, a ripening process is generally indicated prior to administering oxytocin to women with unfavorable cervixes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Bishop score'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=see_link\">",
"       \"Techniques for ripening the unfavorable cervix prior to induction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women who wish to avoid potential drug-related side effects, we suggest amniotomy for induction of labor as long as the cervix is partially dilated (&ge;3 cm) and the vertex is well-applied (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although weekly membrane stripping (sweeping) at term shortens the interval of time to onset of spontaneous labor and reduces the need for formal induction, we suggest not routinely stripping the membranes (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There is no evidence that this practice results in an improvement in maternal or neonatal outcome. (See",
"      <a class=\"local\" href=\"#H7537841\">",
"       'Amniotomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7537993\">",
"       'Membrane stripping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no standards for what constitutes a failed induction. It is important to allow adequate time for cervical ripening and development of an active labor pattern before determining that an induction has failed. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Failed induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      should not be administered in hypotonic solutions, as this can lead to excessive water retention and dilutional hyponatremia. (See",
"      <a class=\"local\" href=\"#H10700347\">",
"       'Hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/1\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/2\">",
"      Murthy K, Grobman WA, Lee TA, Holl JL. Trends in induction of labor at early-term gestation. Am J Obstet Gynecol 2011; 204:435.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/3\">",
"      Moore LE, Rayburn WF. Elective induction of labor. Clin Obstet Gynecol 2006; 49:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/4\">",
"      Rayburn WF, Zhang J. Rising rates of labor induction: present concerns and future strategies. Obstet Gynecol 2002; 100:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/5\">",
"      ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/6\">",
"      Spong CY, Berghella V, Wenstrom KD, et al. Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 2012; 120:1181.",
"     </a>",
"    </li>",
"    <li>",
"     Induction of labour (CG70) www.nice.org.uk/CG70.",
"    </li>",
"    <li>",
"     Crane J and Maternal-Fetal Medicine Committee.  Induction of labour at term.SOGC Clinical practice guideline No. 107, August 2011. www.sogc.org/guidelines/public/107E-CPG-August2001.pdf (Accessed on May 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/9\">",
"      Nicholson JM, Parry S, Caughey AB, et al. The impact of the active management of risk in pregnancy at term on birth outcomes: a randomized clinical trial. Am J Obstet Gynecol 2008; 198:511.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/10\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/11\">",
"      Mozurkewich E, Chilimigras J, Koepke E, et al. Indications for induction of labour: a best-evidence review. BJOG 2009; 116:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/12\">",
"      Ehrenthal DB, Hoffman MK, Jiang X, Ostrum G. Neonatal outcomes after implementation of guidelines limiting elective delivery before 39 weeks of gestation. Obstet Gynecol 2011; 118:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/13\">",
"      Clark SL, Miller DD, Belfort MA, et al. Neonatal and maternal outcomes associated with elective term delivery. Am J Obstet Gynecol 2009; 200:156.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/14\">",
"      Elective Induction of Labor: Safety and Harms. AHRQ Comparative Effectiveness Reviews. 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/15\">",
"      American College of Obstetricians and Gynecologists. Patient Safety Checklist no. 5: scheduling induction of labor. Obstet Gynecol 2011; 118:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/16\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 561: Nonmedically Indicated Early-Term Deliveries. Obstet Gynecol 2013; 121:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/17\">",
"      Nielsen PE, Howard BC, Hill CC, et al. Comparison of elective induction of labor with favorable Bishop scores versus expectant management: a randomized clinical trial. J Matern Fetal Neonatal Med 2005; 18:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/18\">",
"      Laughon SK, Zhang J, Grewal J, et al. Induction of labor in a contemporary obstetric cohort. Am J Obstet Gynecol 2012; 206:486.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/19\">",
"      Cammu H, Martens G, Ruyssinck G, Amy JJ. Outcome after elective labor induction in nulliparous women: a matched cohort study. Am J Obstet Gynecol 2002; 186:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/20\">",
"      Seyb ST, Berka RJ, Socol ML, Dooley SL. Risk of cesarean delivery with elective induction of labor at term in nulliparous women. Obstet Gynecol 1999; 94:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/21\">",
"      Luthy DA, Malmgren JA, Zingheim RW. Cesarean delivery after elective induction in nulliparous women: the physician effect. Am J Obstet Gynecol 2004; 191:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/22\">",
"      Vrouenraets FP, Roumen FJ, Dehing CJ, et al. Bishop score and risk of cesarean delivery after induction of labor in nulliparous women. Obstet Gynecol 2005; 105:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/23\">",
"      Vahratian A, Zhang J, Troendle JF, et al. Labor progression and risk of cesarean delivery in electively induced nulliparas. Obstet Gynecol 2005; 105:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/24\">",
"      Yeast JD, Jones A, Poskin M. Induction of labor and the relationship to cesarean delivery: A review of 7001 consecutive inductions. Am J Obstet Gynecol 1999; 180:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/25\">",
"      Prysak M, Castronova FC. Elective induction versus spontaneous labor: a case-control analysis of safety and efficacy. Obstet Gynecol 1998; 92:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/26\">",
"      Ehrenthal DB, Jiang X, Strobino DM. Labor induction and the risk of a cesarean delivery among nulliparous women at term. Obstet Gynecol 2010; 116:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/27\">",
"      Osmundson S, Ou-Yang RJ, Grobman WA. Elective induction compared with expectant management in nulliparous women with an unfavorable cervix. Obstet Gynecol 2011; 117:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/28\">",
"      Cheng YW, Kaimal AJ, Snowden JM, et al. Induction of labor compared to expectant management in low-risk women and associated perinatal outcomes. Am J Obstet Gynecol 2012; 207:502.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/29\">",
"      Stock SJ, Ferguson E, Duffy A, et al. Outcomes of elective induction of labour compared with expectant management: population based study. BMJ 2012; 344:e2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/30\">",
"      Dietz PM, Rizzo JH, England LJ, et al. Early term delivery and health care utilization in the first year of life. J Pediatr 2012; 161:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/31\">",
"      Zhang X, Kramer MS. Variations in mortality and morbidity by gestational age among infants born at term. J Pediatr 2009; 154:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/32\">",
"      Escobar GJ, Greene JD, Hulac P, et al. Rehospitalisation after birth hospitalisation: patterns among infants of all gestations. Arch Dis Child 2005; 90:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/33\">",
"      Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004; 114:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/34\">",
"      Wetta L, Tita AT. Early term births: considerations in management. Obstet Gynecol Clin North Am 2012; 39:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/35\">",
"      Kaufman KE, Bailit JL, Grobman W. Elective induction: an analysis of economic and health consequences. Am J Obstet Gynecol 2002; 187:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/36\">",
"      Crane JM. Factors predicting labor induction success: a critical analysis. Clin Obstet Gynecol 2006; 49:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/37\">",
"      Hatfield AS, Sanchez-Ramos L, Kaunitz AM. Sonographic cervical assessment to predict the success of labor induction: a systematic review with metaanalysis. Am J Obstet Gynecol 2007; 197:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/38\">",
"      Tanir HM, Sener T, Yildiz Z. Digital and transvaginal ultrasound cervical assessment for prediction of successful labor induction. Int J Gynaecol Obstet 2008; 100:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/39\">",
"      Baacke KA, Edwards RK. Preinduction cervical assessment. Clin Obstet Gynecol 2006; 49:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/40\">",
"      Bakker JJ, van der Goes BY, Pel M, et al. Morning versus evening induction of labour for improving outcomes. Cochrane Database Syst Rev 2013; 2:CD007707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/41\">",
"      BISHOP EH. PELVIC SCORING FOR ELECTIVE INDUCTION. Obstet Gynecol 1964; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/42\">",
"      Johnson DP, Davis NR, Brown AJ. Risk of cesarean delivery after induction at term in nulliparous women with an unfavorable cervix. Am J Obstet Gynecol 2003; 188:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/43\">",
"      Laughon SK, Zhang J, Troendle J, et al. Using a simplified Bishop score to predict vaginal delivery. Obstet Gynecol 2011; 117:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/44\">",
"      Arulkumaran S, Gibb DM, TambyRaja RL, et al. Failed induction of labour. Aust N Z J Obstet Gynaecol 1985; 25:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/45\">",
"      Xenakis EM, Piper JM, Conway DL, Langer O. Induction of labor in the nineties: conquering the unfavorable cervix. Obstet Gynecol 1997; 90:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/46\">",
"      Kiss H, Ahner R, Hohlagschwandtner M, et al. Fetal fibronectin as a predictor of term labor: a literature review. Acta Obstet Gynecol Scand 2000; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/47\">",
"      Garite TJ, Casal D, Garcia-Alonso A, et al. Fetal fibronectin: a new tool for the prediction of successful induction of labor. Am J Obstet Gynecol 1996; 175:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/48\">",
"      Tam WH, Tai SM, Rogers MS. Prediction of cervical response to prostaglandin E2 using fetal fibronectin. Acta Obstet Gynecol Scand 1999; 78:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/49\">",
"      Blanch G, Ol&aacute;h KS, Walkinshaw S. The presence of fetal fibronectin in the cervicovaginal secretions of women at term--its role in the assessment of women before labor induction and in the investigation of the physiologic mechanisms of labor. Am J Obstet Gynecol 1996; 174:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/50\">",
"      Ahner R, Egarter C, Kiss H, et al. Fetal fibronectin as a selection criterion for induction of term labor. Am J Obstet Gynecol 1995; 173:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/51\">",
"      Sciscione A, Hoffman MK, DeLuca S, et al. Fetal fibronectin as a predictor of vaginal birth in nulliparas undergoing preinduction cervical ripening. Obstet Gynecol 2005; 106:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/52\">",
"      Reis FM, Gervasi MT, Florio P, et al. Prediction of successful induction of labor at term: role of clinical history, digital examination, ultrasound assessment of the cervix, and fetal fibronectin assay. Am J Obstet Gynecol 2003; 189:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/53\">",
"      Ojutiku D, Jones G, Bewley S. Quantitative foetal fibronectin as a predictor of successful induction of labour in post-date pregnancies. Eur J Obstet Gynecol Reprod Biol 2002; 101:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/54\">",
"      Pevzner L, Rayburn WF, Rumney P, Wing DA. Factors predicting successful labor induction with dinoprostone and misoprostol vaginal inserts. Obstet Gynecol 2009; 114:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/55\">",
"      Clark S, Belfort M, Saade G, et al. Implementation of a conservative checklist-based protocol for oxytocin administration: maternal and newborn outcomes. Am J Obstet Gynecol 2007; 197:480.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/56\">",
"      Alfirevic Z, Kelly AJ, Dowswell T. Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev 2009; :CD003246.",
"     </a>",
"    </li>",
"    <li>",
"     Calderyro-Barcia, R, Sereno, JA. The response of human uterus to oxytocin throughout pregnancy. Oxytocin. Calderyro-Barcia, R, Heller, H (Eds), Pergamon Press, London 1959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/58\">",
"      Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984; 150:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/59\">",
"      Thornton S, Davison JM, Baylis PH. Plasma oxytocin during the first and second stages of spontaneous human labour. Acta Endocrinol (Copenh) 1992; 126:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/60\">",
"      Ryden, G, Sjoholm, I. The metabolism of oxytocin in pregnant and non-pregnant women. Acta Obstet Gynecol Scand Suppl 1971; 9:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/61\">",
"      Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol 1984; 150:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/62\">",
"      Hayes EJ, Weinstein L. Improving patient safety and uniformity of care by a standardized regimen for the use of oxytocin. Am J Obstet Gynecol 2008; 198:622.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/63\">",
"      Freeman RK, Nageotte M. A protocol for use of oxytocin. Am J Obstet Gynecol 2007; 197:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/64\">",
"      Patka JH, Lodolce AE, Johnston AK. High- versus low-dose oxytocin for augmentation or induction of labor. Ann Pharmacother 2005; 39:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/65\">",
"      Merrill DC, Zlatnik FJ. Randomized, double-masked comparison of oxytocin dosage in induction and augmentation of labor. Obstet Gynecol 1999; 94:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/66\">",
"      Satin AJ, Leveno KJ, Sherman ML, et al. High- versus low-dose oxytocin for labor stimulation. Obstet Gynecol 1992; 80:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/67\">",
"      Smith JG, Merrill DC. Oxytocin for induction of labor. Clin Obstet Gynecol 2006; 49:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/68\">",
"      Girard B, Vardon D, Creveuil C, et al. Discontinuation of oxytocin in the active phase of labor. Acta Obstet Gynecol Scand 2009; 88:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/69\">",
"      Diven LC, Rochon ML, Gogle J, et al. Oxytocin discontinuation during active labor in women who undergo labor induction. Am J Obstet Gynecol 2012; 207:471.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/70\">",
"      Daniel-Spiegel E, Weiner Z, Ben-Shlomo I, Shalev E. For how long should oxytocin be continued during induction of labour? BJOG 2004; 111:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/71\">",
"      Ustunyurt E, Ugur M, Ustunyurt BO, et al. Prospective randomized study of oxytocin discontinuation after the active stage of labor is established. J Obstet Gynaecol Res 2007; 33:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/72\">",
"      Hauth JC, Hankins GD, Gilstrap LC 3rd, et al. Uterine contraction pressures with oxytocin induction/augmentation. Obstet Gynecol 1986; 68:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/73\">",
"      Blakemore KJ, Qin NG, Petrie RH, Paine LL. A prospective comparison of hourly and quarter-hourly oxytocin dose increase intervals for the induction of labor at term. Obstet Gynecol 1990; 75:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/74\">",
"      O'Driscoll K, Foley M, MacDonald D. Active management of labor as an alternative to cesarean section for dystocia. Obstet Gynecol 1984; 63:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/75\">",
"      Thorp JA, Boylan PC, Parisi VM, Heslin EP. Effects of high-dose oxytocin augmentation on umbilical cord blood gas values in primigravid women. Am J Obstet Gynecol 1988; 159:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/76\">",
"      Cummiskey KC, Dawood MY. Induction of labor with pulsatile oxytocin. Am J Obstet Gynecol 1990; 163:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/77\">",
"      Tribe RM, Crawshaw SE, Seed P, et al. Pulsatile versus continuous administration of oxytocin for induction and augmentation of labor: two randomized controlled trials. Am J Obstet Gynecol 2012; 206:230.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/78\">",
"      Bricker L, Luckas M. Amniotomy alone for induction of labour. Cochrane Database Syst Rev 2000; :CD002862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/79\">",
"      Howarth GR, Botha DJ. Amniotomy plus intravenous oxytocin for induction of labour. Cochrane Database Syst Rev 2001; :CD003250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/80\">",
"      Selo-Ojeme DO, Pisal P, Lawal O, et al. A randomised controlled trial of amniotomy and immediate oxytocin infusion versus amniotomy and delayed oxytocin infusion for induction of labour at term. Arch Gynecol Obstet 2009; 279:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/81\">",
"      Macones GA, Cahill A, Stamilio DM, Odibo AO. The efficacy of early amniotomy in nulliparous labor induction: a randomized controlled trial. Am J Obstet Gynecol 2012; 207:403.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/82\">",
"      Keirse MJ. Natural prostaglandins for induction of labor and preinduction cervical ripening. Clin Obstet Gynecol 2006; 49:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/83\">",
"      Egarter C, Schurz B, Wagner G, et al. [Comparison between prostaglandin E2 gel and oxytocin in medically indicated labor induction]. Geburtshilfe Frauenheilkd 1987; 47:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/84\">",
"      Silva-Cruz A, Godinho F, Pinto JM, et al. Prostaglandin E2 gel compared to oxytocin for medically-indicated labour induction at term: a controlled clinical trial. Pharmatherapeutica 1988; 5:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/85\">",
"      Wing DA, Fassett MJ, Guberman C, et al. A comparison of orally administered misoprostol to intravenous oxytocin for labor induction in women with favorable cervical examinations. Am J Obstet Gynecol 2004; 190:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/86\">",
"      Boulvain M, Stan C, Irion O. Membrane sweeping for induction of labour. Cochrane Database Syst Rev 2005; :CD000451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/87\">",
"      Kavanagh J, Kelly AJ, Thomas J. Breast stimulation for cervical ripening and induction of labour. Cochrane Database Syst Rev 2005; :CD003392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/88\">",
"      Kavanagh J, Kelly AJ, Thomas J. Corticosteroids for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/89\">",
"      Kelly AJ, Kavanagh J, Thomas J. Castor oil, bath and/or enema for cervical priming and induction of labour. Cochrane Database Syst Rev 2001; :CD003099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/90\">",
"      Kavanagh J, Kelly AJ, Thomas J. Hyaluronidase for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/91\">",
"      Kavanagh J, Kelly AJ, Thomas J. Sexual intercourse for cervical ripening and induction of labour. Cochrane Database Syst Rev 2001; :CD003093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/92\">",
"      Tan PC, Yow CM, Omar SZ. Effect of coital activity on onset of labor in women scheduled for labor induction: a randomized controlled trial. Obstet Gynecol 2007; 110:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/93\">",
"      Kelly AJ, Munson C, Minden L. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev 2011; :CD006901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/94\">",
"      Lim CE, Wilkinson JM, Wong WS, Cheng NC. Effect of acupuncture on induction of labor. J Altern Complement Med 2009; 15:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/95\">",
"      Dove D, Johnson P. Oral evening primrose oil: its effect on length of pregnancy and selected intrapartum outcomes in low-risk nulliparous women. J Nurse Midwifery 1999; 44:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/96\">",
"      McFarlin BL, Gibson MH, O'Rear J, Harman P. A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice. J Nurse Midwifery 1999; 44:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/97\">",
"      Omar NS, Tan PC, Sabir N, et al. Coitus to expedite the onset of labour: a randomised trial. BJOG 2013; 120:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/98\">",
"      Chaudhry Z, Fischer J, Schaffir J. Women's use of nonprescribed methods to induce labor: a brief report. Birth 2011; 38:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/99\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/100\">",
"      Bakker PC, Kurver PH, Kuik DJ, Van Geijn HP. Elevated uterine activity increases the risk of fetal acidosis at birth. Am J Obstet Gynecol 2007; 196:313.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/101\">",
"      Jonsson M, Nord&eacute;n-Lindeberg S, Ostlund I, Hanson U. Acidemia at birth, related to obstetric characteristics and to oxytocin use, during the last two hours of labor. Acta Obstet Gynecol Scand 2008; 87:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/102\">",
"      Simpson KR, James DC. Effects of oxytocin-induced uterine hyperstimulation during labor on fetal oxygen status and fetal heart rate patterns. Am J Obstet Gynecol 2008; 199:34.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/103\">",
"      Peebles DM, Spencer JA, Edwards AD, et al. Relation between frequency of uterine contractions and human fetal cerebral oxygen saturation studied during labour by near infrared spectroscopy. Br J Obstet Gynaecol 1994; 101:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/104\">",
"      Flannelly, GM, Turner, MJ, Rassmussen, MJ, Strong, JM. Rupture of the uterus in Dublin: An update. J Obstet Gynaecol 1993; 13:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/105\">",
"      Catanzarite V, Cousins L, Dowling D, Daneshmand S. Oxytocin-associated rupture of an unscarred uterus in a primigravida. Obstet Gynecol 2006; 108:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/106\">",
"      Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997; 177:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/107\">",
"      Wing DA, Miller H, Parker L, et al. Misoprostol vaginal insert for successful labor induction: a randomized controlled trial. Obstet Gynecol 2011; 117:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/108\">",
"      Brummer HC. Interaction of E prostaglandins and syntocinon on the pregnant human myometrium. J Obstet Gynaecol Br Commonw 1971; 78:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/109\">",
"      Gillespie A. Interrelationship between oxytocin (endogenous and exogenous) and prostaglandins. Adv Biosci 1973; 9:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/110\">",
"      Wikland M, Lindblom B, Hammarstr&ouml;m S, Wiqvist N. The effect of prostaglandin I on the contractility of the term pregnant human myometrium. Prostaglandins 1983; 26:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/111\">",
"      Baguma-Nibasheka M, Wentworth RA, Green LR, et al. Differences in the in vitro sensitivity of ovine myometrium and mesometrium to oxytocin and prostaglandins E2 and F2alpha. Biol Reprod 1998; 58:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/112\">",
"      Chan WY. Uterine and placental prostaglandins and their modulation of oxytocin sensitivity and contractility in the parturient uterus. Biol Reprod 1983; 29:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/113\">",
"      Tan PC, Daud SA, Omar SZ. Concurrent dinoprostone and oxytocin for labor induction in term premature rupture of membranes: a randomized controlled trial. Obstet Gynecol 2009; 113:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/114\">",
"      Khan RA, Khan ZE, Ashraf O. Concurrent versus sequential methods for labor induction at term. Int J Gynaecol Obstet 2007; 96:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/115\">",
"      Christensen FC, Tehranifar M, Gonzalez JL, et al. Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term. Am J Obstet Gynecol 2002; 186:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/116\">",
"      Coleman FH, Rayburn WF, Burks LS, et al. Patterns of uterine activity. Using oxytocin after intracervical PGE2. J Reprod Med 1997; 42:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/117\">",
"      Tan PC, Valiapan SD, Tay PY, Omar SZ. Concurrent oxytocin with dinoprostone pessary versus dinoprostone pessary in labour induction of nulliparas with an unfavourable cervix: a randomised placebo-controlled trial. BJOG 2007; 114:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/118\">",
"      Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/119\">",
"      Sharma SK, Gajraj NM, Sidawi JE. Prevention of hypotension during spinal anesthesia: a comparison of intravascular administration of hetastarch versus lactated Ringer's solution. Anesth Analg 1997; 84:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/120\">",
"      Pullen KM, Riley ET, Waller SA, et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. Am J Obstet Gynecol 2007; 197:414.e1.",
"     </a>",
"    </li>",
"    <li>",
"     www.ihs.gov/medicalprograms/mch/f/documents/Tachysystole2.pdf (Accessed on May 24, 2012).",
"    </li>",
"    <li>",
"     Care of the patient receiving oxytocin for labor induction or augmentation. University of Michigan Hospital. November 2010. obgyn.med.umich.edu/sites/obgyn.med...edu/.../ind-aug_labor.pdf (Accessed on May 24, 2012).",
"    </li>",
"    <li>",
"     mail.ny.acog.org/website/OxytocinForInduction.pdf (Accessed on May 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/124\">",
"      Porreco RP, Clark SL, Belfort MA, et al. The changing specter of uterine rupture. Am J Obstet Gynecol 2009; 200:269.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/125\">",
"      Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/126\">",
"      Lilien AA. Oxytocin-induced water intoxication. A report of a maternal death. Obstet Gynecol 1968; 32:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/127\">",
"      Bilek W, Dorr P. Water intoxication and grand mal seizure due to oxytocin. Can Med Assoc J 1970; 103:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/128\">",
"      Moen V, Brudin L, Rundgren M, Irestedt L. Hyponatremia complicating labour--rare or unrecognised? A prospective observational study. BJOG 2009; 116:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/129\">",
"      WHALLEY PJ, PRITCHARD JA. OXYTOCIN AND WATER INTOXICATION. JAMA 1963; 186:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/130\">",
"      Feeney JG. Water intoxication and oxytocin. Br Med J (Clin Res Ed) 1982; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/131\">",
"      Davies GA, Tessier JL, Woodman MC, et al. Maternal hemodynamics after oxytocin bolus compared with infusion in the third stage of labor: a randomized controlled trial. Obstet Gynecol 2005; 105:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/132\">",
"      Rouse DJ, Owen J, Hauth JC. Criteria for failed labor induction: prospective evaluation of a standardized protocol. Obstet Gynecol 2000; 96:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/133\">",
"      Simon CE, Grobman WA. When has an induction failed? Obstet Gynecol 2005; 105:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/134\">",
"      Hoffman MK, Vahratian A, Sciscione AC, et al. Comparison of labor progression between induced and noninduced multiparous women. Obstet Gynecol 2006; 107:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/135\">",
"      Macer JA, Macer CL, Chan LS. Elective induction versus spontaneous labor: a retrospective study of complications and outcome. Am J Obstet Gynecol 1992; 166:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/136\">",
"      Janakiraman V, Ecker J, Kaimal AJ. Comparing the second stage in induced and spontaneous labor. Obstet Gynecol 2010; 116:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/137\">",
"      Rouse DJ, Weiner SJ, Bloom SL, et al. Failed labor induction: toward an objective diagnosis. Obstet Gynecol 2011; 117:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/138\">",
"      Beckmann M. Predicting a failed induction. Aust N Z J Obstet Gynaecol 2007; 47:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/37/31322/abstract/139\">",
"      Harper LM, Caughey AB, Odibo AO, et al. Normal progress of induced labor. Obstet Gynecol 2012; 119:1113.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4476 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31322=[""].join("\n");
var outline_f30_37_31322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10700778\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR DELIVERY BEFORE ONSET OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7531323\">",
"      Obstetrical and medical indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elective induction at term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cesarean delivery rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pediatric issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Health care cost estimates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10700886\">",
"      CONTRAINDICATIONS TO INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREDICTING A SUCCESSFUL INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bishop score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2571235\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10701134\">",
"      PREINDUCTION ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533648\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7537379\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7537386\">",
"      - Regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7537841\">",
"      Amniotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10699126\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7537917\">",
"      Ancillary outpatient procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7537993\">",
"      - Membrane stripping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10698997\">",
"      - Breast stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMPLICATIONS AND SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10701403\">",
"      Oxytocin or prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Tachysystole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10701721\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10699992\">",
"      - Uterine rupture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10700224\">",
"      - Amniotic fluid embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10700452\">",
"      Side effects of oxytocin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10700347\">",
"      - Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10700374\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10700381\">",
"      - Neonatal hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10701387\">",
"      Side effects of prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FAILED INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10701485\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10701493\">",
"      Previous cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/41/27291\" title=\"table 1\">",
"      The modified Bishop score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/46/4843\" title=\"table 2\">",
"      C-S rate by Bishop score no PG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/15/25851\" title=\"table 3\">",
"      C-S rate by Bishop score and PG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/3/1084\" title=\"table 4\">",
"      Examples of oxytocin infusion protocols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/42/6826?source=related_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28535?source=related_link\">",
"      Cervical ripening and induction of labor in women with a prior cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/60/21449?source=related_link\">",
"      Cesarean delivery: Postoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9189?source=related_link\">",
"      Latent phase of labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38311?source=related_link\">",
"      Management of intrapartum category I, II, and III fetal heart rate tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42952?source=related_link\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=related_link\">",
"      Management of premature rupture of the fetal membranes at term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22662?source=related_link\">",
"      Management of the fetus in transverse lie",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/13/4313?source=related_link\">",
"      Obstetrical management of pregnancies complicated by gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=related_link\">",
"      Reducing adverse obstetrical outcomes through safety sciences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/4/44102?source=related_link\">",
"      Rupture of the unscarred uterus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/18/20775?source=related_link\">",
"      Velamentous umbilical cord insertion and vasa previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_37_31323="Paraneo pain synds";
var content_f30_37_31323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pain from paraneoplastic syndromes in cancer patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Syndrome",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristics",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic sensorimotor neuropathy",
"      </td>",
"      <td>",
"       Mild to moderate distal symmetric sensorimotor defects with symmetric pain that begins in the feet and gradually ascends",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Hypertrophic osteoarthropathy",
"      </td>",
"      <td>",
"       Clubbing of fingers, periostitis of long bones, and occasionally a rheumatoid-like polyarthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain, tenderness, and swelling in the knees, wrists, and ankles",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paraneoplastic gynecomastia",
"      </td>",
"      <td>",
"       Breast enlargement, usually presenting with pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Paraneoplastic pemphigus",
"      </td>",
"      <td>",
"       Widespread mucocutaneous lesions involving the lips, conjunctiva, and genitalia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When severe, desquamation can occur and death may occur from fluid loss, infection, or an associated bronchiolitis obliterans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paraneoplastic Raynaud's phenomenon",
"      </td>",
"      <td>",
"       Intense vasospasm of digital arterioles leading to pallor, followed by cyanosis and subsequent hyperemia of the fingertips",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subacute sensory neuronopathy",
"      </td>",
"      <td>",
"       \"Pins and needles\" or electric-shock sensations initially affecting an extremity and progresses to involve other extremities, the face, abdomen, and trunk",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31323=[""].join("\n");
var outline_f30_37_31323=null;
var title_f30_37_31324="Treatment summary II BCC";
var content_f30_37_31324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of treatment options for basal cell carcinoma (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment modality",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Five-year recurrence rate, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary BCC",
"       </td>",
"       <td class=\"subtitle2\">",
"        Recurrent BCC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Curettage and electrodessication",
"       </td>",
"       <td rowspan=\"4\">",
"        8",
"       </td>",
"       <td rowspan=\"4\">",
"        18-40",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cost effective, relatively quick, requires a single visit, relatively easy wound care, well suited for multiple lesions, usually affords good to excellent cosmetic results, no sedation or general anesthesia required, and offers low recurrence rates in small primary BCCs that lack \"high risk\" features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not margin-controlled. Recurrence rate unacceptably high with larger (&gt;5 mm) lesions located in high risk sites, requires special equipment, requires experience in its use to achieve higher cure rates. Poor choice in most BCCs of the head. Must be cautious in patients with pacemakers.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Radiation therapy",
"       </td>",
"       <td rowspan=\"4\">",
"        7-9",
"       </td>",
"       <td rowspan=\"4\">",
"        10",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noninvasive. High cure rate for selected lesions. Relative sparing of critical structures. Good for patients who are not otherwise candidates for surgery. Relatively painless.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-margin-controlled. Requires repeat office visits. Poorer long-term cosmetic results. Generally avoid in younger patients, in lesions located on the trunk or extremities, in deeply invasive lesions, or previously irradiated sites. Relatively expensive compared to simple excision, cryotherapy and electrosurgery.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Topical 5-fluorouracil and imiquimod",
"       </td>",
"       <td rowspan=\"4\">",
"        Variable, depending upon patient population",
"       </td>",
"       <td rowspan=\"4\">",
"        NA",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Advantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noninvasive. Rarely causes scarring. Avoids operative risks. Able to use in patients who are otherwise not candidates for surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Limited role for superficial BCC's located in low-risk areas. Brisk inflammatory reaction that can be poorly tolerated. Requires prolonged application.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31324=[""].join("\n");
var outline_f30_37_31324=null;
var title_f30_37_31325="Gram stain CSF 4";
var content_f30_37_31325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain CSF 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31325=[""].join("\n");
var outline_f30_37_31325=null;
var title_f30_37_31326="Hyperopia farsightedness";
var content_f30_37_31326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/72862/hyperop_conv.mp4?title=Hyperopia+farsightedness\" style=\"width:336px;height:226px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 209px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADRAU4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1uiiivzw+vCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijFFK4BRRRRcYUUDmilcQUUDmjFMAooooAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgCiilpAFBxWRb6jd60+3w1bLcQfdOozkrag5x8hHMxH+zheCC6kVpw+DrW42v4gup9XfgtHKfLtvp5K/Kw/66bzx1716uFyeviPel7q8zjrY2nS0WrM2TxDpSXL20d4tzdISHt7NWuJlx1zHGGYflUkepXVwf9B0LV7hcfeaFbf8ASZkP6VNc+OvCGhwrZ21/byLAu1bfTITMI8fw4iBCcjvj8K5+9+M+j26sF03UFcHjz5LeJfx/eEjj2/8ArenHJsLDSpO7MFicVV1p0zcN1q4J/wCKX1bGOvnWmP8A0fmoBrWwhbrSdbgfj5f7Olm/8eiV17etc8nxt09nwumbiey38OT+tbEHxa0iTY8ml6xFEesvlQuo98RyMxH0BqnlWB6St8x82OWrplyx1/SL65Fta6lavdEZ+z+YBKPqh+YfiK1O2aqx+KfBfipFsbm70+63OAlpqMOx3bttjmAJ+oBqSXwZDAS2gahe6ZIOkPmGe2PoPKkJ2r7RlPrWFXIG1ehO4lmHK+WrGxNSVlXN1qWiqzeILINaKMnULANJEAMnMkf34+OT95R3etG2uIbq3jntZY5oJVDpJGwZWU9CCOorxK+Gq4Z2qxsd9OtCqrwZJRS0hrnuaBRRRTAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgCiigUhkN7dQWVpLdXcqQ28Sl5JHOAoHc1UsdDuPEirda9DLbaQDui0xvlecdmuPQHtF/33knap4ctT4lv4tXulzo1u+/Toj0uXH/Lyw7qP+WY6cb+6FdL4g+KF8KeHJbyNY5b6X91aQueHkI6nH8IAJPPbHpX1OWZbGjH6xX36LsePisVKpL2NIq+OPHOl+DoY7UoLnUpEzDYwkAhOgZzjCJkYBwSegBwQPIfN8W/EvUZEupRFoyZDlgRbIc/dWMH98wwPvkgY7Hg89oGk3vijxGsM9zLNdXTme+vWA37Bjc3oOyqOgyOMCvoCxtLfT7OG0s4lht4VCIi9ABV4zHSlpDY7MNg40dXrI5XTfhz4ftY0F5BJqUijAa7feo+kYwi/gB0retNC0mzI+yaZYwEZwY4FU+/OK0yaSvIleW523ZVuNOs54zHLbxsh/hxx9ax7vwT4duQ5OlWySv1lSMCQZPZuoPuOa6KjNQqceiHd9zzzVfhxG0Ui6deyrG3HkXI+0Rke+87iT/vgVhW954m8EtiK4ns7OPqpJuLLHujYaJck5K7FzxuavYM0yaCKZNsqAj9R/hWsKtai705ff8A5jlJTXLUV15mR4V+JlhqMkFlrkS6VeykLHLv320xPTbJgbT/ALLYyTgFq2NU8KbLmXUPDUqaffOxklgIzbXbHqZEH3WP/PRMHnLBwAK858UeBRDHLPokcSxMD5tm4/cyA9eOiE+oG31UZLiv4I8b3vhuQWV8Li60WI+TJBIC1xYED+HqXjAP3eTjGwkYU+xh8wpYteyxC1/r+rnm18t5f3uEe3T/AC7noOmaoLmaSzu4XsdUhXM9pKcsBnG5T0dCejD6HBBA0setTavpen+KtMtbu2ulEijzbHUrRwzRE45VuQynHzKcqw4PrWNp1/N9sm0vVY1g1a3UO6qCI54ycCWPPO0ngjkqeDngt5OZZXLDfvKesfyDCYxVvdlpI0qKWkrxkd4UUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopKQBRSGjv0pb6IewE4qzd+D5vEukta3N7PY2NwCk5gA82SMggqrHITJIy2CcZAwSGG5oeibttxeL7oh7+5/wqfxVrkul/ZbDTIUn1e+D/AGZZAfKjVMb5ZCP4V3L8o5YsoGASy/SZblNrVq+/Rf5niYzHuT9lR+85b+zNM0TxbaWGiy3iQ2Vi8l9519NOiKxVYUYSMQM7JGBHKhMcB+fCfHniWTxV4hnvlLCzj/dWaHtGP4vqx5P4DtXofxJ1my0TwjcaRp+pLe6vq0ha8uA6tLIrY8ySTbwAVAjA4AXAXhMDxsRvO6xJ8skpCL7MxAH6kV6GNrX/AHaOjLcPZOpLc9g+FOkLY+HRfOv+kX583JHSIcIB7EZb/gddqajtYEtbWG3hXbFEgRAOygYA/KpDXhSd5NnpiGkoNFIYUUUUAFLSUZoAdmuN8aeFVvx9tsNkN/ChVJCSFI67HwOU6+6k5HVgexpc1FSHNqtGtmEZOLujyjwJ4sfwhfTpeRyJpDylb+2PLWMv8Uqgfw8gsBwQQ6553+weI9Hi16yt5rWaOO/t/wB/Y3a/MEYjoQPvRsDhh3HQghWHm3j/AMOsp/tbToi08S4liQZM0Q5K47suSy+vzL3XFz4OeJxE6eHbuYPbPGZdLk3AjZjLQA/7I+ZMfw5AwEGfbyzGqvB0K3p/X6HDmOFUl9aoqzXxW/P/ADOm0XUG1G1ZpoGtbyFzDc27HJhlGMrnuMEEN0KkEcGr9VfGUB0q+i8QwBRANtvqYH/PHJ2TemYyeT/cZyfurVvP8q8DMsE8JW5fsvYvC11WhfqJRQaK4UdIUUUUwCiiigAooooAKKSigYtFJRQAtFJRQAtFJRQAtFJRQAtFJR+dIAzSUtJSYCE10nhvSgxW7uB8v/LNSOvvWboViL28Hmf6mPlvf2rrL67jsbYyNjABCqO59P0r6LJcu57V5r0/zPGzLGcv7qHzJru6itI98pwTwFB5J9K4nxMtn4itxDrFpaXFpH+8WKeNZAh2n5ssDg4OM8VLd3Ml1cNJNkseOnA56D2rA8XX/wDZfhTU7tRl44G2A/3zwvHpkr+v0r6/2cacXKR4MW5zUY9TwnULGG/fVtV8P2EsWnrepFa2sKcYZHLHHRRlUYA8KJMcAYrR0Tw1NHLp+oX90IvJmtbswRp90faUG1myei8kjH3SOldR4KtzB8P7GxsoZbm/1W6naG2hAMjBFaPdyQAo2JliQBuGSOK0vEWhaxpOnzjXrBLKxvLdbaTUIZhNDaEwMgMnQr85UlsbVI+9zzzUcFh50nUqP32jtxOYYmFdUafwJ6+Z3OT3pDWfoWojVtGs74LsaaMF4z1jfoyH3VgQR6ir9fGtOLsz6paq4Giik/GgYtFJmloAKKKKAClFJQKAEmjEsbKxIz0I6g9j9e9eOeI9Ol0LXh9gf7OWk+12UgX5YZ0ILIB/dyVbb3WQr0U17L2rlvH2lPqOjSm1iL3cX7+BV6tKgJCj/eUun/Ax6VjOToTVZfP07/L8i6c1F+9s9/Q7jw3qdt4q8L2180KmC8iMc1vINwVuUkjII+bDBl9Dg9q5vw8JLJbrRrh3abTJPKRnOWkgI3Qvnqfkwpbu6P6Vz3wU1hU1G/0oSBre8jGo2uO7DakgH1BiIHqXNdf4riFj4k0jU0wqXatp1x1APBkhY9sKVkUe81fQ5hTWMwftFutTxIweDxcqL2/qxaNJS0lfHI9cKKKKoQUUUUAFFFFAE/2G5/55H8xR9huf+eR/MVv5ozUcx5/1uZgfYbn/AJ5H8xR9huf+eR/MVv5ozRzB9bmYH2G5/wCeR/MUfYbn/nkfzFb+aM0cwfW5mB9huf8AnkfzFH2G5/55H8xW/mjNHMH1uZgfYbn/AJ5H8xR9huf+eR/MVv5ozRzB9bmYH2G5/wCeR/MUfYbn/nkfzFb+aM0cwfW5mB9guf8Anl+opPsFz/zyP5iugzRmlzD+tzLGhCKy09Y3cCVjufjvWTrM811dsRG/lpwuAenr9eKu0dq97DcQ1MOlHkTSPLq4VVG5N6mERhcEAfy/z/8ArrjPi6ZR4GuVj8whpot+wZ+USAj9QP5V6gOetRvbwupDxI2cg5FdkuKI1IOM6dr9mRTwbpzU072OM+AejS2vg201rUY2W81GP9wOjRWxYska/wC+SZCeOGUH7oI9Qkt4Hgdbi3i8tlKugAKsp4KkY5ByeDxWPaYs7eCC1VYYYIxFFGigKiAABQOwAAqwt3KsgcYz39D9aunn+Gsk00FTD1Jycu55da6KngnxNdaDbMRol8XvdLDH/UnjzrcewLB19VZuu0mt4GtzxJpqa5ZQQs/kTW1wlxBMg5jZT0x6FC6H/Zdu9Vjo7/wzL+K4rzsXi8NUqc9J6M9fBV+WnyVd0ZmeKKvvpM46NG341C2nXS9I8j2IrnVWD2Z2qtTfUrUZqVrS4HWCT/vnNRtG6/eRx9RV8y7mnNHuJmlzTaKY9B1FJRmgB9Q3SM9u/l8SD5l/3hyP1qTp1pT0qKkOeLi+ojyCxdfDnju2ki2rb2WpJsOML9muABj2VEnP4x17T49gefwhqbwKWnt4xdwgclpYWEqD3+ZAK8b+JVg76kgjIT7bp8tshznb5MjKCfwmX8q9z8P351bQtN1ELtF5ax3O3pjem7H6/wCe/s5HV9vheWWv9Wf4nm5vG3sq3y+4x4ZEnhSWJg0cih1YHOQehpxrG8GnZ4Y0+3YYe0j+xuD/AH4SY2/VDWz3r5aceSbj2O6D5kmFFFFSUFFFFMAooooA6WiiisTxgooooAKKKKACiiigAooooAKKKKADNJmlxSYoAM0ZoxRikMWiiikAUZoooAUUUgpcUCYtFJSgZpiCl/Ck6UZHqKAGNFG3WND9VFMa0t36wp+AxTzLEo5kQfVhUb3luvWZPwINWufpctc/QjfTLU/wEfRqiOkQHo0g/L/CpG1O2X+Mt/wGmNq8A6JIfwrWPt+lzVe36XIjow/hlI+opj6RIOkin8CKkbWQPuxE/U1G2sSH7saCtorEGsViDifHHgzV9RuNOlsYYpfKNwr/ALwKQHKEEZ6/crrvA9jeWHgzRLDUYBDd2lrHAyZDfcXaOQTzgD/PFcv468W6rplhZyWMixO+ofZ3Plg/J5DvxnPcL+VdP4B1G91Lwbo9/qDiW7uIFlZmULuzkg4A6EY9ua9DIninCUcPa13v6mWP9o6MVV2u7WMzQtPu4LW7Wa1uI86heyDdGRlWuZWB+hBBB7g5q4ylDhgQfeqWh6je3NndNPdTuVvryJdzk/KlzIqj8FAFXSzPy/Jry8RdVp8292dlBS5FfsFFFFZXNwooopiCiiigDp8UYrA+33P/AD1P5Cj7fc/89T+QqeU8/wCqTN/FGKwPt9z/AM9T+Qo+33P/AD1P5CjlD6pM38UYrA+33P8Az1P5Cj7fc/8APU/kKOUPqkzfxRisD7fc/wDPU/kKPt9z/wA9T+Qo5Q+qTN/FGKwPt9z/AM9T+Qo+33P/AD1P5CjlD6pM38UYrA+33P8Az1P5Ck+33P8Az1P5CjlD6pM38UYrA+33P/PX9BSfb7n/AJ6/oKOUPqkzfoq7YrFeacskajzGTBPo2Oa5qYzRSMkjSAqSDyfavfw/DdWtHm50eVUxipuzWpsfU1Dc3lrawSz3NxFFFEhkd3cKFUckknoBg1knJ55z7ZH+e/SuM+LU17b+CL37BJsV2WGf5AcxP8pGCOhJA9cE4INdb4XhTi5TqbdkTDGOpNQitz1RYJWwFjY556VIbSUfeAUZAyTWN8JvEX/CT+AdK1GdzJqCQrb3ufveagG4kDpuBDgY6OPWupLKxz5iuf4VU9/erp5Bht22xVMVOLaZk3/l6fa3F1eTRxW1uhklkPIRVUsxP0UZrnbDxBNd6fbXEtj9mlliWRoZGyY2IBKnpyCcU74nXa3IsvDkLILjUP314o/htUKl9wz/AMtGCRYPVWkx901Rx0rix2CwtGShTWvU9TL6bqxc6nyNBtWnPRY1/A1E2o3R/wCWmPoKq4oriVGC6HpKjTXQma7uG6zv+dRNI7fedj9TSUVaUVsi1GK2QlGKXFLVaFCUUtGKQAKKWmThmhkWNtrlSFPoe1DdlcDz34o3ax29ipzxdvcFh02Rwsrf+PSgfga9R8EW72ngvw/bSLiWHT7eJvYrGoP8q5Hxl4Pi8YaBbxWdybC4iSSIO6eYMOMOjDIycgHIOcr3Gc9Anie5sRjxHpU9r63Vnuu7foOpCh075LIFGPvGnwzm2EcZU6k1Gbb0enU8vMZOpCMYrZsry+HtW06a4fRbu0uraaeS4NrfZjZWkdnbbMgb5dzEhShPJ+bGMV2u9Wtv+P8A8P34VfvzWskdxH9VAYSt/wB+8+1dbYX1pqVutzpt3b3du5IEsEgkViDzgjI4q1jPGOPSvoq+UYWu+a1m+xwU8dVpq1zgm8UaRCQL27/s9m+6NRie0LfTzQufwrYikSWNZInV42GVZTkEeoNdJ/vfjx3+lc/c+DtBncyxaetjcNktNYO1o75/vNGVLevzZFebV4ej/wAu5/edUMzt8cRKTNVJfDes2vOma4LlAP8AU6nArHPoJIthUe7K5qo99qlg2NX0O6RM48/Tz9si9uFAl9f+WeB615NfKcVR1tdeR2U8bRn1NeiqGmatp+ph/sF5DcNGcSIjjdGfRl6qeDwQDV7NedJOLtJWOpNPYKKWiqGJRS0UAJRS0UAJRS0UAJRS0UAJSU6igBtBpcUVLA2vDF+Le5NtIcRynCnsD/8AXrR8QacZVNzEuWUfMo7j1HvXJZIYEdRXZ+H9S+22/lTH9+g5/wBoetfV5FmGnsZPVbeh4OaYSz9rHZ7nMYJJzwTz0/H8se/asPx5Zi+8G61AAQ32Z2THJ3KCyjH1X+nFehanoqzky2wCsTlk7H6ehrmdU09prO5sboNGLiJozwScEY4/yK+olNVINI8am3CafmeafCjXz4b0S21KKOWaxuJ2stRjgXeyspZ4rhVH3isZCMoyzKExygVvVr74haEbdBpF9DrOoSj91YWDB5Wb0k/55Ady+O/U8H55sdZu/C+i6ro01uk93HqKebGrDGGidWZD/wBs1Iz6jpXQ6Rq9vf6A62Nyq31zZfYgEcb7dppkjViB/dMpP4EVzYf2MqN3K0orVG+MhWjidI3jJ6M6jwWb7UkvvEetTJNqOsSiVTHny47deIY484+TGXGQD+8JPJNdLTbeCK2giggQJDEoREHRVAwB+VPxXxtWo6s3N9T66lBU4KC6BikxSmipNBMUtFFAgooooAKKKWgBBTBG893HCshjUozsVxnggDqD61J2yelefePtflhZdPspzBJcp5lxKjbWjtgSBhuxds8j+FG6HBrjxvtKkFRou0pde3djUZTfLHdnqFrClvEIoySBySTkknkn881IfqDXnnwz8GXEfhmLVbO/uNMvb6Q3MUagvB5BACLJCThtyqHLDa/z43DGD0b67PpOI/FVqLADGL+Ji9m5OBy/WM5PSQAdgzda+dzThTHYNe2j78Xrdb/NHmKvBzcb6omvvDen3V3JeQpJYai3W8sX8mVumN5XiQDA+Vwy+1CT+I9LI3GDXLYHknFvdAZ/79yN7fuhxWyrAjKkEdcilrgwGf4/L3alN2XR6r/gfIc6MJ7ooab4q0y7uY7OZ5LDUGIVbS+Qwyse+zPyyfVCw966CsW/srXUbZ7a+toLm3k4aKaMOrfUHispNGu9P58P6pPaqOlrdg3NsfYKxDqPQI6qPQ19vl/HNCraGMhyvutV/n+ZxVMC94M688HHSk9v8/5/z9eWj8SXlgwXxBo9xCg6XVhm7hPpkKolU+vyFR/ere03UbHVLZbnTbu3vbckqJYJBIuR2yO4z07V9lhcZh8XHnoTUl5HFOnKDtJFfWNC0zWdh1KximljH7qYDbLFyD8kgwynj+EisZ/DGpWpxouuukJJ/dalb/bAgz0Rg6P+Ls56V1eRjqKXucj+X9aqrhadbSpFMcK06fws56iiivz0+oCiiigAooooAKKKKACiiigAooooAKQ0tFIBtPt5pLedJYSVdDkGmmkoTcJKUXqhOKkrS2O80jUo7+3DAgTL99PQ+v0rG+I3h+fxD4fWC1zJLBKLj7IZmiS8AVgYXZSCAd2QeisFYg4wcO0uJLa4SaFtrr+Vdno+qw6h8qsq3CDc0W7JA6Z+ma+wy3Mlio8k9JL8T53GYR4eXPH4T5j+IHhnSdPstM1vw5DNDp120kEsE5Znt5xncrFiWDfK4YE8Mh9a5/wtFDL4r0Y3CblW7jYdiGB+X/x4ivdfi14ZWVrlLYKkWuYC7jhY9RjXdE+SflEiIY2P+ygAyxz89Wtw1rcQXUat5lvKswUrzlGzgjHB4wf/AK1TjKfJK66nsYCsqtKz3R9KGmmmwTR3EEc0Dq8Uih0ZTwQRkGnmvFOxDT1ooxRTGFFFFABQBRiloAKOKWqmo30NhayTTyxxoil2aRtqqo6sx7Adz/UionUUFzSAo+JtWg0rTZri63mFFBcIfnck4WNf9p2wo5Hc9q868I6Hc+MvE8y6iFaHct1qrIPkC9I7ZfYhQv8AuK2cMwzDf3Wo+LdftbfTInld2ZrK3kyAMjD3Uw6qMHGP4VIUfMxB9VEUHgXw3Z6PogjudavWby2l48+YgeZcSY52KME+wRAfu13ZZhHd4vEafou3+f8AwDnxeIdCHs4fHL8F/mzq47y0kvZbKO6t2u4VDPAsi70B6FlHI6+nfipnUFWVlDKeoI45/wA/57cHD4Y0saZBaXlsl5JGzTG5mX960zHLyhxyrlucrjHbGBUtvd6zoB+Vptb0wf8ALJ2Au4B2COcCUD0Yhup3OcCvRw+eUKs+SWnbseTUy+pCPMtS/L4WawLy+FrldNY8mykBks2I9IwQYs/9MyBnkq1QL4g+xOkHiO1bSZmYIkruHtZSTgbJuBz2VwjH+7XRaTqtlrNn9q024WaLcUPBDIw6qynBVh3UgEdxVq4hiuYJIbiOOaGVSrxyKCrA9QQeo68Vz5nw1gczXPblm/tL9e5jTxM6XusoggjIPFGeax5PDVxpyl/C939lReRp90TJbH2T+KLsBtJQD+Amk0zXUmvBp2px/wBn6wBk2kjcOOu6JiAJVxzleR0YKcgfm2bcM4zLbza5od1+q6Ho0sRCptubJ5FZGo+H7C9upLvy3tNQZdv2yzkMExGMAF1wWA4+VsrxyK1+vIIPvSfjXh0a9WhLnpScX5aGzimrMxEfxHpYwskGu2wz8soW2uQP95R5bnrxtj7ZNWovGmjQnZql1/Y9wMgxamPs+f8AdcnY/wDwBiK0abgN94A19dl/G2Mw/u4hKovuf3/8A5qmEhPbQpUUUV3nqBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRSAQVmaxBeRz2mq6P/yFdOZnhQsFE6NjfCx7BgBgnoyoecYOpR2qqVWVGaqQ3RNSCqRcZbFGfxXfeMfBJhGg3UWozPHJbzQOklsJ4plYFiSrpsdBvR1BBBUb+/nvxn8KnS9W/tuzj/0C9f8AfgdIpz1P0bk/727P3gK7uaG80rUJtV0RTK8oAu7AuFS5AGN6k8LKAAAejABW6KydDaXmkeMdEuYSFuLaQGC5tpVKSRN3R0OCjDqPzB6Gvs8PiKWYUdNJdjxOWeBq3Xwnm3wn1xbvSm0mdh9psh+7BPLQ54/75Py+wC+td6RXhnivRdV8AeJY3tpX2Bi1heuu5JFP/LJ8cbscEcZHzDHb0bwb4603xHDHFIVsdU2/PZzMASRkEof414PI/HBrx8RQlTlqj26dSNRKUTq6KWiuZM0EoxS4pCQBliAPehtIApaydV8Q6VpUXmX19BEpztBcDefQc8n261xGv/ESQxSHTIRbQDg3V7mJB9FOGPpj5PZjUqTl8CuUoSlsjt/EGu2WiWry3UqpjgDqSx6KAOSx7KASf1rzG7vNW8Y60tjaWrSM5WWKyJGFAPE9wwyFUdlGQD03vg1f8NeCtd8T3CX1409pbMB/p96n711PUQw4+QHA+Zgo6Nh+a9KR9H8CWMel6NaPd6ncDzFtUcNPcnp5krnoueCzYAHyqOAtelhcs19tinov6/p/kclfGwovko+9P8F/mQ6NpemfDnRXmuZnvdUvpFjd0XEt3NzsijXOFUfNgZwBuZj9403SrCcXdxqurOk2sXYCyNHkxwxjO2GPP8IySTwWYliBwA6wsbl7s6nrUsdzqjgquwfu7VD1jiB5x6sfmYgZwAqrp1x5nmXt/wBzR0gvxMcNhnFurV1kwpDSmkrxbHcZV7pW+7+36dcPp+pgAefEoIlUdElQ8SL7HkfwlTzV3SfFGLmPTvEUMen6jIwSGVSTb3TH/nm56Nnny2w3XG8AtViq97aW99ayW17BFcW8g2vHKgZWHuD1r08DmlXC6PWPY48Rg4VtdmdTjJAx/wDXqpqum2eq2b2mpWsVzbsdxSQbgCOjD0I7Ec1yVu2seHyPsDvq+ljrZ3Ev+kRDPPlSsfnH+xIf+BgcV0eh+IdO1tZRZSyLPEF822njaKaLPTcjgHHUBsYPODX12Gx1HFR9x/I8arh6lF6mRLo+s6KpbRbk6raL/wAuV/KfOA54jnOSe2BICT3dRU2l65aX1w1q3mWuoom+Syul8uZVzjdt/iTPG9Syk9Ca6ToP0/z/AJ/wqjq2kWOsQJHqVsspQ7o5ASskTf3kcYZG91INeBmvCODx150V7Oflt80aUsZKGktUNNBx3IrFax13Q0JtJTrtinIimKx3iDjhX4SX23bD6sxqzpGt2WqmRLWUx3MQBmtp0Mc0Oem+NsMPY4we2etfm2Z5Djctf72N491qj0adaNRe6Oooor6o7wooooAKKKKACiiigAooooAKKKKACiiigAooooAKBRRSAXtWbf6RFcXaX1tNLY6pGuxLy3wH25ztYHKuuedrAgHkYPNaVFVTqSpy5oOzJlFSVpGVd6o8lg+neNNHS/sXG1rqyhaaNvQtCMyRtnoV3gddy9K5C5+GGmatYvL4O1qxvtO8wsLa7PnqjkkkCZTuTGf4ldvevRRWbfaHp17ci6mtgl6AFF1A7QzqPQSoQ4HsDXtUs55ko4mN/NbnJHDzovmw8rfkcCvhP4gaM5isJL2RABtFvfRXEef+3na4HsMU9pPifbxjztLJXpuNtBIx+ojuD+eAOK7qKz1W0C/YPEN9tQ/JDeRx3EePRmKiU/XzM+9Tm+8Tx8/atGuPVTaSw/iD5rflj8a6FXy2rq20OVbGLeKZ5xLN8RrorGLG8jJOP3FnHET/AMCkkIH1NM/4RPx1qcixXsepgZ4a61CCJE98wEv+hr0o6p4n/wCeejH8ZaQ3fid1/wCQhpEWf4RYSuV/Hzhn64H07VSllkftXD6zjHtBI4zRvhFffaDLqOo2Vkzn979jiM8zj/rtJjn6o1dXa6L4P8ESQz3LxPqnJhmumNxdSHofKQZOeeViUe4pH029ucf2hr+rXCdfLikW1UH2MKo+PYsam0vSbDShINOs4bdpTmR0X55D6u3Vj7kmpnm+Fo/wIXfmZzpYnEfxp6dkFzrGt6wCumQtotmx5urlFe5cf7ERyqZGMM+SCOY6NJ0m00pJBaoxlmYNNPIxeWZumXc5LHHAz0HAwABV/NHSvGxWPrYp++9Ox00cNCivdQUUmaK5LG4UUUUAFFFFFgCs/U9Lg1BoZXMkN3ASYLqBtksJPXa3oe6nKnoQRxWhQaIylB80XZiaUlZmda+JrrRiIPFW02owqatEm2I9v36j/VH/AG/9X7pwtdkGDqGQhlPIIOQa50gEEHGD61jQaddaExl8MOkUWcvps7n7K4zk7Ophbryo288qx5H0uBz37GI+/wDzPKxGX/apfcdyMDHb0NUNV0XS9ZEY1bTbO98rPl/aYFk2Z64Jz1/oPSq2g+IrTV3ktiJbTUYRumsrkBZEXONwwSGU/wB5SV7E5yBsFSQAevv/APXzX0UZxqRutUeW1KDs9GYFFFFfnJ9UFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUgFzRSUUWAWikozSsAtFJmjNFgFopKKdgDNFFFABRRRTAKKKKACiiigAooopAFFFFKwyhq2k2uqRRi5VlmiO6C4icxywN03I45U9uOo4ORkVFDrmtaMPJ1GwuNbh6RXdj5aTduJY2ZFz/tIcH+4vGdSiuzCY+thPgd12Zz1sNCsveCiiiuU3CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAUUUUhn//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperopia is also known as farsightedness. The image of an object twenty feet or more away (optical infinity) is focused behind the retina resulting in blurry near vision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the University of Michigan Kellogg Eye Center, file://www.kellogg.umich.edu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31326=[""].join("\n");
var outline_f30_37_31326=null;
var title_f30_37_31327="Suspected infectious pharyngitis";
var content_f30_37_31327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Sore throat: suspected infectious pharyngitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 673px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_37_31327=[""].join("\n");
var outline_f30_37_31327=null;
